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To cease smoking is the easiest thing I ever did; 
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ClI<lptU 1 - Illfroduction 
Tnble 1 
CiiOP!fI 1 - Introduction 
Effect of smoking 
In the last decades, extensive research has demonstrated that smoking causes many 
diseases and premahue death. nle famous British Doctors' Shtdy' showed in a 40 
years follow-up survey a significant association of smoking with twenty-four diseases. 
The overall mortality rate was almost twice as great in sl1lOkers as in life-long non-
smokers (Risk Ratio I.8, 95% confidence interval I.7 to I.9, Table I). Accordingly. 
smokers had an 8 years shorter median survival than non-smokers. 
Mortality by smoking habits (m11l1wl mortality per 100,000 men) 
Type of disease non ex 
smoking s<~_~_k~~.~ smo~ing RR * 95% CI 
Vasculii-r 
Tschael11ic"-jleartndisease 572 6;>8 892 ':a; 1.4 - 1.7 
Arteriosclerosis 22 ,8 40 1.8 1., - ).1 
Hypertension )2 )) 44 1.4 0·9 - 2.2 
eVA '52 '58 203 ,.) '" - 1.6 
Subaracchnoid haemorrhage 7 w '5 2.' 0·9 . 5·) 
All vascular diseases 1,037 1,221 ,.643 1.6 1.5 - 1.7 
Respiratory 
cor5 w 57 "7 12·7 - 24.2 
All respiratory diseases w7 '92 3'3 2·9 2.) - ).6 
~_~_()~~_I.~s!_~'~_n _ "n __ ' ,,_, __ "_' ___ , __ 
Upper respiratory I ) 24 24.0 ).2 
- '77·4 
Lung 
'4 58 209 '4-9 8·7 . 25.6 
Oesophagus 4 ,6 )0 7·5 2.6 - 21.3 
Pancreas ,6 2) )0 1.9 1.0 - )·4 
Bladder ') ., )0 2.) 1.2 - 4·4 
Stomach 26 25 4) 1.7 1.0 - 2·7 
Alllleoplastic diseases )05 )84 656 2.2 1.9 - 2·5 
All causes of death 1,7°6 2,113 ).0)8- 1.8 1.7 - 1.9 
* Risk Rotio smoking vs. Iloll-smokillg (ad(lpledfrom Doll eI a!., 1994) 
The risk ratios showed a consistent pattern: all disease ratios were positively related 
with smoking. Chronic obsh'ltctive pulmonary disease and cancer of the respiratory 
system are highly correlated with smoking. The overall calculated risk ratio of 
ischaemic heart disease in smokers compared to non-smokers was 1.6. A higher risk 
ratio was found in middle aged « 65 years: 2.1) compared to older age (> 80 years: 
1.2). 11ms, smoking causes premahlre ischaemic heart disease, which is most 
profound at young age.In absolute numbers, cardiovascular diseases are the most 
frequent cause of mortality, and smoking related death is particularly related to 
vascular disease (heart disease and stroke, Figure r). 
Cardiovascular diseases are the main cause of mortality. In the Netherlands, over 
50.000 persons (37%) die of cardiovascular diseases each year.a 
3 
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Figure I Mortality per major disease group. (Adapted from Doll et al., 1994) 
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Moreover, ischaemic hart disease causes almost roo,ooo hospital admissions each 
year.' In '995, 27% of the vascular deaths in men aged 35-69 could be attributed to 
smoking. In women of the same age, this percentage was r6%. In men and women 
of70 years or older, the percentages were r8% and 2% respectively.4 In r997, 22,926 
(49%) people died in the Netherlands because of four major diseases associated with 
their smoking habits; 6,096 (31%) coronary deaths were caused by smoking.s 
Smoking figures 
In Europe, smoking percentages range from 23% in Nonvay and Finland, comparable 
to the United Stated of America and Aush'alia, to almost 50% in Turkey and Russia 
(Figure 2)_' 
In 1998, )4% of the Dutch population smoked (30% of the women and 37% of the 
men, Figure 3). The percentage smokers in the Netherlands has decreased 
considerably during the second half of the last cenhtry, but since the eighties it has 
been rather stable. Approximately one fifth of the Dutch smokers made an attel~lpt to 
quit in 1998. About four fifths of these smokers had relapsed within 12 lllonths. Of 
those who made a successful attempt, 74% did not use any aids to stop smoking? 
Perspectives of costs 
In view of the enormous increase in health costs, it is to be expected that more effort 
is invested in (secondary) prevention, particularly in decreasing tobacco use. In the 
Netllerlands, only 2% of the health care budget (60 billion guilders in '999) is spent 
(/iilpla i • /l1troductioll 
on prevention," Also, compared to money spent on drugs and invasive procedures, 
health promotion and education plays a minor role in public health. 
Figure: 2 Percelltages of smokers ill Europe ill 1997 (average for both men and women). 
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The Dutch Foundation on Smoking and Health had in '998 a budget of only 9 
million guilders.7 In contrast, as illustration, 600 million guilders are spent on lipid-
lowering drngs in the Netherlands.s Dnlgs used to stop smoking, such as nicotine 
replacement therapy and bupropion, are not reimbursed in the Netherlands. It is very 
difficult to obtain accurate figures on how much the tobacco industry spends on 
advertising in the Netherlands. In '993, approximately 6 billion dollars were spent 
worldwide on marketing of tobacco.9 
Beneficial changes in the coronary risk profile can improve prognosis in patients with 
already established coronary artery disease. Chapter 2 describes the favourable effect 
of smoking cessation with regards to mortality and myocardial (re)infarction in 
coronary patients. However, these outcomes do not result in smoking cessation by all 
patients who suffered a coronary event. At least half of the patients continue or relapse 
(iirJ(ilf! ,. Inlrod/lnion 
Figur~ J Percentages of smokers iff tIle Netherlands. 
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in smoking after a coronary event. The second part of chapter 2 gives an overview of 
the efficacy of smoking cessation interventions, which have been offered to coronary 
patients. 
Chapter 3 describes the effect of smoking cessation in a particular subgroup of 
coronalY patients: those who lmdenvent a coronary bypass operation. This major 
coronary event is expected to have an enormous impact in patients' smoking 
behaviour as well as other changes in lifestyle. 
The current management of smoking by cardiologists is described in Chapter 4- The 
extent of regish'ation, advice to stop smoking, referral to additional smoking cessation 
support or counselling, and the effect on the achlal smoking cessation of coronary 
patients was investigated in nine European countries. 
In order to address assistance in smoking cessation to those, who would benefit most, 
predictors of smoking cessation were investigated. Cilapter 5 deals with demographic, 
clinical and psychological predictors of long-term smoking cessation in patients who 
suffered a myocardial infarction. 
Most published shldies on smoking cessation interventions for cardiac patients are 
executed on the cardiology wards. Chapter 6 describes a smoking cessation 
Cllf!lda j - Introduction 
intervention offered to coronary patients in an olltpatient setting. In this intervention, 
two different tools were utilised. A 'minirnal intervention strategy' offered by nurses, 
and a tailored letter, adjusted to the patients' individual situation. 
The results of the intervention described in chapter 6 are discussed in Chapter 7. 
Fmthermore, predictors of smoking cessation were investigated, in order to detect 
which patients are helped by this intervention program and for whom other means of 
support should be explored. 
Resnlts of the previons chapters are discussed in Chapter 8. Furthermore, additional 
subjects, which were not described in the previolls chapters, such as costs of smoking 
cessation interventions, are reflected upon recommendations for future smoking 
cessation programs are given, and implications for future practice and new research 
areas are delineated. 
7 
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CI!!lpJa; - Impact oJsmokillg cessation and smoking intefllentiolls in corollary patients 
Summary 
Aims TIle overwhelming evidence that smoking causes cardiovascular disease and new 
events in patients with CHD justifies the promotion of smoking cessation. TIlis article 
gives a review of the observational shldies on the effect of smoking cessation in 
patients with coronary heart disease as well as of smoking cessation interventions that 
have been offered to cardiac patients. 
Mel/lods A Medline search for English language papers from 1966 until 1998 evenhtated in 
nineteen observational shldies exploring the effect of smoking cessation in coronary 
patients. Furthermore. nine shldies on smoking cessation interventions for patients 
with established coronary heart disease were published. 
Re-sults Mortality or non-fatal myocardial infarction declines with an average of 35%. The 
relative risk of lllortality after the coronary event compared to persistent smokers 
ranged from 0.13 to 0.72, while the relative risk of death or myocardial infarction 
ranged from 0.23 to 0.68. In trials of smoking cessation programs in coronary heart 
disease patients. 20% more patients quitted smoking after being subjected to a special 
smoking cessation program as compared to those in the usual care. 
COllclllslOIl This systematic review of observational shtdies on the impact of smoking cessation on 
the prognosis of coronary heart disease patients confirms that this lifestyle change is 
one of the most powerful measures in reducing mortality and recurrent coronary 
events. Special smoking cessation prograrns improve the success in quitting smoking. 
" 
Cliilfll~r ) - Impoct of smoking cessation and smoking intervenliolJS ill coronary patients 
Introduction 
Although it is well known that smoking is strongly associated with coronary heart 
disease,'" many patients continue or resume smoking after being diagnosed with 
coronary heart disease (CHD) and even after an important event such as a myocardial 
infarction, angioplasty or coronary bypass surgery. The evidence that smoking causes 
cardiovascular disease and new events in patients with coronary heart disease, among 
other serious disorders such as lung cancer and emphysema, justifies the promotion 
of smoking cessation. All recommendations on the prevention of coronary heart 
disease emphasise the importance of smoking cessation in the reduction of the risk 
of coronary death and non-fatal coronary events.H nle recent EUROASPIRE shldy on 
the status of secondary prevention of coronary heart disease in nine European 
countries has shown, however, that success in smoking cessation among coronary 
heart disease patients is far from satisfactOly.1 In this era of evidence-based medicine, 
information from systematic reviews of published shldies should guide physicians 
and other health professionals advising patients in smoking cessation. With this in 
mind, we have carried out a systematic review of published observational shldies on 
the impact of smoking cessation on the prognosis, and on smoking intervention trials 
in patients with coronary heart disease. 
Methods 
A Medline search for English language papers from 1966 until the beginning of '999 
was performed by the first author, using the keywords: 'coronary disease' or 
'myocardial infarction' or 'angina pectoris' or 'angiography' or 'coronary artery 
bypass' or balloon angioplasty' (about 200,000 hits) and 'smoking (restricted to 
focus), or 'smoking cessation (restricted to focus), (about 25,000 hits), which 
produced a list of I,I91 publications. All these publications were screened; reading 
titles and, if appropriate, abstracts. All articles about mortality and myocardial (re-) 
infarction in patients with coronary heart disease and smoking cessation after a 
cardiac event were selected, supplernented with references regarding occurrence of 
myocardial infarction and mortality in coronary patients after smoking cessation, 
which yielded I9 publications. Furthermore, all publications on smoking cessation 
interventions used as secondary prevention for coronary patients were selected. 
Again, related references concerning the effect of smoking cessation interventions in 
coronary patients were added, eventuating in 10 articles. 
For each study comparing quitters and continuing smokers, odds ratios and 95% 
confidence intervals for mortality alone, and the combined outcome of death and non-
fatal myocardial infarction were calculated. Chi square tests were applied to evaluate 
statistical significance. Subsequently, sequential meta-analyses were performed and 
odds ratios with 95% confidence intervals were determined based on the combined 
study data beginning with the oldest; subsequent studies were added step by step in 
chronological order. 
'3 
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Results 
Impact of smoking cessation on prognosis 
Tables I and 2 review of 19 observational shtdies. exploring differences in mortality or 
(reo) infarction between patients who quit or continue smoking after a coronary 
event.'" Time of publication ranged from '975 to 1997 (Table 1). Most studies 
concerned patients after a (first) myocardial infarction. The average age was 
approximately 56 years. Most studies had an upper age limit ranging from 60 to 67 
years. while one study focussed on elderly people with a lower age limit of 55 years. T} 
In aH studies but one, men were over-represented; in six (early) studies only men were 
included.6.7.9·n.l9 while in one shtdy only women were enrolled.'4111e average number 
of smokers at baseline was 53%. A significant decrease can be observed over time. 
form 71% in the decade '975"984 to 33% during '985"994. This was in spite ofthe 
noted excess of the Japanese study, where smoking prevalence had increased. 
corresponding with overall smoking rates in Japan.19 
Duration of foHow-up ranged from 1-13 years. Definitions of 'smoking' and 'quitting' 
varied, while some studies did not clearly specify smoking or quitting. To be 
designated a 'smoker' in studies in which smoking was defined, patients had to have 
smoked from one to five cigarettes a day during a period which ranged from 'at 
baseline' to 'the last two years'. Smoking cessation at follow-up was always self-
reported and varied from not smoking for 3 months to I year. Prognosis at follow-up 
(up to 13 years) was. in all cases, related to smoking status determined at one year or 
earlier after baseline. 
The percentage of patients who quit ranged from 28 to 60%. with an average of 49% 
(fable 2). This percentage decreased from 50% in the decade '975"984 to 42% 
during '985"994. The percentages of deaths and, if investigated, non-fatal 
myocardial (re)infarction of patients who continued smoking were compared with 
those who had stopped smoking after the coronary event. In all publications. smoking 
cessation reduced mortality at follow-up. In 10 articles.- a significant difference was 
found in mortality between the two groups: the odds ratio for dying ranging from 0.13 
to 0.72 for quitters compared to those who continued smoking. In the other nine 
articles. most of which had a small number of patients or a shorter follow-up. a similar 
trend was reported without reaching statistical significance. Twelve articles assessed 
the occurrence of death or non-fatal myocardial (re-) infarction: in the two groups. In 
nine of these a significant difference was found, the odds ratio ranging from 0.23 to 
0.68. \Vith regards to age, smoking cessation also improved prognosis in elderly 
coronary patients.'O.'7 
Multivariate analyses were performed in eleven of the 19 studies. Although the odds 
ratio increased in most cases. the effect of smoking cessation appeared to be 
independent. Combining the data Of13,019 smokers, ofwho1115,776 (44%) had quit 
smoking after the event, 1,0ID (17%) of the quitters died albeit at different follow-up 
intervals, compared to I,838 (25%) in the current smokers: odds ratio 0.62 (95% 
confidence interval 0.57 to 0.68). Sequential meta-analysis of the nineteen studies 
Table 1 Reviewed articles on prognosis of CHD for coronary patients after smoking cessation. ~' 
Author Ref Yea. N* Prevalence Inclusion Age % men FU baseline 'smoker' follow-up quitter t 
of Cigaret.s Duration 
smoking t (years) (years) per day (months) (months) .[ 
" ~
Wilhelmsson et aI. 4 '975 4 05 77 1St AMI, discharged aIive < 67 IOO 2 ~ I 3 3 post-AMI -2, 
" 
Mulcahy et al. 5 1977 '90 87 1st UAP IAMI; 28days survival < 60 IOO 5 ~ 5 6 <:: 6 post-AMI " 
Sparrow et al. 6 1978 202 52 lSt AMI. discharged alive (Fram) 60 74 6 > I 2: 12 post-MI ! 
Salonen 7 I980 535 60 AMI, 6 months survival < 65 IOO 3 <6 post-AMI ~ 
Aberg et al. 8 1983 983 78 1St AMI strat. • 100 5 ~ I < 3 3 post-AMI 
g-, 
, 
Daly et al. 9 1983 374 74 ISt AMI/UAP, 2 year survival < 60 IOO 13 
• 5 
< 6 2: 3 post-AMI " , ~ 
R.0nnevik et al. IO 1985 9
'
9 53 AMI. timolol·trial 79 cont· I post-AMI 
" Perkins et al, 1985 60 AMI. r month survival 59 ' 76 at baseline post-AMI 
0 II II9 1 ~ 
Johansson et al. l2 1985 156 61 Ist MI, discharged alive strat. ' 0 ~ I < 3 3 post-AMI 
~' 
~: 
Hallstrom et al. 13 1986 3'0 57 sudden arrest out-hospital 56 ' 80 4 ~ 
Vlietstra et al. '4 1986 4165 34 CAG: <:: 1vessel <:: 50% stenosis ~ 55 5 at baseline < I2 before baseline , g. 
Hermanson et al. 
'5 1988 1893 22 I-V 2: 50%, no CABG • 55 78 6 at baseline < 12 before baseline 
" Cavender et al. 16 I992 284 40 CAG <:: 70% stenosis ~ 65 90 IO at follow-up 6 post·AMI s· 8 
Sato et al. 
'7 1992 87 86 AMI > 30 100 3 ex-smoker 2 ;; 
Gupta et al. 18 
'993 225 43 CHD 54 ' 79 6 > 5 since CHD ., 
Herlitz et al. 
'9 1995 302 37 AMI 70 ' 69 5 at follow-up " ~. Greenwood et al. 20 
'995 532 44 AMI 5·5 at follow-up 
, 
~ 
Voors et al. 21 1996 169 41 CABG, 30 days survival 53 ' 9 0 15 at surgery stopped since surgery 
Hasdai et al. 22 '997 u69 22 PTCA +5 
* Number of patients sdected for this study 
j' Percentage of smokers at baseline 
.' 
-.' 
mwn 
§ median 
, stratified 
continuously 
'" 
e, 
Tabk2 Mortality and incidence of coronary events in patients with coronary heart disease who quitted or continued smoking. ,~ ~ 
Author Quitters Mortality Univariate OR Adjusted OR Mortality oj. non-fatal MI Univariate OR Adjusted OR 
at (ollow.up quitters smokers quitters smokers 
" ;; 0 
(%L -(%) 1%) (9S%. CI) (95% CI) ~.,,(%). (%L_ _(9~CI) (9~%CI) ~ 
.a, 
Wilhelmson et al. 231 57 'S 7 22 I3 t 048 (0.22. I.OI) 35 15 53 30 0.41 (0.24. 0.68) i 
Mulcahy et al. 89 47 I3 15 23 23s 0·s8 (0.25.1.3°) 
~. 
Sparrow et aI. 56 ,8 10 19 40 30s 0.S8 (0.24.1.3°) I8 33 66 49' 0.57 (0.28. !.IS) ~ 
" Salonen 221 41 26 12 Go 20t 0.56 (0.33.0.95) 0.63 t." a' , 
Aberg et al. 542 55 97 IS 126 29' 0·54 (O·40.0·74) o.p t.~ 201 37 253 5S' 0·44 (0.34,0·57) 0 , ~ 
Daly et aI. 217 58 80 37 129 82' 0.13 (0.07.0.21) ~ R.0nnevik et aI. 55! 60 37 7 29 SS 0.84 (049. I45) 81 15 74 20t 0.68 (043.0.99) 5-
Perldns et al. 52 44 30 451 0.26 (0.10.0.65) 044 (0.20,0'95)"''1 15 29 32 48'~ 0-44 (0.I9,I.02) " 9 '7 ~. 
Johansson et al. 8, 5' I4 '7 27 36t 0.37 (0.r6. 0.83) 0·37 32 37 48 63' 0.37 (0.r8. 0·74) ~ Hallstrom et al. 91 29 34 37 104 47$ 0.66 (0.39. I.U) 0.51 ~.[ g. 
Vlietstra et al. 
'490 36 234 16 548 21" 0.72 (0.6r. 0.86) 0·57 340 23 850 J' 0.63 (0.55.0·74) a 
Hermanson et al. 80743 39' ,6" 0.63 (0.51,0.77) 0·59 (O·50. 0·71)' 466 5S 8'5 76" 0.67 (0.59.0.83r 
;s. 
210 26 0-43 (0·35. 0·53) 8 
Cavender et al. 97 34 19 20 58 3It 0.54 (0.28. I.OI) 0.64 g 
Sato et al. 60 66 5 9 6 21$ 0.34 (0.07.1.51) 5 9 8 29t 0.23 (o.05. 0.93) 0.32 (O.IO.I.O)f 
., 
" Gupta et al. '73 77 56 3' 24 46$ 0.56 (0.28.1.11) 0 ~. 
Herlitz et al. lI5 53 20 '7 58 3It 047 (0.25,0.85) 30 26 6736s 0.63 (0.36.1.08) 
, 
" Greenwood et al 396 74 64 16 29 21$ 0.76 (0.51. 1.12) 0.56 (0.33. 0'98) 
Voors et al. 72 43 26 36 37 39s 0.92 (0-46,1.80) I.II (0.63.2.OjS 37 51 65 67" 0.52 (0.27. 1.02) 
Hasdai et al. 435 37 4' 9 97 13$ 0.68 (0.45.1.02) 0.69 (0-47.0.98) 50 II II9 r6S 0.67 (0.46, 0·97) 
Total 5.776 44 1,010 17 1,838 25 0.62 (0.57.0.68) 1,310 23 2,460 34 0.57 (0.53, 0.62) 
" <0.05: ~: <0.01; J <0.005; * <0.001; $ '" not significant 
, Stratification for age, previous MI/AP, heart failure/arrest 
Stratification for age 
f Age and gender 
£ Adjustedfar five risk strata (Na CHD, ATMI, Na Hx, Hx afMI, Hx afCHF) 
'" o
(I;oplcr ) . Impact of smoking cessation and smoking intcwcntiollS in coronary patients 
(OR 0.59. 95% confidence interval 0.53 to 0.66; Figure I) shows convincing evidence 
of the effect of smoking cessation in the late 1970s, while the reduction of 40% 
mortality was demonstrated by 1986.,6 As regards mortality and non-fatal myocardial 
infarction. 1,310 (23%) events occurred in the quitters as opposed to 20460 (34%) in 
the smokers (odds ratio 0.57, 95% confidence interval 0.53 to 0.62). The difference in 
inclusion criteria partly accounts for the large differences in effect between the 
various studies. Baseline characteristics as age, gender, cardiac event and period of 
first survival differed between the studies. Also, different definitions of current 
smoking and fonner smoking were used. 
Smoking cessation is considered to decrease other endpoints as well. Restenosis rate 
7 months after angioplasty was higher in continuing smokers than in those who 
stopped smoking post·PTCA (55% VS. 38%, P ~ 0.03). Smokers after a coronary bypass 
surgery have a 3.3 times increased risk for re·CABG after 5 years (P ~ 0.03)." 
Prinzmetal anginal attacks appeared in 62% of the smokers vs. 21% in quitters after 
three months (P < 0.05).,6 
Figure 1 CUnlJllative Odds Ratios on morlafity of quitters compared to smokers of tile nineteen studies. 
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Trials of smoking interventions for coronary patients 
Ten shlciies on smoking cessation interventions in patients with established coronary 
heart disease were published between '974 and '999 (Tables 3 and 4). Five studies 
'7 
;, 
Table 3 Description of smoking cessation intervention studies in coronary patients. i'· 
Author Ref Year Country Population N' smoking Follow-up 'non·smoker' 'Ie IN)' Quitters (%) ,.<:, p 
1%) intervent. control 1%) ~ 
0 
Burt et aJ. 27 '974 England AMI. male 223 78 1-3 years CO < la, thioc < lIO' I25/98 63 28 35 < 0.001 
~ 
"'-Pozen et aI. 28 '977 USA AMI, ~ 70 years IO, 6 months self.reported 55/47 39 2I I8 < 0.05 ~ 0 
Barr Taylor et al. 29 1990 USA MI, :5 70 years '73 46 I year self.reported 86/87 7I 45 26 < 0.001 i Ockene et al. 34 1992 USA post·CAG 267 26 6 months no puff 'Z; I week I35/ '32 62 5I II :: 0.06 ~ Engblom et al. S J2 1992 Finland post.CABG 45 20 xyeat self-reported 25/ 20 44 20 24 < 0.01 0 
Rigotti et al. J3 '994 USA CABG 87 23 5.5 years cotinine < 20 ng/ml 44/43 44 44 0 ns g' 0 
DeBusk et aI. 30 I994 USA AMI, :5 70 years 585 43 I year cotinine S IO ng/ml 293/ 292 70 53 I7 < 0.001 %. 
Haskell et al. 35 '994 USA CAG:CHD 34 II 4 years CO, thiocyanate 12/22 0 0 0 ns ~ 0 
Carlsson et al, 3
' 
I997 Sweden AMI, > 50 years 67 40 I year self.reported 32 / J5 
~ 
50 '9 2I < 0.05 s· ., 
Johnson et al. 36 I999 USA Cardiac treatment I02 6 months self-reported 50 /52 46 3I I5 ns ::-~ 
;< 
I,685 857/ 828 6I 
, 
Total 42 I9 < 0_0001 5"-
" :s-
t Number of patialts forming the trial population 8 c § number of patients in Intervention group (1) and Control group (C) , 0 
~~ differrncc of number of patients in Intervention group (I) and Control group (C) 
., 
~ 
0 
Carbonmonoxick < 10, Thiocyanate < ltO (mcl/tJ ;r-, 
* High-risk group (/,ow-risk not mentioned) ~ 
$ subset: of smokers in a multifactorial intervention_ 
Tabk4 Smoking cessation interventions in coronary patients 0 ~ 
Author Multi- Intervention Duration'" Intervenor Indiv/group Written info Additional Setting Phone Family ~ 
factorial 
% 
Burt et al. yes Information, ?,? nurse+wd.ioC- indiv info+advice no hasp. + no yes t ~ 
reinforced advice fu clinic ~ Pozen et al. yes In-hospital talks > ± 5 hr,? nurse both literature no hasp + x/week yes ! visits/phone ~ Barr Taylor et al. no In-hospital and ?,6months nurse indiv manual tapes (NRT) hasp + outpatient l/w-I/m no 
telephone contacts clinic (if smolting) ~f 
Ockene et al. In- + out-hospital I·Shr., Nm health educator indiv (both) ifno hosp + outpatient 0 no no 4 no , ~ 
and telephone counselling clinic ~ Engblom et al. t yes pre- and post· ?, 10 weeks multi· both no (?) no hasp/rehabilitation no no ,. 
CABG rehabilitation disciplinary "" ;:;:. 
Rigotti et al. no 3 sessions I hour,? nurse indiv manual video hasp + I post- yes ~ 
in-hospital discharge telephone , 
DeBusk et al. yes Risk-factor and zhr, 6 m nurse incliv manual. video, hosp I/m no 
~. 
rehabilitation tailored tape,(NR1) (+ I visit if relapsed) s· 8 
Haskell et al. yes rehabilitation ?, ? psychologist indiv goal+ no out-patient clinic no no 0 , , 
programme instruction 
'" ~ Carlsson et al. yes education at 1.5 hr, 3 m nurse (cardiol) both yes no? 2r prevention unit no no ~~r 
outpatient clinic ~ 
Johnson et al. no info and increasing ?, 3 months nurse group (?) manual video 2 in.hospital 6/3m no 
self-efficacy sessions 
hr .. hour; m .. months; w ... week; cardiol .. cardiologist; indiv .. individual; NRT", nicotirn: rtplacenumt therapy; hosp - hospital 
" numbe:r of contact hours. period ofintmlcnrion 
t subset of smokers in a multifactorial intmlcntion 
.:;; 
ClIOI,/·;r ) - /nlpucl of smoking assatiol] and smoking interventions in coronary pOlienls 
were performed on patients who had had a myocardial infarction/7-l1 two shldies on 
patients who undenvent coronary bypass surgery,P,)) two on patients with coronary 
heart disease on the angiogramJ--J.Jl and one on patients with a need for cardiac 
treahnent )6 (Table 3). Six studies were performed in the U.S.A., one in Canada and 
three in Europe. In almost all shldies, the smoking cessation program was part of a 
multi-factorial intervention or rehabilitation program, which included physical 
exercise (Table 4). Two studies were not randomised .],)6 and one was not controlled!7 
Smoking rates were measured at the time of follow-up (definition often not clearly 
stated) and biochemically validated in four programs. All interventions were started in 
hospital and in most cases carried out by a nurse. Most counselling was individual. 
though some hospitals also provided additional group therapy. Written material was 
provided to enforce information and advice given orally. Some interventions provided 
additional aids as (relaxation) cassettes or videotapes and some prescribed nicotine 
substitution for highly addicted patients. 
Figure: 2 Cumulative Odds Ratios on smoking of control patimts compared to tllOse W}lO received a 
no: 
0 
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In six of the interventions, follow-up telephone calls were made, varying from one 
post-discharge call to weekly calls. Length of contact ranged from approximately 1-5 
hours within 3-6 months, but many interventions were not described precisely. Most 
shtdies did not include family members in the intervention. 
'0 
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In six of the 10 studies a significantly higher number of quitters was found in the 
intervention group (Table 3). In these studies, differences between percentages in 
quitters in the intervention and the control group varied from 14 to 35%. In two 
Shldies no difference was found between the two groups, and in two studies more 
quitters were found in the intervention group. but this was not significant. Sequential 
meta-analysis of the 10 intervention studies resulted in a total population of 1,685 
smokers; with 61% qnitters in the intervention group and 42% in the control group 
(OR = 0.50, 95% confidence interval 0.41 to 0.61, Figure 2), thus 19% more quitters 
were observed if an intervention was offered. It is difficult to discern characteristics of 
the successful but very diverse shldies, apart frOln the fact that none of the less 
effective studies had myocardial infarction as an inclusion criterion. 
In three articles, multi-factorial risks were shtdied and smokers formed only a small 
part of the total study group, therefore a significant difference between the 
intervention group and the control group could not be expected. Interventions that 
had the smoking cessation intervention as part of a larger program described the 
intervention less extensively. This raises the question as to whether the interventions 
were less elaborate than programs aimed only at smoking cessation. Differences 
between the diverging results can be explained by varying circumstances. Inclusion 
criteria, demographic characteristics, intervention, intervenor and smoking 
definitions differed widely, which makes comparisons among them unreliable. 
Moreover, because up to now only a few shtdies have been performed on smoking 
cessation interventions for coronary patients, further investigations are needed. 
Discussion 
Patients who continue smoking at follow-up have a worse prognosis compared to 
those who stop smoking after a myocardial infarction. Mortality declines by an 
average of 35%, and mortality or non-fatal myocardial (re-) infarction by 36% in those 
who have stopped smoking. The relative risk of mortality following a coronary event 
for quitters cOlnpared to permanent smokers ranged from 0.13 to 0.72, while the 
relative risk of myocardial infarction ranged from 0.23 to 0.68. Publication bias, 
however, should be taken into account. Short-term effects can be explained by the 
withdrawal of nicotine, whidl increases heart rate and blood pressure and thus caUses 
an increase in myocardial oxygen demand)7, and carbon monoxide, which, by 
carboxyhemoglobin formation, decreases the oxygen-carrying capacity of the blood.)s 
Long-term effects could, in part, be explained by a positive effect on the lipid profile", 
but exact Inechanisms are stin not clear. 
Many articles support smoking cessation in patients with coronary heart disease. 
Simple smoking cessation advice from a physician alone resulted in 3% quitters 
without relapse within I year. Additional support in the form of letters, visits and 
information folders, resulted in a mean efficacy of 5%.40 Interventions in special 
groups such as healthy patients with high-risk of coronary heart disease, are more 
effectiveY In this review, differences of up to 35% with on average almost 20% more 
quitters, were found among those who participated in a smoking cessation program, 
compared to those who received the usual care. Publication bias could explain the 
" 
" 
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high odds ratios found in the first three studies and the gap in the studies in the 
1980s. Smoking cessation seems to be most effective in myocardial infarction 
patients, since this is often a (first) serious warning and great emphasis is put on the 
risk factors. Patients, on the other hand, who undergo coronary interventions, are 
often believed to be cured and therefore the need of smoking cessation could be 
underestimated by both the physician and the patient. Many different approaches and 
tools for smoking cessation interventions are applied. To date, the most effective 
approach in specific categories of smokers has not been investigated. No particular 
intervention was shown to be more effective than any other is, but reinforcement is 
important. In general, smoking cessation interventions, with a high number of 
contacts and prolonged duration, are the most successfulY Furthermore, a 
multidisciplinary approach with face-to-face contacts are determinants of success, as 
are the number of intervention modalities. The exact contents of the interventions are 
often not described in detail. The risk for clinical complications in coronary patients 
who continue smoking is obviously high, and can enhance motivation to stop 
smoking. So far, only general smoking cessation programs have been used in 
coronary patients, and have been shown to be successful. 
Nicotine substitution has proved to be effective as an aid to stop smoking,4l However, 
clinicians are cautious about prescribing nicotine replacement for cardiac patients, 
because of adverse cardiovascular effects, especially if patients continue smoking.44 In 
a randomised, placebo-controlled shldy of transdermal nicotine in 156 patients with 
coronalY heart disease, no difference in adverse affects was demonstrated between the 
nicotine replacement therapy group and the control group.4l 1111s was confirmed in a 
study of 584 outpatients with a diagnosis of cardiovascular disease.46 
Socio-demographic predictors of smoking cessation were shown in several Shldies: 
older age, male, higher educational level, recent hospitalisation; and in women the 
number of cigarettes and marital stahls.47-49 For patients, the following clinical 
predictors for smoking cessation were found: a history of coronary heart disease, a 
long hospital (CCU) stay as well as a higher creatine phosphokinase elevation.mO.l] An 
intervention, such as PTCA and CABG and the presence of other coronary risk factors 
predicted continued smoking, whereas having unstable angina was associated with 
quitting smoking.48.s' 
In addition, the psychological aspects of behaviour change need to be taken into 
account when offering cardiac patients a smoking cessation intervention. The 
continuing smoker has a less negative attitude to smoking and tends to be more of a 
worrier than the ex-smokerY In a Shldy of r64 post-myocardial patients, the 
relationship between personality characteristics and smoking behaviour modification 
was investigated. Persistent smokers appeared to have higher levels of anxiety and 
depression than quitters 5 months after the myocardial infarction. This applied 
especially to the elderly smoking patients, who also were characterised by a low level 
of somatisation. 51 A history of major depressive disorder is often found in smokers, 
while more smokers are individuals \vith a history of major depressive disorder. 
Smokers \vith a major depressive disorder were less successful in their attempts to 
(i:')piU 2 - Impact oJ smoking cessation and smoking in/eweIlliollS in coronary patients 
stop smoking, since smoking cessation for these patients can result in depressive 
symptoms.1-! Several shtdies found a high incidence of psychiatric disorders in cardiac 
patients. in particular depressive symptoms. 51 Only a minority of depressive cardiac 
patients received anti·depressive treatmcnt,l6 presumably because of inadequate 
diagnosis and reluctance by cardiologists to prescribe antidepressant drugs because of 
cardiovascular side-cffects.>7·18 Recently, the positive effect of bupropion on smoking 
cessation was published, which could be of additional help in the future. 59 Smoking 
cessation interventions should be adjusted in the light of psychiatric disorders, such 
as depressive symptoms. and also social, financial, and other possible individual 
influences should be taken into account, to enhance the effect. 
Clinical implications 
It is generally accepted that it is the physician's task to repeatedly draw the patient's 
attention to his/her unhealthy behaviour. In the new recommendations of the 
European Task Force on coronary prevention, it is stated that patients should be 
encouraged and supported to stop smoking) However, making patients stop smoking 
is a difficult task. cost-effectiveness It is important to identify at what stage patients 
are to be given appropriate support. Prochaska et al. divided smokers' intention to 
change in five continuous stages: precontemplation (do not want to stop), 
contemplation (consider stopping), preparation (makc preparations to stop), action 
(attempt to stop) and maintenance (sustain non-smoking). \Vith a few simple 
questions, a patient's stage of change can be assessed. Matching cessation 
intcrventions to the stage of change improves its success.60 Unfommately, it is very 
difficult to offer help to smokers who do not wish to stop smoking. Infonnation about 
the hazards of smoking and evidence of the effects of smoking cessation, as offered 
in this review, could persuade thcm to consider quitting. Subsequently, a smoking 
intervention can be offcred to enlarge motivation, so that preparations can be made to 
set a date to stop smoking. In addition to a regular smoking cessation counselling, 
written material could be offered and possibly nicotine substihttion to those who are 
heavily addicted. Social support seems to enhance the chance of sllccess,6, so 
involvement by the family could be profitable. Research on how to help cardiac 
patients who continue to smoke is scarce. Shldies performed so far are promising, but 
intervention programs need further elaboration to assess which intervention is most 
effective for whom. 
'3 
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Summary 
Aims To determine the influence of smoking cessation on mortality after coronary artery 
bypass surgery, which has still not been established clearly. 
Cigarette smoking is one of the known major risk factors of coronary artery disease. 
Mel/lOds One thousand and forty-one patients undenvent coronary artery bypass surgery 
between 1971 and 1980. TIle pre-operative and post-operative smoking habits of 985 
patients (95%) could be retrieved and were analysed in a multivariate Cox analysis. 
Rcsults TIle median follow-up was 20 years (range 13-26 years). Smoking stahlS before 
surgery did not entail an increased risk of mortality: patients who had smoked before 
surgery and those who had not smoked in the year before surgery had a similar 
probability of survival. However, smoking cessation after surgery was an important 
independent predictor of a lower risk of death and coronary reintervention during the 
20-year follow-up when compared to patients who continued smoking. In analyses 
adjusted for baseline characteristics, the persistent smokers had a greater relative risk 
of death from all causes (RR 1.68, 95% confidence interval 1.33 to 2.13) and cardiac 
death (RR 1.75, 95% confidence interval 1.30 to 2-37) as compared to patients who 
stopped smoking for at least I year after surgery. The estimated benefit of survival for 
the quitters increased from 3 percent at 5 years to 14 percent at 15 years. The quitters 
were less likely to undergo repeat coronary artery bypass surgery or a percutaneous 
coronary angioplasty procedure (RR 1.4', 95% confidence interval 1.02 to 1.94). 
COIlc1I15ion Patients who continued to smoke after coronary bypass surgery had a greater risk of 
death than patients who stopped smoking did. They also underwent repeat 
revascularisation procedures rnore frequently. Cessation of smoking is therefore 
strongly recornmended after coronary bypass surgery. Clinicians are encouraged to 
start or to continue srnoking-cessation programs in order to help smokers to quit 
smoking, especially after coronary artery bypass surgery. 
)2 
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Introduction 
It is well established that cigarette srnoking is a major contributor to the risk of 
coronary heart disease.'" Previous studies have shown that smoking is strongly related 
to myocardial infarctionl '5 and cardiac death6 in the general population. A recent shldy 
has shown that cessation of smoking after percutaneous coronary angioplasty (PTCA) 
may have an important beneficial effect on the clinical course following the 
procedure.7 Some shldies suggested that continuation of smoking is a greater risk for 
atherosclerosis of vein grafts than non-smokerss,?, whereas two other shldies showed 
a beneficial effect on clinical events after coronalY artery bypass surgery (CABG).'o,,, 
However, the effects of smoking and smoking cessation after CABG on mortality have 
not been clearly established. In the present study, we assessed the relation between 
smoking cessation and the mortality risk after CABG and determined whether 
smoking cessation after CABG affected the need for repeat revacularisation 
procedures. To this end, a group of 985 patients who were operated upon between 
1971 and 1980 were therefore followed during a 20-year period. 
Patients and methods 
Patient population 
All 1,041 consecutive patients who undenvent a first CABG surgery between February 
1971 and June I980 at the Thoraxcenter were considered for this study. The bypass 
grafts in all these patients were all of saphenous vein material only. TIle medium-term 
and long-term survival probabilities of this group have been published previously.12'4 
The smoking habits before and after surgery could be retrieved from 985 patients. 
The population consisted of866 males (88%) and "9 females (I2%) with a mean age 
of 53 and 55 years respectively. Multivessel disease was present in 81% of the patients 
and impaired left ventricular ejection fraction ( < 55%) was found in 27% of the 
patients. 
Follow-up 
Follow-up for vital status was obtained by contacting the civil registry in writing and 
was complete in 98%. Median follow-up was 20 years (range 13-26 years). Mortality 
\vas divided into peri-operative mortality (death occurring within 28 days after 
surgery) and late mortality. The latter was subdivided into: 
I death at re-CABG or PTCA; 
2 acute cardiac death (within one hour after beginning of complaints, believed to 
be of cardiac origin); 
3 death caused by myocardial infarction (ascertained by enzyme measurement 
and ECG); 
4 death caused by chronic cardiac failure; 
5 death from a non cardiac cause; 
6 unknown cause of death. 
The cause of death was determined by checking our own hospital records, by 
contacting the referring hospitals (for autopsy reports or letters to the general 
practitioner) or the attending general practitioner. 
33 
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Smoking behaviour 
In 1981, all patients were queried about their smoking stahls before surgery and after 
surgery. At that time, May 1981,64 (6.2%) of the original group Of1,041 patients had 
died and another 8 had moved abroad_'4 The remaining patients were sent a 
questionnaire to ascertain their post-operative condition and smoking habits. 
We were able to retrieve the pre-operative and post-operative (recorded at least I year 
after surgery) smoking habit status of 985 patients (95%, Figure I). The small number 
of patients'" who started to smoke after CABG were excluded from the present 
analysis. In the 56 patients whose smoking stahls at least one year after CABG was 
unknown, 48 of the 56 patients had died at the time when the patients were queried 
about their smoking behaviour (peri-operative mortality: 12 patients; I-year mortality: 
33 patients, of which 25% non-cardiac). The baseline characteristics of these 56 
patients were similar to the group of patients in whom the smoking was known. The 
median duration between CABG and the assessment of smoking behaviour was 2.8 
years (range II months to 9.5 years). The shldy population was divided into two 
groups: smokers and non-smokers (both ex smokers and never smokers) in the year 
before CABG; the smokers before surgery were further subdivided into quitters who 
had stopped smoking in the first year after the index CABG (most immediate after 
CABG) and persistent smokers, those who smoked before CABG and continued to 
smoke for at least one year after CABG. 
Figrlf('l Flow-chart of the subdivision of tile smoking habits of 1041 comecutive patients who Imdenveut a 
first CABG surgery betwem 1971 and 1980. 
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Data management and statistics 
Differences between the smokers and non-smokers, as well as quitters and persistent 
smokers were calculated by means of the Shtdent's t-test for continuous data or the 
chi-square test for categorical data. Pre-selected variables were age, sex, and extent of 
vessel disease, pre-operative ejection fraction and complete or incomplete 
revascularisation. A vessel was considered diseased when the luminal diameter 
narrowing of at least 50% was seen in more than one projection. Ejection fraction was 
angiographically calculated in 705 patients and considered impaired if less than 55%. 
A complete revascularisation was defines as "no remaining main artery stenosis of at 
least 50%." TIle survival data were analysed using the Kaplan Meier method. The log-
rank test was used to compare survival CUIVes. Univariable Cox proportional-hazard 
model was used to estimate the unadjusted relative risks for non-smokers as 
compared to smokers at the time of surgery and to compare quitters and persistent 
smokers after surgery. A multivariate Cox model, adjusting for the pre-selected 
clinical and angiographic parameters, was used to estimate the adjusted relative risks. 
Table 1 Baseline characteristics of 985 patients undergoing successfill coronary artery bypass surgery 
accordillg to smoking status. 
Event 
Male 
Vessel disease {%J t 
2-vessels 
3-vesseIs 
left main 
Ejection fraction (%J 
""- 'l'l~'~I-;laf~~-~-"--' 
11= 
moderate UO - 55%) 
poor (s 30%) 
unknown -t 
Revascularization 
incomplete 
Non-smokers 
at time of 
surgery 
5E .. 
83 ..... 
2.8 
17 
32 
42 
9 
25 
3 
15 
79 
21 
Smokers at time of surgery 
all quitters' persistent 
smokers 
556 
. 
5,~',,2 
"?,~ 
2.6 2.6 2. 
20 26~'"'- - ~6" 
29 25 35 
42 40 43 
7 9 6 
58 58~ .. 58 
22 23 22 
3 2 3 
17 17 17 
79 
""" -"'"·-8o-·~"--
79 
21 20 21 
J QllillefS wm: defined as plltitlllS who quit sl1lokillgfor at le-asl olle }'lilr after lilt: illdtx proud!lulllld persistent 
smokers as palitllfs wllO wue still smokiIJg allulS! aile }'lllr after Ihe j/Jdex prowfllre. 
* p < 0.05 comparing slllokers vs. 1I01l-s/Iloktrs; 
t wlltll (omp{lrillg quitters alld persirtent smokers (2X4 lable) a p < 0.05 u'OSfolmd; 
-t dlle 10 ill5!iffident quality or absw(-t oJlhe ~'mtriculogralll. 35 
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Results 
The baseline clinical characteristics of the smokers and non-smokers are shown in 
Table 1. Smokers at the time of surgery were four years younger and more often male 
compared to non-smokers. The clinical characteristics of quitters and persistent 
smokers were comparable except for a larger proportion of multivessel disease 
amongst the persistent smokers. 
Median follow-up was 20 years (range '3-26 years). Death occurred in 234 (54%) of 
the 429 non-smokers at the time of surgery, of which 65% due to cardiac causes. Of 
the 556 smokers before CABG, 3" patients (56%) died within 20 years; of which 65% 
due to cardiac causes (Table 2). Of the 238 patients who stopped smoking after CABG, 
I09 patients (46%) died within 20 years, whereas 202 (64%) of the 318 persistent 
smokers died during the follow-up. A cardiac cause of death was found in 62% of the 
quitters and in 68% of the nOll· quitters. 
Table2 Numbcrojcvnlt-s (%) 
Event 
Death from all causes 
Sudden death 
ll= 
Fatal myocardial infarctioJ'l 
Reintervention death 
Other cardiac death 
Non-cardiac death 
Unknown death 
PTCA 
Mortality 
Non·smokers Smokers at time of surgery 
at time of all quitters persistent 
surgery smokers 
54 56 
26 29 
'4 13 
8 5 
17 19 
26 25 
9 10 
. !l 11 .~,-""~, ... ~ 
... 35... ... 33. 
46 
26 
14 
5 
18 
26 
12 
...... 9. 
4 
22 
23 
9 
I) 
In the univariable analysis (Table 3), the persistent smokers had higher risks of death 
from all causes (relative risk IRRJ 1.56, 95% confidence interval 1.24 to 1.97) and also 
from cardiac death (RR 1.70, 95% confidence interval 1.26 to 2.29) compared to the 
quitters. The smoking habit was the strongest predictor of mortality in a stepwise 
multivariate Cox analysis, even when all other baseline risk factors were forced into 
the model. The persistent smokers had a significantly greater risk of death from all 
causes (RR 1.68, 95% confidence interval 1.33 to 2.13) and of cardiac death (RR 1.75, 
95% confidence interval 1.30 to 2.37) compared to patients who quit smoking after 
CABG. 
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The estimated survival curves for the patients who quit smoking and those who 
continued to smoke diverged approximately 4 years after the index operation, and the 
difference between the two curves increased throughout the follow-up period 
(Figure 2). The estimated benefit in survival associated with the cessation of smoking 
increased from 3 percent at 5-year (98 vs. 95%). to 10% at 1O-years (88 vs. 78%) and 
15% at 15-year (70 VS_ 55%). After 2o-year the benefit was still 8% (47 VS. 39%). 
Table 3 UlIivariable mid adjusted relative risks of total mortality, cardiac deatli, repeat coronary bypass 
surgery or coronary angiopJasty_ 
srnokers persistent srnokers 
". ". 
non·smokers quitters 
Event RR 95% CI RR 95~ CI __ 
Deaths of all causes 
Unadjusted relative risks 1.04 0.88-1.22 1.56 1.24-1.97 
Adjusted relative risks • 1.18 0.99-1.40 1.68 1.33-2.13 
Cardiac death 
Unadjusted relative risks 1.05 0.85-1.30 1.70 L26-2.29 
Adjusted relative risks • I.Lj 0.91-1041 1.75 1.3°-2·37 
PTCA 
--U~~-~dj~;~-t~d ~~i~ti~~-' ~i-~k~ 0.78 0·55-1,12 1.50 0.89-2.5) 
Adjusted relative risks • 0.66 0.46 '0.97 1.56 0.88-2·79 
,R~peat C~~~_-. 
Unadjusted relative risks 1.00 0.79-1,27 1.)8 l.or-1.89 
Adjusted relative risks 0.82 0.64'1.04 1.42 1.01-1.97 
Repeat CABGIPTCA 
Unadjusted relative risks 0.91 0·74-1,13 1.42 1.05'1.90 
Adjusted relative risks • 0.76 0.61'0·95 J.41 1.02-1.94 
* A(ljusrfa for age:, se:x, )'(-5';e/ ai5fme. ejectio/I jramo/I, complere ril'OSfularizalion. 
Repeat procedure 
Repeat coronary bypass surgery was performed in 27% of the patients who quit 
smoking and 3I% of the persistent smokers. During [oHow-up, repeat coronary artery 
revascularisation (either CABG or PTCA) was performed more frequently among the 
persistent smokers compared to quitters (RR 1.42, 95% confidence interval LOS to 
1.90). An identical survival rate and a repeat coronalY artery revascularisation rate 
were found between the smokers and non-smokers at the time of surgery. Also, when 
adjusted for baseline characteristics, repeat CABG or PTCA was more frequently 
found among the persistent smokers compared to patients who quit smoking (RR 
1.41, 95% confidence interval 1.02 to 1.94). 
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Figrm; 2 Twenty-year survival Jrom all causes curves Jor patieflts who quit smoking after CABG, persistent 
smokers after CABG and non-smokers. 
100 l~:::=::~:-::::-
901 
80-] 
70i 
60 -I 
-i 
50 -j 
-I 
40 -1 
• 
)0 -1 
~ 
20~ 
Quiters 
Non smokers 
10 J p < 0.0001 
o ----r----r----r-----r--
o 5 10 lS 20 
at risk years 
'38 q!lilfers '08 ,65 '5 
3'8 persislort smokers '46 '7' 46 
409 11011 smokers 338 '50 49 
Figure 3 Twenty-year freedom from a corOllary reinterventioH (CABG or PTCA) Jor patients who quit 
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the rates were similar up to ten years, after which the curves for quitters and 
persistent smokers diverged. 
Discussion 
The present Shldy examined the influence of patient's smoking habits before and after 
coronary bypass surgery on mortality and repeat revascularisation procedures. The 
relatively high proportion of smokers at the time of surgery (56%) in our study group 
is due to the fact that our patients date from the 70S. Since health care programs in 
the 80S encouraged patients to stop smoking, the percentage of coronary patients who 
smoke, has steadily decreased to around 30% in the Netherlands. However. this figure 
still compares unfavourably to other West-European or North American countries. 'I 
TIlere has been much controversy about whether smokers should receive the same 
opporhmities for coronary bypass surgery as non-smokers.'6.17 Discussion on this 
subject was mainly based on the consistent finding that continued smoking after 
CABG increased clinical complications, such as myocardial infarction and repeat 
coronary revascularisation. Voors et al.", demonstrated that at one year after surgery 
smokers had more than tw'ice the risk for myocardial infarction and reoperation as 
compared to patients who had stopped smoking since surgery. Previous short- and 
medium- term shldies or studies on subpopulations have shown improved survival in 
patients whom stops smoking after myocardial infarction.41s-'2 A recent publication of 
the Mayo Clinic investigators7 showed an increased relative risk of 44% of death 
among the persistent smokers compared to quitters after percutaneous coronary 
revascularisation. However, to the best of our knowledge, the benefit of smoking 
cessation on the risk of death after coronary bypass surgery is still unknown. 
Survival 
In our study, after adjushnent for clinical and angiographic characteristics, the 
persistent smokers had a greater risk of death from all causes as compared to patients 
who stopped smoking after surgery during the very long follow-up of 20 years. 
Improved survival rates were seen fronl approximately 4 years after CABG. During 
that time the risk of death from any cause was 68% greater in patients who persisted 
in smoking after coronary bypass surgery than in those who quit. The estimated 
survival curves for the two groups diverged at 4 to 5 years after surgery and continued 
to diverge throughout the entire follow-up period. The benefit of smoking cessation 
on mortality may be explained largely, by the reduction in cardiac deaths, since the 
relative risk of cardiac death was 75% higher for the persistent smokers than for the 
quitters. Voors et al.", found a similar relative risk of mortality of 1.7. However, 
probably due to the limited number of patients, this risk was statistically not 
significant. 
Repeat procedure 
In agreement with the findings ofVoors et al ", we found that persistent smokers do 
need more repeat coronary revascularisation procedures than quitters do. In that 
study, patients who continued to smoke after surgery had a 41% higher risk of 
undergoing a repeat coronary bypass operation or a percutaneolls angioplasty 
39 
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procedure. In our Shldy coronary reintervention up to 10 years was rare after coronary 
bypass surgery. Thereafter this incidence increased, probably due to graft 
atherosclerosis and progression of native coronary artery disease. Nevertheless, the 
reintervention rates diverged; starting at 10 years postoperative, in favour of the 
quitters when compared to persistent smokers. 
Smoker's paradox 
Many investigations have demonstrated that srnoking is associated with higher rates 
of heart disease. It is therefore surprising that smoking habits at the time of surgery 
did not signifIcantly influence survival and reintervention rates during the follow-up 
period. In addition Hasdai et aU, reported that smokers had fewer adverse events at 
the time of a PTCA than non-smokers did. Other studies stich as the GUSTO·! 
investigators') have speculated on the paradoxical beneficial effects of smoking on 
thrombolytic therapy after myocardial infarction. In these studies the better prognosis 
for smokers was mainly explained by the difference in clinical baseline characteristics 
such as an age difference. After adjustment for all clinical baseline characteristics, 
these shldies showed no significant difference in mortality between smokers and non-
smokers. In our study, the similarity in risk of death and reintervention rate between 
the two groups can not completely be explained by these baseline parameters, as the 
smokers were only four years younger than non·smokers. Another explanation could 
be selection bias, since many smokers tend to die of fatal myocardial infarctions 
before they having the chance to undergo coronary bypass surgery:4 TIntS, those 
operated upon are different from the entire smokers cohort with coronary artery 
disease. Moreover, only patients who survived the immediate post· operative period 
were included in our study, which could have caused further selection. Another 
explanation may be that coronary bypass surgery facilities were scarce at the titne, 
causing long waiting lists. Only the survivors of the waiting time were operated upon. 
Finally, our data do not support the proposal that smokers should receive fewer 
opportunities for coronary bypass surgery than non-smokers, as the survival rate of 
non·smokers and smokers were similar at the time of surgery. 
The study consisted of patients who underwent coronary bypass surgery using vein 
grafts in the 70S. To extrapolate the findings of this shldy to current practice it needs 
to be realised that operation techniques have been changed and present day 
populations are different. Total arterial revascularisation is currently propagated to 
prevent premature death due to graft sclerosis. The present study has some 
shortcomings. We did not recorded the number of cigarettes smoked. Second, there 
may have been other factors intercorrelating with smoking behaviour that we did not 
record. For example, smoking cessation could be accompanied with other life style 
changes such as a diet. TI,e MRF!T study group has investigated that in 12,866 high 
risk men smoking cessation was the strongest predictor of lower rates of coronary 
disease as compared with other changes in risk factors sHch as cholesterol and blood 
pressure lowering interventions. z.\ However, the effect of risk factors such as diabetes 
and hypercholesterolaemia was not yet clearly established in the 70S. Only variables 
already known to influence survival at that time such as left ventricular function and 
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extent of vessel disease, were consistently reported and therefore used for further 
analysis. Smoking stahls was assessed by asking patients about their smoking 
behaviour and, if necessary, from the hospital records. This remains a possible cause 
of bias, as we were not able to check reported data against biochemical validation. 
However, self-reports of smoking in observational studies in an adult population such 
as this have a high sensitivity and specificity.'6 
Conclusions 
Our results strongly indicate that after coronary bypass surgery patients who do not 
stop smoking have a markedly elevated risk of premature death and a higher rate of 
repeat revascularisation procedures compared to those who do stop. Cessation of 
smoking is therefore strongly recommended after coronary bypass surgery and 
clinicians are encouraged to start or continue smoking-cessation programs>7 in order 
to help patients to stop smoking. 
4' 
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Summary 
Aims To establish to what extent smoking status and its management are recorded in 
coronary patients' medical records, and to investigate their motivation to change 
smoking behaviour. 
Me/lJods In EUROASPIRE, a survey on secondary prevention in 21 hospitals in the Czech 
Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, Slovenia and 
Spain, data were collected from records of 4,863 consecutive patients (70 years of age, 
with previous (> 6 months) admission for coronary bypass operation, angioplasty, 
myocardial infarction or ischaemia. Of these, 3,569 patients were interviewed 1.6 
years following their index hospitalisation. 
Re.m/ls Of the 82% patients whose pre-hospitalisation smoking behaviour was known, 34% 
were smokers. Documentation was significantly better in younger patients, in males 
and patients requiring angioplasty or bypass operation. In only 35% of 1364 smokers 
was the smoking habit recorded again after discharge from hospital. At the time of the 
interview, 554 of the intelviewed patients were still smoking. In over 90% of the 
smokers, advice to quit smoking was reported at interview. A positive relationship was 
found between receiving advice and seeking help to stop smoking, between receiving 
advice to stop smoking and attempting to stop, as we1l as between seeking help and 
attempting to stop. 
Conclusion In almost 20% of coronary patients, smoking habits are not documented in medical 
records, and in only 35% of the smoking patients is smoking stahlS documented at the 
follow-up. After a cardiac event requiring hospitalisation, as many as 50% of the 
patients continue their smoking habit and so there is further potential to reduce the 
risk of recurrent coronary disease. Advice to stop smoking motivates patients to seek 
help and to attempt to stop smoking. Physicians repeated advice to stop smoking is 
important and smoking stahts should always be documented at follow-up. 
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Introduction 
In recent decades, a large number of epidemiological studies demonstrated a 
relationship between cigarette smoking and the occurrence of cardiovascular 
diseases. !,':> A high incidence of cardiovascular disease is reported in smokers 
compared to non-smokers, and hence a higher rate of cardiovascular deaths in 
smokers. In the extensive British doctors shldy, the observed cardiac mortality in a 40-
year follow-up among smokers under 65 was more than twice that of non-smokers.} 
TIlerefore, the effect of smoking cessation was also investigated. In a shldy of 2336 
healthy smoking young men, the rate of a myocardial infarction among those who 
stopped smoking at some time during 18 years of follow-up was only half the rate of 
those who continued.~ 
TIle favourable effect of smoking cessation on the prognosis of patients with 
established coronary artery disease, especially after myocardial infarction,s but also 
coronary bypass operation,6 has been well established. Stopping smoking after a 
coronary event significantly diminishes the probability of death and myocardial 
infarction7; besides this, lower hospitalisation rates were observed.s Furthermore, 
smoking cessation is by far the most effective and cost-effective way to reduce the risk 
of cardiac complications.9 
In 1994, the recommendations on prevention of coronary heart disease of the 
European Society of Cardiology, the European Atherosclerosis Society and the 
\ European Society of Hypertension were published.''' As part of the strategy to enable 
the adoption, dissemination and implementation of these recommendations, a 
European survey on the evaluation of current secondary prevention practice was 
started (EUROpean Action on Secondary Prevention through Intervention to Reduce 
Events; EUROASPIRE). The primary aim was to determine to what extent major risk 
factors for coronary heart disease and their management are recorded in the files of 
coronary patients. A second objective was to describe patients' lifestyle at least 6 
months after hospitalisation for a coronary event." In the Guidelines on acute 
myocardial infarction, smoking cessation is described as potentially the most effective 
of all secondary prevention meaSUres and therefore much effort should be devoted to 
this end. Support and advice is needed during rehabilitation and a smoking cessation 
protocol should be adopted in each hospital." EUROASPIRE made an inventory of the 
registration and management of smoking behaviour in coronary patients in several 
hospitals across Europe and the change in lifestyle after hospitalisation for a coronary 
event. 
Methods 
The furoaspire survey 
Between May 1995 and April 1996, twenty-one selected hospitals from nine regions 
in the Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, 
Slovenia and Spain participated in this survey. 4,863 consecutive patients ($ 70 year) 
were enrolled following hospitalisation for either a first coronary bypass operation, a 
first angioplasty, a first myocardial infarction or an episode of acute myocardial 
ischaemia: the so-called index event. Demographic data, information about risk 
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factors, treatment and prescribed medication were collected from the medical records 
over the period before, as well as after, the index event. 3,569 patients were 
interviewed (73% response), on average 1.6 years after the event. Information was 
obtained about life style, and about advice received concerning the coronary risk 
factors; besides this, measurements of blood pressure, height and weight, cholesterol, 
glucose and carbonmonoxide were performed. A detailed description of the 
EUROASPIRE survey has been published." 
Present study 
TI,e present study is based on data from the EUROASPIRE survey. Data which were 
collected from the medical records were used to describe the cardiologists' policy with 
regard to registration, and management of patients' smoking behaviour. Data from 
the interview were used to describe patients' smoking behaviour after the index event, 
as well as actions taken to change to a healthier lifestyle. Self·reported smoking habits 
were compared with the measured expired carbonmonoxide, with the threshold set at 
10 particles per millilitre. Other coronary risk factors were also evaluated. Patients 
were categorised according to their smoking status at the time of the hospitalisation 
Figure 1 Overview oj all 4,863 participatitlg patients. 
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and at the interview. Current smokers are those who were smoking at the time of 
recording or interview, respectively. Non-smokers were divided into ex-smokers 
(those who had smoked sometime before the recording or interview) and never 
smokers. 
Statistics 
Univariate comparisons of differences in baseline and outcome variables between the 
groups were done by a Chi-square analysis for categorical variables and a Kruskal-
Wallis test for ordinal variables. Multivariate analyses of the effects of all demographic 
variables were done by multiple logistic analysis. Differences were considered 
statistically significant if the P-value was less than 0.05. 
Results 
Quality of documentation of smoking behaviour 
Pre·event 
Smoking status (current smoking or non-smoking) was documented before the index 
event in 3,967 (82%) of all +863 patients (Figure I). Pre-event smoking 
documentation was significantly more frequent (P < 0.001) in younger patients «50 
years: 85%; 50-60 years: 84% and 60'70 years: 79%, Table I). In addition, smoking 
documentation was more common in males (85% vs. females 73%) and in those 
enrolled for bypass surgery or angioplasty (87% and 84% respectively vs. 78% for both 
myocardial infarction and ischaemia). 1,364 (34%) patients of those, whose pre-
hospitalisation smoking stahts was recorded, were smokers and 2,603 (66%) non-
smokers. In 442 (17%) of the recorded non-smokers, no past history of smoking (ex-
smoking or never smoking) was recorded. Prevalence of other coronary risk factors 
was less frequently recorded in the medical records than smoking behaviour: 
hypertension in 78% of the cases, diaJ:>etes in 75%, hyperlipidaemia in 59%, and 
family history of coronary heart disease in 69%. In records without information about 
smoking stahlS, all coronary risk factors were entered significantly less frequently 
than in records in which smoking stahlS was recorded. 
Post-event 
Smoking behaviour after the event, in pre-event recorded smokers, was documented 
in 472 (35%) patients, on average 1.2 years (median 1.0 year, interquartile range 0.7 to 
1.6) after the index event. Almost half of the patients (221) were still smoking. In 57% 
of the post-event smokers, some action of the cardiologist, to change patients' 
behaviour, was recorded. In 48%, simple oral advice was given to stop smoking. in 
9% some form of counselling was encouraged. 
Smoking behaviour as assessed during the interview 
Current srnokers 
At the time of the interview, on an average 1.6 years post-event, 554 (16%) of the 3,569 
interviewed patients were self-reported current smokers (Table 2). 1,294 patients 
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(of whom 281 had died) did not attend the interview. Compared to patients who did 
attend the interview, those who were not interviewed were more likely to be women 
(p < o,OS), more likely to belong to the acute ischaemia and myocardial infarction 
group, less often had a history of coronary artery disease and were more often pre-
event smokers (p < o,oor). 
Table. 1 Pre-event recording oj smokiflg status and smokil1g belwviollr witliin different categories. 
n Re<:orded Smoking Non-smoking 
snl0king Ex Never Unknown 
status 
All 11= 4,86) ).967 1,)64 1-,_1_?~,,_ ,2.60,., __ _____ i'F _ 
(82%) (34%) (54%) (29%) (17%) 
~g_e 
< 50 yr. 1,007 85% 55% 28% 10% 7% 
50 -60 yr. 1,56) 84% 36% 34% 20% 10% 
> 60 yr. 2,293 79% 23% 40% 23% 14% 
Gender 
Male 3,66; --85% --38-% 41% 13% 8% 
Female 1,201 73% 23% 17% 39% 21% 
Country 
C'~~~f~"'R~p~;b-iic 526 . -85% 33% 40% 20% 6% 
Finland 5)1 84% 21% 39% 31% 9% 
France 546 84% 42% 36% 18% 4% 
Gcmlany 52 4 84% 37% 30% 27% 6% 
Hungary 546 66% 43% 20% 22% 15% 
Italy 619 92% )2% 38% 28% 2% 
the Netherlands 5J5 68% 41% 24% 4% 31% 
Slovenia 526 74% 29% 37% 20% 14% 
Spain 510 97% 33% 46 % 0% 20% 
Index event 
CABG 1,179 87% 24% 46% 19% 12% 
PTCA 1,156 84% 30% 43% 17% 10% 
AMI 1,)87 78% 50% 24% 18% 8% 
Ischaemia 1,141 78% 33% 28% 23% 16% 
Hx of CAD 
No 1,547 81% 22% 19% 8% 
Yes ),286 82% 27% 42% 19% 12% 
ullimriate chi-square test 
* P < o.oos 
t p < 0.001 
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There was good agreement (K'-value 0.7) between self.reported smoking habits and 
breath carbon monoxide measurements. In fewer than 5% of the patients who said 
they were not smoking, the breath carbonmonoxide value exceeded 10 particles per 
millilitre. 
Of the 946 pre-event smokers, 378 (40%) were still smoking at the time of the 
interview (Table 3). In eight patients, information about smoking stahlS was missing. 
TIle pre-event smoking stahlS was not recorded in 76 out of the remaining 176 
Table 2 Characteristics of the patiel1ts who did attelld tile interview according to smoking behaviour at 
interview. 
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interviewed smoking patients, while 100 patients were recorded as being non-
smokers. A large majority (512) of the 554 smoking patients at the time of the 
interview smoked cigarettes. The average number of cigarettes smoked per day was 10 
Table J Differences in characteristics between pre-event smokers who stopped sll10killg after the iudex 
event mid those who persisted to smoke. 
Age 
< 50 yr. 
50 -60 yr. 
> 60 yr. 
Gender 
-Malc' 
Female 
Countryt.1 
Czech 'R'epliblic 
Finland 
France 
Gennany 
Hungary 
Italy 
The Netherlands 
Slovenia 
Spain 
Index event t .1 
CABe 
PTCA 
AMI 
Ischaemia 
Hx ofCAOt.i 
No 
Yo, 
Advice offered! 
No 
Ye, 
When offered t 
'---B-e"fore event 
In hospital 
After event 
5' 
Persisted 
n = 378 
-- -4-4%-'-
41% 
36% 
Stopped 
560 
-56%---
59% 
64% 
---41%'~-" --~-'-59% 
38% 62% 
)4% 66%----
54% 46% 
39% 61% 
30 % 70 % 
51% 49% 
45% 55% 
62% 38% 
29% 71% 
22% 78% 
-------'j7Ajr~' .. · '''-''--63%-
43% 57% 
31% 69% 
57% 43% 
----A-~j4%~ -66%-~--"" 
46% 54% 
'is-%--- '"-82%'--
44% 56% 
"49% ' 5'1%-
35% 65% 
61% 39% 
"* Multivariate P-mlue < 0_05 
r Unil'arirlte P-mllle < 0.001 
§ M[I/timriate P-I'a/lIc < 0.001 
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Tnh1e J - continued· 
Persisted Stopped 
n = 37~ 560 
"~ __ £!'J? ~o,U,f;tI_l.t,t 
No 
Yes 
,Atte,'!1pt ,!?_,~t?J?_~~ ______ 
No 
Yes 
Howt 
Abstinence 
Reduction 
Nicotine substihttioll 
Other 
f Univariate P·mllle 
37% 
59% 
90% 
36% 
23% 
78% 
68% 
56% 
63% 
41% 
10% 
64% 
77% 
22% 
32% 
44% 
(interquartile range 5 to 20). In a multivariate analysis, patients who underwent 
angioplasty or were admitted for acute ischaemia, and those with a history of coronary 
artery disease were least likely to stop smoking. Smoking cessation figures differed 
widely between the countries (Table 3). In patients who persisted in smoking, advice 
to stop smoking was recorded more frequently, mainly before the index event. More 
than 80% of the persistent smokers had made an attempt to stop smoking: one third 
tried reduction and 20% used additional help such as nicotine substitution. In the 
patients who stopped smoking, almost 90% totany abstained frOlll srnoking 
immediately. 
Of the total of 554 patients who were smoking at the time of the interview, 512 patients 
reported that they had received advice to stop smoking (92%). In 64% of the patients 
- mainly those who underwent an intervention - the advice was given before the index 
event, and in only 31% patients - mainly those who had an acute ischaemic syndrome -
during hospitalisation. The advice was given to 70% of the patients by the hospital 
doctor, and by the general practitioner to 50%. No significant differences in 
characteristics were found in patients who received advice to stop smoking and those 
who did not. II4 patients (21%) had sought help to stop smoking, mostly before the 
event (69%). Help was asked mainly from the hospital doctor and the general 
practitioner (30% and 47% respectively). A positive relationship was found between 
receiving advice and seeking help to stop smoking (p < 0.001). 
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457 patients (83%) had attempted to stop smoking in the past: 45% of these tried to 
abstain, 35% tried to reduce and 16% used nicotine substitution. A positive 
relationship was found between receiving advice, seeking help (p < 0.001), and 
attempting to stop smoking (p < 0.001). 
Current non-smokers 
Of the 3,015 patients who stated at the interview they were non-smokers, 2,056 (68%) 
had been smokers at some time before the interview; thus, 2,610 (73%) of the 
interviewed patients had a positive smoking history. Patients, who had smoked in the 
past, had the same characteristics as current smokers, TIle median length of time 
since they had stopped smoking was 48 months (interquartile range 21 to 180). 
The other major coronary risk factors (hypertension, diabetes and family history of 
coronary artery disease) had a higher prevalence in never smokers than in smokers, 
but hyperlipidaemia, known as adversely affected by smoking, was mostly seen in 
smokers (Table 4). Ex-smokers had an intermediate prevalence of risk factors. 
Table 4 Prevalence of other coronary risk factors in ifltervicwed patients (%). 
54 
All patients 
n = l,~69 (%) 
Hypertension' 
Hyperlipidaemia t 
Obesity! 
diabetes 
family history of CAD 
1.892 
1,212 
900 
641 
1,812 
53 
34 
25 
18 
51 
* SBP;" '40 mmHg or DBP;" 90 IIImHg 
t total c1lOksterof ~ 5-5 11111101/1 
f BMI;"Jokglm, 
Discussion 
smoker ex·smoker never smoker 
554 2,0,56 959 
49 51 59 
50 42 45 
24 25 26 
14 18 21 
50 51 56 
Registration of smoking status, as assessed in this survey, is far from optimal. For 
896 patients (18%), no entry could be found in the medical record, on smoking 
behaviour at any time before the index event; in 442 of the non-smokers (17%) no 
information on a history of smoking was recorded. According to the 
recommendations on prevention of coronary heart disease of the European Society of 
Cardiology'} and the Guidelines on acute myocardial infarction," much effort should 
be devoted to smoking cessation. Support and advice is needed during cardiac 
rehabilitation and a smoking cessation protocol should be adopted in every hospital. 
To assess a patient's risk, information about current smoking and a history of 
smoking should be entered in every medical record. In addition, to evaluate fUhtre 
risk factors, recording of past smoking is important, in case of a relapse. Even so, the 
percentage of registration of smoking is higher than any other monitored coronary 
risk factors. Registrations of risk factors in other studies were similar: 89% in 258 
medical records of patients who underwent a bypass operation and 90% in II2 
patients admitted for acute chest pain syndromes.'4.', 
(b]fl!<'I .; . Registration and malJOgement of smoking behaviour in corollary patients 
In both studies, registration of smoking had the highest prevalence of all coronary risk 
factors. The actual attention paid to smoking behaviour may have been higher, 
because the topic, although raised during the consultation, may not have been 
recorded. This is to be expected, in non-smokers in particular. The number of ex-
smokers at the interview confirms this assumption. TIlis exceeds the number of pre-
event ex-smokers plus the quitters at interview. About 155 of the 442 non-smokers, 
whose pre·event smoking history was unknown, were ex-smokers, so the majority had 
never smoked. TIlOse undergoing coronary intervention were more frequently asked 
about their srnoking behaviour than those admitted for acute ischaemia or myocardial 
infarction, while those who underwent an acute isdlaemic syndrome smoked more. 
Presumably, patients with the highest risk of coronary complications and the highest 
expected gain from smoking cessation are more likely to be asked about their smoking 
habits; they may also have had a longer medical contact. Post-event registration of 
smoking stahls was present in only 35% of all pre·event smokers. Consequently, in 
65% of the smokers the unhealthy behaviour has been ignored. It is most probable 
that these patients have not changed their behaviour, and therefore this 'no change' is 
not recorded, which means that the patient is still smoking. It is also possible that the 
subject of smoking has not been raised again. 
Smoking behaviour 
Of all patients whose smoking status was known from the records or interview, 3293 
had smoked at some time. At the time of the interview, 560 (59%) of the 946 pre· 
event smokers had stopped smoking, which is very encouraging. Apparently, a 
coronary event together with the knowledge of the risk of smoking encourages over 
half of the patients to give up smoking, which is in agreement with other reported 
data.57 Since these patients less often received advice to stop smoking and looked for 
help, they were probably very determined to stop. 111erefore, time and efTort should 
be targeted at the 41% less motivated patients, who need more attention and support 
to stop smoking. Furthermore, relapse should always be taken into account and 
tllerefore continued documentation of smoking stahts at follow-up is important. 
As far as advice for smoking cessation is concerned, some action was recorded in 57% 
of the smoking patients. It is likely that more patients received advice to stop smoking, 
but the cardiologist did not consider it necessary to record this in the patient's notes. 
TIle result at interview, that 92% of tlle current smokers had received advice to stop 
smoking, confirms tllis. According to the recommendations of the Task Force on 
prevention in coronary heart disease, a physician's firm advice to stop smoking is of 
crucial importance to start the smoking cessation process, particularly at the time of 
diagnosis of coronary artery disease. Referral to a specialised smoking cessation 
intervention is very low (9%). Since offering help to stop smoking is time· consuming, 
referral to a special cessation program offered by, for example, a nurse or health 
counsellor could be efficient,,6 but it is still very important for the cardiologist to give 
repeated advice about the importance of stopping smoking. 
TIlere were striking differences among the various countries for pre-event recording 
of smoking behaviour, with Spain (97%) and the Hungary (66%) at the extremes. 
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Fig!lr.; 2 Recommelldatiolls for actions to be taken for smoking patients. 
First Visit Askfor smoking status 
LI "ne",v",e,-r ",sm=ok",e",d,--,f----..-I no action 
I stopped smoking f----..-I ask when stopped f---.-I follow-up (relapse) 
current I smokin I give information 
I check motivation 
give advice to stop 
+ consider 
additional support 
follow-up 
Follow~up Ask again for smoking status 
ex smokers 
recent smokin 
check for possible 
relapse 
give advice to stop 
+ consider 
additional support 
written information 
nicotine substitution 
nicotine substitution 
referral to counselin 
Since only between one to three hospitals were included per country, differences 
between the various countries should be carefully interpreted. Differences may be 
attributed to different policies in the various hospitals, rather than countries_ 
Dissimilarities beh\'een hospitals in these countries could be ascribed to differences 
in professional behaviour, professional society or national guidelines, government 
policy and cultural and economic differences. 
Study {imitations 
Since only few hospitals per counhy were included, conclusions could not be 
extrapolated to the countries as a whole_ Of the 4,863 patients included, 3,569 
attended the interview_ As shown in the results, patients not attending the interview 
CI)(l!!!~' -1 . RegislfOlion and management ofsmokillg behaviour ill (oronrJry pafienlS 
had different characteristics. They were nlOre likely to be female, to have been 
hospitalised for an acute myocardial infarction or ischaemia, and to have no past 
history of coronary heart disease. More pre-event smokers did not attend the 
interview. Patients were enrolled at least 6 months after the index event. Pre-event 
information obtained from the medical record is more reliable for patients who 
underwent an intervention, since in patients admitted with a myocardial infarction or 
an acute ischaemic episode, less pre-event information will be available. Results 
concerning the attempt to stop were not dated, so no relationship to the coronary 
event can be given. 
Conclusion and perspective 
An attentive attitude by the cardi9logist with regard to smoking behaviour and 
intensive support to quit smoking is recommended (Figure 2). Although recording in 
the medical notes was good, improvement is still desirable, particularly in relation to 
post-event recording of smoking habit. The importance of raising the subject of 
smoking should be reflected in the need to record this infonnation. Patients who are 
known to be smoking should be followed and repeatedly reminded and motivated, 
othenvise, they could mistakenly draw the conclusion that the need to change 
behaviour is no longer recommended. Attempts to quit smoking immediately are 
more likely to succeed than a gradual decrease in the number of cigarettes, thus 
patients should be encouraged to stop completely. In 3-5% of the patients, insistent 
motivation by the specialist or general practitioner can help the patient to change his 
lifestyle. CJ Smoking intervention programs, in addition to physician advice, can 
improve these results with 70% quitting smoking as a result of an intervention group 
vs. 53% in a normal care group's and 62% quitting smoking in an intervention group 
vs. 51% in a cessation advice only group.'" Although, for some patients, the physician's 
advice to stop smoking is in itself sufficiently effective, more support should be 
offered to other patients. Smoking cessation interventions conducted by, for example, 
a nurse, offer an effective and cost-effective tool for coronary patients during 
hospitalisation as well as for ambulatory patients. 
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Summary 
Aims Prognosis of patients with established coronary artery improves if smoking is stopped. 
Still, about half of patients who suffer a myocardial infarction continue smoking after 
that event. In order to predict to whom additional support should be offered, various 
baseline characteristics were compared with smoking stahls at short-term and long-
term follow-up. 
Methods Demographics, medical history, presence of coronary risk factors, psychological 
determinants and the clinical course were recorded in a group of 530 unselected 
consecutive patients who had been admitted with a myocardial infarction and were 
smoking. Patients who were smoking at admission, and who were alive at 4 year 
follow-up, were shldied to relate smoking stahls and baseline characteristics. 
R<,slI/ts At 3 months, persistent smokers were younger than quitters, were shorter adtnitted to 
the hospital, undenvent less often revascularisation procedures, smoked more 
cigarettes per day at baseline and were more socially isolated. After 4 years, patients 
who stopped smoking had a larger myocardial infarction and a lower displeasure-
score than those who continued smoking. Also, quitters received more support from 
their social environment. 
Conc/rlsiOII Although the majority of the patients try to stop smoking after a myocardial 
infarction, about half smokes after 4 years. In the fuhtre, special support should be 
offered to smokers who undenvent a myocardial infarction, especially to those whose 
psychosocial profile are less favorable. 
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Introduction 
Many epidemiological studies have shown an increased risk of coronary artery disease 
among smokers.'" Furthermore, prognosis of patients with established coronary 
artelY disease is impaired if smoking is continued, and improves if smoking is 
stopped. Patients who continue smoking after a myocardial infarction have a 35% 
increased risk of re-infarction or death within the first decade compared to those who 
refrain from this hazardous behavior {25% vs. I7%).3 
Hospitalization and the diagnosis of coronary heart disease are predictors of smoking 
cessation in a general population.4 Indeed, about half the patients who suffer a 
myocardial infarction, stop smoking after that event. The o.ther half who continue 
smoking should be offered more support to stop their habit. In order to offer effective 
support to those who continue smoking after a coronary event, insight into factors 
which predict smoking cessation or continuation is needed. The objective of this study 
was, to compare demographic, clinical and psychological characteristics of smokers to 
non-smokers in I,472 consecutive patients who were admitted with a myocardial 
infarction. Predictors of smoking cessation by coronary patients are summarised in 
Table 1. In previous publications, focus was often limited to either demographic, 
clinical or psychosocial determinants in a relatively small number of patients. The 
present study examines all these aspects in combination. Moreover, in the majority of 
fonner studies follow-up was limited to one year whereas in this study patients were 
followed for 4 years. Differences behveen patients who stopped smoking at short-tenn 
and long-term foHow-up, and those who continued smoking were shtdied. Finally, 
determinants of continued smoking cessation were investigated in relation to relapse 
after short-term quitting. 
Methods 
A group of I>472 unselected consecutive patients who had been admitted with a 
myocardial infarction between May I993 and October I995 to four different hospitals 
in Rotterdam, the Netherlands, was shtdied.$ Demographics, medical history, 
presence of coronary risk factors, and the clinical course of all patients were recorded. 
At hospital day 5, the Heart Patients Psychological Questionnaire (HPPQ) was 
presented to most patients, measuring wellbeing (score 12-36), feeling of being 
disabled (score 12-36), displeasure (score 10-3°) and social isolation (score 6-18).' At 3 
months follow-up, data on complications, such as re-hospitalization and coronary 
intervention. smoking and medication were collected from the medical records. 
For the present shldy. a 4 year follow-up of survival was performed by inquiries at the 
register offices for all I472 patients. Patients who were smoking at admission or had 
smoked during the year before the hospitalization and who were alive at follow-up, 
were asked by mail to complete a postal survey. Those who did not respond were sent 
a reminder. The postal survey consisted of several psychological questionnaires, 
measuring anxiety. depression, fatigue, vigor, tension, anger, somatisation of 
neurotic complaints and vital exhaustion. (Appendix: I) Furthermore, questions about 
attihlde, social influences and self-efficacy (ASE modelF regarding smoking cessation 
were asked. Grade of nicotine addiction was measured by the Fagerstrom 
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Questionnaire (range 0 to IO):~ Finally, cardiac events which had occurred after 
hospitalization were collected. 
In order to predict which smokers will or will not stop of their own accord after being 
admitted for a myocardial infarction, and to whom additional support should be 
offered, various baseline characteristics were compared with smoking status at short-
term and long-term follow-up. Comparisons of differences in baseline and outcome 
variables between the groups were performed by a Chi-square analysis for nominal 
variables, a Mann \Vhitney test for ordinal variables and a T-test for continuous 
variables. An analysis of variance for repeated measures was used for the mean 
number of smoked cigarettes_ Multivariable analysis on survival was performed by 
Cox regression analysis, and on smoking cessation by logistic regression analyses 
including independent variables which appeared to be significant in univariable 
analyses. Differences were considered statistically significant at the 0.05 probability. 
Results 
Figure I shows the smoking habits of all 530 (36%) baseline smokers with regard to 
survival and smoking behavior. Of the 530 baseline smokers, 107 smokers had died 
and 10 patients could not be traced, on average 3.8 years after the myocardial 
infarction. The remaining 413 smokers were invited to participate in the study, to 
which 77 (r8%) patients did not respond. Of the 336 responders. 59 (r8%) patients did 
Figure; 1 Smoking habits at s/lOrt-tenn aud long-term follow-up 
3 months 
rn lost 
rn 
4 years 
., 
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baseline 
smoker 
~ lost 
rn died 
total 
Table 1 
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not want to participate_ Reasons for not participating were: not motivated (n = 36), 
language problem (n ~ r), otherwise (n ~ 5) and no reason given (n ~ 17). 277 Patients 
were willing to participate and were sent a questionnaire. Fifty-one patients were sent 
a reminder. 260 (63%) of the potential 4I3 patients returned the questionnaire, and 
6r patients reported their smoking stahlS via the returned Jetter. 
Characteristics of bas eli lie smokers CHId non-smokers (f1=lJ472) 
(Percentages given unless othenvise specified) 
smokers non-smokers p 
n~ SJo ,fH_~ __ ,_ 
Sodo.demographic 
Male 79 < 0.0001 
Mean age (years) 59 69 < 0_0001 
Partner 78 72 0.045 
Occupational state (working) 48 28 < 0.0001 
~ ed ic~ _1_~!.~_t5~,ry, __ 
No coronary history 74 69 0_02 
AP < 4 weeks 8 6 I1S 
AP> 4 weeks '4 '5 I1S 
AMI 24 28 0.052 
CABG 5 5 I1S 
PTCA 5 5 I1S 
hypercllolesterolaemia 24 '5 < 0.0001 
hypertension 25 27 I1S 
diabetes 8 ,6 < 0.0001 
Body mass index (kg/H12) 26 26 I1S 
Other illnesses 2) 2) I1S 
Physical active 57 )7 < 0.0001 
Medication (%) 
Acetylsalic}'/acid u 
'4 lIS 
ACE-inllibitors 5 9 0.009 
Beta-b/ockers 
" 
'3 liS 
Cllo/esterollowering 4 3 liS 
_t'_~~p!~~1 stay 
CPK maximum (CPK-MB) 1422 (1I2) 992 (82) < 0.0001 
Thrombolytics 5' 34 < 0.0001 
Intervention 27 20 0.006 
Duration (days) <2 n 0.02 5 
~~y,~~(~logy 
Well being 2) 2) ns 
Feeling of being disabled 24 24 ns 
Displeasure 16 
'5 ns 
Social isolation H n ns 
AMI = (l(H/e. mpxardia/ i/lfarctioll; CABG". (OlOlI(lry artery bypass graft; 
PTCA = pUCH/alUOIIS tralls/rmlil1(l/ foro/wry allgioplasty 
* AllY iIIlle-55 IIImtjolled b}' tlu patiwt or uportfd ill/Ire medical raord 
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Comparison of baseline smokers and non-smokers 
At the moment of admission, the average age of smokers was ten years under that of 
non-smokers (table I): 59 vs. 69 years respectively (p < 0.001). Smokers were more 
often male (79% vs. 63%), had more often a high cholesterol level (> 5.5 mmollI; 24% 
vs. 14%), had less often diabetes (8% vs. 15%) and were more often physically active 
(59% vs. 37; all P<O.OOOI) than non-smokers. Of the 530 smokers, 20% had died after 
4 years, as opposed to 40% (375) of the 942 non-smokers (survival smoking RR 2.2, 
95% confidence interval 1.8 to 2.8). 
After multivariate adjushnent for differences in baseline characteristics, smoking 
appeared not to be an independent determinant for mortality (age-adjusted survival 
RR 1.1, 95% confidence interval 1.0 to 1.5), while age (RR LI), peak CPK (RR 1.0), 
physical activity (RR 1.3), previous myocardial infarction (RR 0.7) and co· morbidity 
(RR 0.7) were all independently significant. 
During hospitalization, smokers suffered a larger myocardial infarction, received 
more often thrombolytic therapy, and underwent more coronary revascularisations; 
moreover they were admitted for a longer period. Psychological profile was similar for 
smokers and non-smokers. 
smoking behaviour after 3 months 
At short term follow-up, on average III days after admission, 14% (103) of the 764 
patients whose smoking stahlS was known were smokers. Of 399 baseline smokers, 
smoking stahlS was traced (30 had died, 101 unknown). Seventy-one percent (282) of 
the baseline smokers had quit smoking. while 8 of the non-smokers had started 
smoking. Persistent smokers were younger than quitters, were in hospital for a 
shorter period, underwent revascularization procedures less often, smoked more 
cigarettes per day at baseline and were more socially isolated (Table 2). Logistic 
regression showed social isolation as a significant independent predictor for short-
term smoking cessation (RR 1.1, 95% confidence interval 1.0 to 1.2). 
Smoking behaviour after 4 years 
At 4 year follow-up, 321 of the 423 surviving baseline smokers had reported their 
smoking stahlS, either by completing the questionnaire (n = 260) or by filling in their 
smoking behavior on the returned letter (n ~ 61); 52% (168) was still smoking. 
(Table 3) Of tllC patients who stopped smoking, a quarter had stopped on the day of 
admission, one third in the month preceding or following admission, one tenth 
before and a quarter after that period. 
Patients who stopped smoking had a larger myocardial infarction (CPK-Ievels 1524 vs. 
1,178; RR 1.0, 95% confidence interval 0.9 to 1.0), and the displeasure-scale of the 
HPPQ was higher in those who continued smoking (17 vs. 15; RR 1.1, 95% confidence 
interval 1.0 to 1.1)_ Both variables were independent predictors for long-term smoking 
cessation. 
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Table 2 Baseline cilaracteristics according to smokiflg status at 511011 ten1l !olfolV-up. 
died quitters smokers unknown P* 
n= ~c:l: 282 . HZ , . 101 
. 1?!:!r_~_~_i~,t.1_~(roU~VJ~up ,(days) J2 IIO . I~5. ns 
~.oci.o_~~,e_!t1,ograp~.iE __ ~_._ 
Male 83 78 76 11S 
Mean age (years) 68 59 56 59 0.042 
Pamler 72 80 76 88 11S 
OCCIIP,~ !i.?!l_~! __ s.!a,te J~v.or_killg) 33 5,1 49 .44. 11S 
.~_~~iE~_!,~ !_~~o_ry_, ," 
No coronary history 40 79 76 70 43 
AP < 4 weeks 10 9 10 5 11S 
AP > 4 weeks 20 12 '5 '7 11S 
AMI 60 20 21 21 11S 
CABG 17 5 4 3 11S 
PTCA 7 3 2 8 11S 
hypercholesterolaemia 30 '7 22 34 0.071 
hypertension 33 25 21 27 11S 
diabetes 
'3 9 6 8 ns 
Body mass index (kg/nt') 25 26 26 25 11S 
Other illnesses 43 18 22 24 11S 
Physical active 63 52 56 66 11S 
Medication (%) 
Acetyls(lliC)'lacid 2) 12 '4 12 liS 
ACE-iullibitors 7 ) 10 6 0_077 
Beta-blockers I) 12 10 12 liS 
Ciiolesterol1olVcrillg 7 ) ) 8 liS 
~,osp~t.a_l_ ~~,ay 
CPKmaximum (CPK-MB) 2,112 (S4) 1,468 (86) 1,234 (70) 1,3'6(76) ns (os) 
Thrombolysis 50 54 48 47 11S 
Intervention 23 29 18 32 0.025 
Duration (days) 
'5 12 10 II 0,01 
~,Ill_o~.in8, 
# cigarettes per day 21 18 25 16 <0.001 
~~y_c_~_~!~,gy 
Well being 24 24 23 21 11S 
Feeling of being disabled 27 24 24 24 11S 
Displeasure 15 16 '7 17 11S 
Social isolation II II 12 10 0.022 
AMI = awle 1U}'omrdial infarf/ioll; CABG = (oroIHn), ar1ery b}1ms5 graft; 
PTCA "" pm:rllaU(OIIS lralis/rrmilHll coronary angiopillsty 
* Tesled btlw{(/1 qrlil/ers and smokers, p'l'(l/rres < a.Jare sllOlIm. 
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Table 3 Baselillc cl1aracteristics according to smoking status at long term follow·up. 
died quitters smokers unknown P* 
n" ,~,!7 ' .. 1~1 168 102 
,[)u rati_()_rl_ ,()f .f()_!!()~_:,,~ ~,,~, ~ ""I_.}, )·9 )·9 )'9. fiS 
~1:)~.i~:~~.~_~,~!.~P~l.~ __ 
Male 77 84 82 0.074 
Mean age ()'ears) 67 58 57 55 us 
Partner 6 84 80 75 us 
Occupational state (working) 29 50 5' 60 us 
.~_~~i~a,I",h,is_tory 
No coronary history 59 8) 77 74 ns 
AP < 4 weeks 12 7 8 5 lIS 
AP > 4 weeks 12 16 
'4 '4 lIS 
AMI 40 '4 21 24 us 
CABG II ) 9 us 
PTCA 6 4 ) us 
hypercholesterolaemia 25 21 27 21 US 
hypertension )2 26 22 22 US 
diabetes 10 7 5 I) lIS 
Body mass index (kg/m') 25 26 26 26 lIS 
Other illnesses 4' '4 2) 'S 0.059 
Physical acti\'e 62 57 59 5' us 
Medication (%) 
Acetylsalicyladd 
'9 II 12 8 us 
ACE-inhibitors 6 5 4 5 lIS 
Beta·blockers I) 10 II I) US 
Cholesterollowerillg ) 4 7 lIS 
,~o~pi,tal,st,a)' 
CPK maximum (CPK-MBj (8,) 1.524 (91) 1,178 (68) 1,4)0 (8.) 0.026 (ns) 
Throlllbolytics 46 56 5' 49 fiS 
Intervention 25 29 24 28 us 
Duration (days) '4 II II II ns 
~mC?,ki,ng 
# cigarettes per day IS '9 20 24 us 
~_~r~!~()!_?ro', 
Well being 2) 25 2) 2I 0.070 
Feeling of being disabled 26 2) 24 24 us 
Displeasure 16 
'S '7 '7 0.016 
Social isolation II II II 10 ns 
AMI = acule lII}w-ardial infarction; CABG = coroHary artery bYPllss graft; 
PTCA = percutmJe(Ju5 tWJJSlumiJl(lI corollary IlllgioplllSly 
* reslnl belwull quilters Gml slIIokers 
68 
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Table 4 Cliaracteristics at follow-up quitters and persistent smokers (fl=26o)_ 
quitters smokers p 
.. ,.,' ~.~ ~,,-,~,.-
n· 
,,,,
12l, _-'H .. 
p_~_~,!~ __ i.~,:! _<?ff~!!~x~:~J~ (y_~_~_r~) .1.0 ~tCl __ IlS 
~_'!1_~~}_r1g N_~_t()_ry 
# cigarettes at baseline 19 IJ < 0.001 
# years 44 4J IlS 
Previous attempt to quit (%) 41 70 < 0.001 
Mean number of attempt(s) 4 4 IlS 
Attitude ,!L 2. < 0.001 
~_~!f,~m~,~,I:)~_" . -- ,-~,,,~~,,,---- ~L -IG < 0.00] 
Sodallnfluence 
Smoking environment -I < 0.001 
Stimulus G 4 < 0.001 
~,~YC;_~~_I~gJ~~' ___ C_~?.r~_ct_e_r,is_t.i~~, 
ABV-Somatisation 19 20 IlS 
Anxiety 
ZBV ;1 ;2 ns 
HAD ; 7 0.01 9 
Depression 
HAD 4 ; < 0.001 
S-POMS J G 0.02 
Anger (S-POMS) ; 7 0.011 
Fatigue (S-POMS) 4 G 0.009 
Vigor (S-POM) 12 II ns 
Tension (S-POMS) 4 G 0.012-
Total Mood (S·POMS) 2; JJ 0.001 
Vital exhaustion (MQ) I; 17 0.099 
Cardiac events since admission 
-~,-- - ........ _. ----.-.-~--,,-. 
Re-illfarction (%) G 7 ns 
PTCA (%) IG G o.on 
CABG (%) I; 10 ns 
HAD", Hospital Anxiety alld D<'pr(.ssioll s((Iie; 
S-POMS", 'S/lOrf(llU/' Profile of Moods Statt.s; 
ZBV", Zelf Broordrlillgs-Vragwlij,!'; 
ABV = 'Amsferdmme Biografisclle Vragmlijsf'; 
MQ'" Malislriclll Qu(.sliolJlwire 
* Numberofcig(lfdlcs smoked dliify before quilling 
6, 
70 
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Relapse 
Smoking status of 207 patients out of the 282 short-term quitters was known after 4 
years: 37 patients had died and 38 patients' long-term smoking status was unknown; 
74 (36%) patients had relapsed (Figure I). Predictors for relapse were not detected in 
this study. Those who continued or relapsed smoked less cigarettes per day. For 
patients whose number of smoked cigarettes was known at more than one point of 
time, the number of cigarettes was significantly lower after 3 months (n vs. 27, 
p < 0.0001) and after 4 years (12 vs. 20, P<O.OOOI) than at baseJine, and also the 
increase between 3 months and 4 years follow-up was highly significant (9 
respectively 14, p < 0.0001). 
Difforences between quitters and persistent smokers (retrospective) 
260 of the surviving baseline smokers completed the questionnaire. Responders 
differed from those who did not respond only with respect to gender: 66% of the men 
returned the questionnaire and 53% of the women (p < 0.05). Almost half (127) of the 
260 participants had stopped smoking (Table 4). Patients who had stopped smoking 
had undergone an angioplasty more frequently than those who continued (p = o.on). 
Almost 60% of the quitters had made no previous attempts to stop. 70% of the 
persistent smokers had ever attempted to stop smoking; 28% had made an attempt in 
the last year. 
TIle smokers had more often smokers in their environment and received less support 
from them. In particular the persistent smokers' partner, family and friends smoked 
more often than those of quitters did (Figure 2). In contrast, quitters experienced 
more support from their parhler. cardiologist. family and colleagues than persistent 
smokers (Figure 3). Seventy-nine percent of the patients did not know whether the 
cardiologist smoked. 
A positive attitude towards smoking cessation was lower in persistent smokers, 
especially because of feelings of anger, stress, and gloom, and the fear of withdrawal 
symptoms (all p < 0.001). Self-efficacy was stronger in quitters, which means they are 
fairly certain they will not light a cigarette in difficult situations. In contrast, persistent 
smokers had a negative self-efficacy which means they do not think they will be able 
to refrain from smoking, for example. during stress, after dinner or when other 
people are smoking. Also, they had significantly higher levels of anxiety and 
depression, fatigue, anger, tension and total mood disturbances. Vital exhaustion was 
higher in patients, who continued smoking, although not significantly so. 
The grade of addiction was 3. The average answer of the smokers to the question 
concerning intention to stop smoking was 'maybe yes, maybe no' (0, range -3 to 3); 
the average answer to the patients' plan about smoking cessation was 'not to stop 
within the next 5 years' (5, range I to 7)· 
In a multivariate analysis, the number of cigarettes smoked at baseline, previous 
attempts, attitude, self· efficacy, depression and fatigue were independent predictors; 
the C-index for the smoking cessation model was 0.949, reflecting good ability to 
discriminate between patients who did and did not stop smoking after four years. 
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Figure 2 Percentages of patients of whom at least half of tile environment (chifdrm,famify, 
friends mid colleagues) smoked, or whose partner smoked. 
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Discussion 
Smokers' Paradox 
Survival after 4 years was higher in those who smoked at baseline; the so called 
'Smokers' Paradox'_9 Smokers, however, had their myocardial infarction on average 
10 years earlier than non·smokers (59 vs. 69 years), which largely explains the 
apparent favorable effect of smoking. 
Smoking 
Percentages of smoking, 36% at baseline and 14% at 3 months follow·up, are within 
the ranges found in other publications.] The number of quitters at three months 
follow·up, 71%, was very encouraging. Unfortunately, after 4 years, less than half of 
the smokers remained ex-smokers, while one third had resumed smoking after short-
term quitting. TInts, although suffering a major event, such as a myocardial 
infarction, induces many patients to attempt to stop smoking, a large proportion does 
not maintain this behavior. Since it is difficult to become an ex-smoker, due to the 
addiction of nicotine and the psychosocial impact, more support should be offered to 
encourage quitting and to prevent relapse. 
Short-term and long-term predictors 
All shorHerm predictors found in the present study, were confirmed, either at short· 
term or long·term, in some earHer published shtdies. (Table 5) Differences among 
these shtdies are likely to be caused by insufficient power_ Only one shtdytO reported 
lower age to be predictive for smoking cessation in contrast to most other 
publications, including the present, where a higher age was associated with higher 
cessation rates. 
A larger myocardial infarction and lower levels of displeasure were predictors for 
long-term smoking cessation. Patients who are aware of the seriousness of their 
illness are more likely to be inclined to improve their prognosis, and are probably 
more frequently urged to stop by their cardiologist Patients with a smaller infarction 
might trivialize their illness, so the importance of smoking cessation should be 
emphasized also to these patients. Displeasure, which is related to depression, was 
found in several articles to be predictive for short-term continued smoking; but was 
not measured in long-term studies. Different predictors were detected at shorHerm 
and long·tenn follow·up. The shorHerm predictors, such as an intervention and the 
number of days hospitalized, were more often related to the motivation to attempt to 
quit smoking_ TIle extent of the infarction apparently makes a profound impression 
and predicts long·tenn smoking cessation, together with psychological factors, such 
as anxiety and depression, which are important to maintain this behavior. In the 
reviewed shtdies in Table 5, also other variables were measured, snch as other 
coronary risk factors, health locns of control, health and risk knowledge, but these 
were not proven to be predictors of smoking cessation. 
Differences between quitters and persistent smokers 
Retrospectively, smoking by significant others had an adverse effect on patients trying 
Table 5 Review of smoking cessation predictors in coronary patients (ordered by diagnosis). 
Diagnosis Follow-up n .g. male relation SES #c:ig attempt Hx # days severity revasc env. A,s-E psych. 9 
SES ~ Social Economic i 
Coronary Angiogram Statu1>; 
Ockene et ai'o • 6 months 267 l' l' l' 
cig ~ cigarata:; 9-HlC = history of • 
12months l' l' myocardial 3 ~ Frid et aPl II months 84 1- 1- l' infarction or heart e: failure: ~. 
Coronary neart disease/iscnemia 
revax = revascularisation ~ 
ink1'Vention; ~ Rice et al. I~ I month I)7 l' env = smoking and ,,-
6 months l' suppcrt of , 
• 
I2 months l' l' environment; • l' ..
A.S·E ~ attitude and self c-Rice et al.'· • I year 255 l' l' l' l' efficacy; ~ 
Ockene et al:J ? ' I04 l' l' psych ~ psycho!ogi.ca! ~ 
problems: g. 
Acute myocardial infarction • 
l' ~ positively related ~ Baile et al. "4 In-hospital 66 l' l' ~. 
Greenwood et al.·s I months l' l' l' 
" 
(eg. higher age, 
5)2 more likely to quit) • 
Huijbrechts et al .• 6 I64 
" 
• S months ..J,. _ nq:ativ.:!y related ~~. 
Havik et al5 6 months 2)0 l' l' 
" 
(eg. more ~ 
4) months 1-
" 
1- psychological 
g. 
• 
Herlitz et al. 10 I year 2I7 
" " 
problems, l= likely ~. 
to quit), 
DiTullio et al .• ~ I8 months 80 l' 1- • = rIOt significant 
Present Study • Predictors of == 
3 months 5)0 1-
" 
l' l' 
" 
of smoking assation 
4 years l' 
" 
intervention 
l' Comparison betw.:cn 
Revascularisation 
patients with first 
isehamti.c tIIent and 
Crouse et al.·9 ~ I year I)5 l' those with earlier 
Bass et al. Jo I year 78 l' 
" -Rigotti et al.JI I year 87 
" 
l' -l- * 
bypass surgery, 
" 
l' angioplasty or ~ 5.5 years angiography alone 
Hasdai et alY' S·I}earS II69 l' l' l' 
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to quit. Cognitive psychological factors have shown to foretell whether patients are 
likely to stop smoking" , but are often not included in smoking cessation interventions 
in clinical settings. Attitude, social influences and self-efficacy were found to be 
predictive in the current study as well. Awareness of the hazards of smoking and the 
health gains of smoking cessation are important and should therefore be explicitly 
notified by health care workers. Both positive and negative support are predictors for 
quitting respectively continued smoking. 12 In fuhlre, when advising patients to stop 
smoking, it would be advisable to involve the partner, and to make the environment 
aware of the importance of smoking cessation for coronary patients. Most patients 
were not aware of their cardiologist's smoking behavior. But still, in conjunction with 
the support of partner and family, the support of cardiologists - even when they 
smoke - proved to be a significant factor for quitters. Self-efficacy, the confidence of 
the patient to be able to stop, might be enhanced by appropriate support such as 
information leaflets and smoking cessation interventions. At baseline, no differences 
were found- between smokers and non-smokers with regard to psychological 
parameters. Patients who still smoked after 4 years had higher baseline levels of 
displeasure, and had higher levels of anxiety and depression at follow-up than those 
who stopped smoking. Since anxiety was not measured at baseline, it is doubtful if we 
may conclude whether these patients had higher anxiety scores at baseline and 
therefore were not able to stop smoking. 
Limitations 
Follow-up was not complete in both short-term and long-term follow-up. Baseline 
characteristics of patients whose smoking stahlS was unknown at short-term or long-
term follow-up did not deviate from those patients whose smoking stahlS was known. 
Information about short-term smoking was mainly collected from the medical files, 
which are known to be incomplete with regard to (follow-up of) smoking status. IJ But 
still, in conjunction with the support of partner and family, the support of 
cardiologists - even when they smoke - proved to be a significant factor for quitters. 
Self-efficacy, the confidence of the patient to be able to stop, might be enllanced by 
appropriate support such as information leaflets and smoking cessation 
interventions. At baseline, no differences were found between smokers and non-
smokers with regard to psychological parameters. Patients who still smoked after 4 
years had higher baseline levels of displeasure, and had higher levels of anxiety and 
depression at follow-up than those who stopped smoking. Since anxiety was not 
measured at baseline, it is doubtful if we may conclude whether these patients had 
higher anxiety scores at baseline and therefore were not able to stop smoking.'t 
Implications 
Tobacco dependence is a chronic condition which needs a tailored intervention of 
varying intensity and duration. Computer-tailored smoking cessation interventions 
have proven to be a successful';, and an addition for smokers who do not want to have 
or are not able to be present at counselling. An admission for an acute myocardial 
infarction or another cardiac event offers a great opporhmity to draw the patient's 
attention to the necessity of smoking cessation. The imposed prohibition of smoking 
in the hospital provides an opporhmity to stop smoking for every patient, so 
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withdrawal symptoms can be dealt with in the hospital setting using nicotine 
replacement therapy. At follow-up, simple advice to stop smoking proved to be 
insufficient for those who continued or relapsed into smoking. Meta-analyses by TIle 
Cochrane Library have shown that individual as well as group behavioural therapy is 
more successful than self-help. Municipal Health Offices often offer special smoking 
cessation programs, but in fuhue, hospitals might offer special secondary prevention 
support Extra attention and support should especially be offered to smokers who are 
younger, to those who have less severe cardiac disease and those with psychosocial 
problems. In case of the latter, referral to a counsellor could be the first appropriate 
step in order to change behaviour. Significant others, such as parhler and family, are 
important in the smoking cessation process and should be informed and encouraged 
to support the patient. Furthermore, follow-up should be offered to all patients who 
have smoked in the past, since relapse often occurs. In this era of secondary 
prevention, every baseline smoker should be asked about his smoking behavior 
during each visit to the cardiology outpatient clinic after discharge. The Agency for 
Health Care Policy and Research (AHCPR) stated in their Smoking Cessation Clinical 
Practice Guideline major recommendations for health care workers: tobacco-user 
identification systems should be used in all clinics and smoking cessation treatment 
should be supported through dedicated staff education and training, changes in 
hospital policies, and the provision of reimbursement for tobacco-dependence 
treahnent.,6 Nicotine replacement therapy has shown to be effective'7 and can be safely 
prescribed for coronary patients. [8 Recently, the antidepressant bupropion helped 
people to stop smoking". and might offer an additional tool to support patients stop 
smoking. More long-term support could be offered by the general practitioner who 
should be informed about the patient's smoking history in the discharge letter 
(Table 6). 
Table 6 List of actions for patients admitted with an acute myocardial infarction 
2 ~,~,~_i,~!~_r,e_~!i_e!l,! __ ~~" ~,~~~!:!l_~.~_~~~.!:!~L~_~:,~!!',~~~,~,,?L_~~Y,~~~,~!!1,?,~~E .,.,' .", ... , .. ,_'" __ ~,_"., __ ,. 
-7 If ex-smoker: ask when patient has quit, if recently, beware of relapse (sec: smoker) 
-7 If smoker: 
-7 inform patients (+ family) about hazards of (continuing) smoking 
-7 advice strongly to stop smoking (also partner) 
-7 prescription of nicotine replacement therapy (and/or bupropion) 
t. ,~,~,~5.lJ!.~~~_~.~~o_~~,~.~.~!?_~~,:~._~~~!!_~_"~~_~L~_~f~_~.~,~_~~_~'!.~,"~~,~,~~!.t"_~_~t£~"~~~"yl.~~ 
-7 If still smoking, consider: 
-7 referral to smoking cessation intervention 
-7 referral for specialised counselling if psychosocial problems are expected 
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Appmdix I 
,6 
.~~I?~P,~~~~U~~~~,~_t>.' __ ~!1~. g~E[,~~_~_i~,!1m (~::I~,I?J , ,_ , ___ bE:~~~~,_,_~,_ ... J?,~.I L~ .. jllL~ .. ~.~, 
{O,2I) 
ASE-model 
-,---~,--~ 
Depression 
...... F;.~.gue_ .• ~~., .. Jo~.~':.4Lj.H). 
Vigour {o, 20} 
Tension {o, 24} 
Depression {o, p} 
Anger {o, 28} 
.~JU<Ie~ ... ~;.I:2+ jlj.J7J 
Sodalinfluences {-I8, I8}' 
{·6, 6)' 
Self-Efficacy {-78, 78) 
* Smoking by partner, childrm,family, mrdio/ogist,friends ami collt-agues 
)~ SJimullls to rtop smoking by portlier, childrm,family, mrdiologist,friends and col/e-aglles 
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ClHlJil~r 6· A baseline description of a new smoking cessation program for corOmA,,! outpatients 
Summary 
Aims In spite of the higher risk of complications, half of the patients continue smoking 
after a coronary event. This article describes the options for a smoking cessation 
program in the cardiology outpatient clinic. The theory of smoking cessation 
interventions, problems with smoking cessation and tools to support patients to stop 
smoking are discussed. 
Met/wds Several approaches have been described with respect to smoking cessation, of which 
four aspects, all applied in this study, require particular attention: motivation to 
change behaviour, the ASE·model, psychological parameters and the grade of nicotine 
addiction. 
Rt.Sllrts TIle shldy population included 248 men and 85 women, with a mean age of 55 years. 
Nineteen percent was in precontemplation, 22% in contemplation, 44% in 
preparation and I5% had quit during the last month. TIlOse who had already quit 
smoking had been significantly more often admitted to the hospital during the lllonth 
preceding inclusion. Eighty-five percent of the patients appeared to be motivated to 
come to the hospital for a smoking cessation. TIlirty·five percent of the patients stated 
not to know whether cardiac complaints and pulmonary symptoms could be 
improved, or the risk of lung cancer decreased, by smoking cessation. Patients 
experienced the most encouragement to quit smoking from their cardiologist (84%), 
followed by their partner and children (both 63%). 
Conelr/sion An important element of the intervention is to find out in which motivational stage of 
change the smoker is, in order to apply appropriate support. In the future, a smoking 
cessation program as described below could be offered in a more general prevention 
clinic. 
8, 
C/JorJ/<r f> • A ba~elit1e description of a new smoking cessation programfore-orollClry Otltpalients 
Introduction 
Cigarette smoking is one of the major risk factors for the development and 
progression of coronary heart disease (CHD).'" Smoking cessation in the scope of 
secondary prevention improves the prognosis of patients with coronary heart disease 
to a large extent.' Still, about half of the coronary patients continue to smoke, and 
therefore strong smoking cessation support should he offered to these patients. 
Indeed, smoking cessation programs for coronary patients, have proven to be 
successfuV 111ese programs, which were offered to patients who were hospitalised for 
a coronary event, might also be useful in an outpatient setting. To test whether 
coronary patients in the outpatient clinic could beneHt from additional support to stop 
smoking, we started a smoking cessation program in the university hospital and three 
general hospitals in Rotterdam, the Netherlands. This paper describes the smoking 
population at the outpatient clinic and the experiences with the implementation of a 
smoking cessation program in this setting. 
Background 
Theory 
Several approaches have been described with respect to smoking cessation, of which 
four aspects, all applied in this study, require particular attention: motivation to 
change behaviour, the ASE-model, psychological parameters and the grade of nicotine 
addiction. 
In order to provide a patient with adequate information and support, it is important 
to find out in which phase a smoker is situated with regard to his or her motivation to 
change the smoking behaviour. 111e motivation to change undesirable behaviour, 
described by the Transtheoretical Model of Prochaska" which can also be applied to 
smoking cessation, can be distinguished in five stages: not considering to quit 
smoking in the next 6 months (precontemplation), considering to stop smoking 
within 6 months (contemplation), planning to quit smoking in the next month 
(preparation), attempt to quit smoking (action), and quit smoking for at least 6 
months (maintenance). This model of smoking cessation has also proven to be valid 
in coronary patients who were scheduled for a coronary angiogram/' 6 or admitted to 
a cardiology ward.7 By determining the patient's motivational stage of change, 
information and support can be tailored to patient's readiness to change. A1so, 
expected problems with smoking cessation should be explored; which component is 
more significant to the patient: the psychological and social (environment, internal) or 
the physical (nicotine addiction)? 
Attitude, social influences and self-efficacy (ASE model)' are considered to be 
important psychosocial determinants of the intention to change behaviour. Attihtde is 
comprised by a person's positive and negative beliefs about consequences of certain 
behaviour, the so-called pros and cons. Social influences consist of the perceived 
social norms of important others with regard to the behaviour in question, the support 
or opposition of these persons and the behaviour people perceive in their 
environment. Self-efficacy refers to a person's expectations regarding his capability to 
8) 
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realise the desired behaviour. In coronary patients, subjects in different motivational 
stages differ in their psychosocial determinants.7 Patients who recognise 
disadvantages of smoking and advantages of smoking cessation, receive support from 
their environment and belief they are able to quit smoking, are most likely to stop 
smoking. Different aspects of cognition playa role in each motivational stage of 
change: in precontemplation, the pros and cons are important; in contemplation, self-
efficacy; in the preparation phase, attihlde and self.efficacy are both important; and in 
the maintenance phase, it is important to prevent relapse.9 By measuring these 
determinants, more individual advice can be offered, for example by providing 
information about the health consequences of smoking cessation, involving 
significant others and offering guidance and tools to overcome difficult situations. 
In order to investigate the psychological profile of smokers, the Hospital Amdety and 
Depression scale,'o the Shortened Profile of Mood States" and the Amsterdamse 
Biologische Vragenlijst - Neurotic SomatisationI2 were presented to smokers, to 
evaluate their probability of smoking cessation, and, if applicable, to take into account 
and incorporate in a smoking cessation program. Higher levels of the psychological 
parameters depression, anxiety and somatisation have shown to be related with 
continued smoking behaviour in patients five months after a myocardial infarction.') 
Compared to other addictive substances such as heroin and cocaine, nicotine is 
equally addictive. '-I The grade of addiction to nicotine can be measured ,vith the 
Fagerstrom Test for Nicotine Dependence containing six questions concerning 
smoking behaviour. Generally, patients who smoke at least 15 cigarettes per day and 
smoke their first cigarette within the first hour after awakening are addicted to 
nicotine and can benefit from nicotine replacernent therapy, which doubles the 
change of quitting. '.I 
Smoking cessation program 
In the presently described smoking cessation program, two different methods of 
interventions were combined: a six-step so-called "Minimal Intervention Strategy" 
and a tailored letter. 
In the Netherlands, a tninimal intervention smoking cessation program was 
developed by the Department of Psychology, University of Twente, in collaboration 
,vith the Deparhnent of Health Education and Promotion, University of Maastricht. 
This intervention was successful in general practice (one-year follow-up: 18% quitters 
in the intervention group vs. 9% in the control group, p < 0.01).,6 In this specific 
individual program, a nurse assists the patient systematically in smoking cessation 
carrying out six steps: assessing the smoking profile, the motivation to quit smoking 
and expected barriers, setting a date to stop smoking, offering supporting aid and 
follow-up. After assessing the patient's stage of motivation, the appropriate next step 
was decided by the nurse (Table I). 
First of all, precontemplators need to become motivated to change, which is achieved 
by discllssing pros and cons of smoking and smoking cessation. To this end, patients 
GilpiN 6 . A baseline description oJ a new smoking cessation programJor coronary O!llpatienls 
are asked to think of their own solutions to overcome expected barriers. Subsequently, 
patients are asked to set a date to stop smoking, preferably within a fortnight. 
Supporting aid is offered by means of self-help brochures addressing attihlde, social 
influence and self-efficacy information. A follow-up care is offered in order to prevent 
relapse, which is expected especially in the first month.I] The patient received three 
phone calls from the nurse: two, four and eight weeks after the first visit and visited 
the nurse again after three months. The endpoint was smoking cessation one year 
after inclusion. 
Table 1 Flowchart for widell step to take after assessiug tile stage of change (= step oue). 
Stage of change -7 Step to take 7 Goal 
"Preconteiii'jifaioi-'- - ~Mofrvation~ -~,-,-~,---~--~ ",' To--dlsci:lss' pro'S:-alld-"coiii'-fo-liicreas-e-liiotiva'tion '" 
CoiitelnplaJor'" "'''' '-ifarrfers'" '''"_~~"''''n __ " "'to"tlllll'l('of'sofii'tioliS'''for''(iimclirCSlhtaHoils-''--
l)-ieparato'r----- - , ~S'et"aa'ai(t'io's'iop""---~ ----To--make"ii ~icoill'il11hilellP~~"-
Actor'~~"--- """ .. ----supp'ort1ngal(r~~~'" 'Towenliit'iice-tlie'p'robibiHiyofa-iiiccessfliratteinpt 
MaIllfaIiler~ ", --Follow:up"''''w'''~''''''''''''''' --, "'-To"pr'e,;eil'Crerap'seO--"'-"--~-.n- ,-
First step ill each patienls is to e-xplor~ the 'Smoking Profile" WIJic/1 means 10 betome- illfonnrd of patient's smoking 
habits and stag~ of chonge-. From Illis, tile- Ilext appropriate step is decided. 
In addition, the department of Health Education and Health Promotion of the 
University Maastricht has developed a software program, which generated tailored 
letters linked to the answers given in the self-administered questionnaire, presented 
at inclusion.'8 This software program was adjusted for cardiac patients specifically for 
this intervention. Items on smoking behaviour, stage of change, perceived outcomes 
and situational self-efficacy levels were converted to individual letters, relating to the 
answers given in the questionnaire, personalised by using patient's name, the amount 
of cigarettes and the number of years smoked. '9 In the letter, information was offered 
on favourable outcomes of smoking cessation such as positive consequences on 
health and the environment. Pros and cons of smoking and smoking cessation were 
restrurntred in order to increase motivation. Furthermore, skills and suggestions for 
coping with difficult mOluents and sirnations were presented, again tailored to the 
personal sirnation. Patients received this letter a week after filling in the questionnaire 
at home, before the visit to the nurse. 
Important aspects to improve the efficiency of success rate of a smoking cessation 
program were to address all current smokers and recent quitters, and to offer an 
appropriate intervention. Cardiologists of the University Hospital Rotterdam were 
asked to systematically evaluate whether patients with established coronary artery 
disease had smoked during the month preceding the outpatient visit and whether they 
wanted to participate in the program. Simultaneously, letters informing the patient 
about the current progralu were sent out to all coronary patients who were going to 
visit this cardiology outpatient clinic the following week and who were not known to 
be non-smokers. Furthermore, three general hospitals participated in order to include 
also "common" coronary patients. After inclusion, patients were asked to fill in an 
8, 
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extensive questionnaire (including the four earlier mentioned aspects) and invited to 
visit a trained nurse at the outpatient clinic within a fortnight. 
Results 
A search through 2,794 medical records of coronary outpatients at the university 
hospital (not performed in the general hospitals), in order to locate smoking coronary 
patients and infonn the cardiologist and patient about the program, revealed that in 
22% of the records smoking behaviour was not mentioned. Only u% of recorded 
patients were known smokers. Twenty-six percent of the 524 (861 letters sent; 
response rate 61%) responders were smokers, of whom almost 90% were willing to 
participate. 
A total of 333 patients were included in the four hospitals, and subsequently 
randomised to either the smoking cessation intervention or the usual care. Of the 
coronary patients in the university hospital who were known to be smoking, but did 
not participate (n ~ 88), 2% did not speak Dutch, 21% responded positively, but did 
not return the questionnaire, 33% did not wish to participate and of 44% patients it 
was unknown why they did not participate. The Shldy population included 248 men 
and 85 women, with a mean age of 55 years. 
Results of the baseline characteristics are shown in Table 2. Nineteen percent was in 
precontemplation, 22% in contemplation, 44% in preparation and 15% had quit 
during the last month. 11lOse who had already quit smoking had been admitted 
significantly more often to the hospital during the month preceding inclusion than 
the continued smokers. Eighty-five percent of the patients appeared to be motivated 
to come to the hospital for a smoking cessation. In this Shldy, more patients who had 
quit in the last month were found among the patients who did not attend the first 
visit. Those who were in contemplation and preparation attended the first visit more 
often, but this difference did not reach a significant difference. 
As far as attihlde was concerned, lack of means to relax (91%) and cope with stress 
(59%), decrease of comfortableness (62%) and weight gain (54%) were mentioned as 
important disadvantages of smoking cessation, while improving general health and 
stamina (botll 82%), improvement ofhealtll of others (84%) and saving money (85%) 
were mentioned as advantages of smoking cessation. Thirty-five percent of the 
patients stated not to know whether cardiac complaints and pulmonary symptoms 
could be improved, or the risk of lung cancer decreased, by smoking cessation. 
Patients thought it would be particularly difficult to refrain from cigarettes after diner 
and in stressful situations. With respect to social influences, half of the patients' 
partner smoked. Seventy-nine percent did not know whether their cardiologist 
smoked. Patients experienced the most support to quit smoking from their 
cardiologist (84%), followed by their partner and children (both 63%). 
With regard to the psychological variables, coronary patients who smoke seemed to be 
more anxious not only than the general Dutch population, but also than patients 
admitted for a Inyocardial infarction.'} Scores of depression and somatisation were not 
Table 2 
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Baselille c1Jaracteristics ofparticipmlfs (ti = 333) 
~,~5_i,?:~~"'!1~~raJ~_~_i:_~_,,_ 
Male(%) 
Mean age (years) 
Partner (%) 
Meannulllber of rears in school 
~_~_?~,i~{L~J~!?rr __ 
---~.~---".-'" Quit smoking preceding month 
Number of cigarettes smoked daily 
Number of years smoked 
Nicotine Addiction (Fagerstrom) {O;IO} 
Attempt to quit 
Last }'ear 
Medialt number of attempts 
Total 
Median number of attempts 
.~-~,~~!~!:!--~!~~~~~~~~,~-~[~~~---, 
Precontempiation 
Contemplation 
Preparation 
Action 
ASE-model 
----Attih;;l~ (-24 ;j;j --
Self-efficacy (-78,78) 
Social Influence 
Smokillg etlvironment{-6;6) 
Support (-IS;IS) 
.~~y~~-~~~~-~~-
Depression 
HAD (0;21) 
V-POMS (o;p) 
Anxiety 
ZBV (20;SO) 
HAD (0;2J) 
ABV-Somatisation {n;46} 
* standard dn'ia/iOIl 
t illterqlwrlile ra/lge 
75 
55 
81 
II 
51 
15 
)5 
5' 
JIg 
2 
244 
j 
64-~~-; 
71 
142 
51 
17 
-) 
8 
6 
3 
50 
8 
2) 
§ Olll}' oftl105e wlJo did /lot quit smoking illlhe past mOllth 
(±n)' 
(±)) 
(IO-2SP 
(29-44) 
()-6) 
(I-j) 
(2-6) 
(I9%) 
(22%) 
(44%) 
(IS%) 
(-19 - I)) 
(-2 - j) 
(3-ll) 
(2-8) 
(o-S) 
(4S-53) 
(5-ll) 
(17-28) 
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higher than this reference group. The median grade of addiction according to the 
Fagerstrom Questionnaire was 5 (interquartiles 3-6). 
Discussion 
Implementation and inclusion 
In our program, we found that in one fifth of the medical files no smoking status is 
recorded, one quarter of the patients was still smoking and almost half of them did 
not consider to stop smoking in the near fuhue. 
Recently, the updated recommendations on secondary prevention of coronary artery 
disease stated that physicians should encourage and support their patients to stop 
smoking:o Awareness of the necessity of smoking cessation is an important step for 
both cardiologists and patients to change patients' smoking habits. Since relapse 
within the first months is considerable, presumed ex-smokers should also be asked 
implicitly for their current smoking habits. In one fifth of our reviewed medical 
records, no information with regards to smoking behaviour was found. TIlis is 
congruent to findings of the Euroaspire I survey on registration and management of 
risk factors in coronary patients: most medical files (82%) revealed whether patients 
were smoking during hospitalisation for a cardiac event/' Furthermore, a quarter of 
the patients was self-reported smokers, although only one tenth were documented 
smokers. So the number of smokers is underestimated and registration of silloking 
stahls needs more attention. In large-scale trials for outpatients. a higher number of 
smokers were found. In the 4S-triai", among patients with coronary artery disease 
26% were current smokers, and the CARE-trial'J, 16% were current smokers of 
patients with a myocardial infarction. A comparable prevalence of smoking was found 
in the outpatient population in the university hospital who underwent a thallium scan 
or stress echo (20%), and the self-reported 26% as mentioned earlier. 
Smoking profile: stage of change 
Nineteen percent of the patients were at the time of inclusion in precontemplation, 
22% in contemplation, and 44% in preparation. Similar motivation levels were found 
in a smoking cessation program performed in the USA,s while cardiac patients 
showed to be more motivated to quit than people in the general population.2..j Even so, 
almost half of our patients did not intend to stop smoking within the next months. 
Nevertheless, the less motivated smokers were also willing to participate in a smoking 
cessation intervention. Total abstinence of smoking in these patients might be a 
bridge too far for these precontemplators, but consciousness-raising of the negative 
effects of smoking and providing information about smoking cessation to progress to 
the next stage, is a more realistic goal. 
Increase motivation 
One third of the patients indicated not to be aware whether smoking cessation would 
decrease their chance of further cardiac problems or lung diseases. This is 
unacceptably high. Providing convincing infonnation is very important to achieve 
awareness and to enhance motivation. Physicians should not assume that patients are 
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aware of the hazards of smoking, but name these explicitly and or rather urge the 
patients to think of it themselves. 
Overcome barriers 
In order to offer optimal individual support, it is important to realise which 
component is most significant for this particular smoker: the psychological or 
physical (or a combination). In this program, these aspects were measured with the 
intention to relate them to changes in smoking behaviour and to formulate predictors 
for smoking cessation. Characteristics as described in the previous paragraph are 
often found in persistent smokers with coronary disease, and should be taken into 
consideration when a smoking cessation program is offered. Since smoking is 
considered by lllany smokers to be a means to relax or to cope with stress, substitution 
for relaxation should be offered. In some programs, but not this shldy, relaxation 
therapy by means of cassettes and breathing exercises is added. For some patients, 
smoking is considered as a manner to reduce feelings of anxiety or stress. 
Psychological support, counselling or anxiolytic therapy could be advised in serious 
cases. Also, anti-depressive therapy should be considered in patients with high scores 
of depression and depressive symptoms. The antidepressant bupropion resulted in 
higher long·term rates of smoking cessation in smokers, regardless of the levels of 
depression!l Weight gain, most often due to a transient increase in food consumption 
combined with the elimination of the acute metabolic effects of smoking, is for many 
people a disadvantage of quitting. On average, the weight gain is 3 kg for men and 4 
kg for women - but weight gain over 10 kg is not exceptional. occurring mainly in the 
first months.'6 Weight control and, if necessary, a referral to a dietician, might be 
added to a smoking cessation program. 
Half of the participating patients were moderately to very addicted to nicotine, shown 
by smoking early after awakening, the first cigarette being the most difficult one to 
give up, and experiencing difficulties when not able to smoke. Criteria for dependence 
according to DSM IV (,nicotine dependence', 350.10) are the same for nicotine as for 
other psychoactive substances such as cocaine and alcohol. They include: intake of 
larger amounts than intended, desire to cut down but making unsuccessful attempts, 
tolerance and withdrawal symptoms. When the physical addiction is a serious 
problem, indicated by the presence of withdrawal symptoms such as irritability, 
concentration problems. restlessness, anxiety and insomnia, nicotine replacement 
therapy should be considered.'l Nicotine replacement therapy doubles the rate of 
smoking cessation, but should be preferably prescribed in addition to a behavioural 
smoking cessation program and accompanied by proper instnlCtions how to use it. 
Design of the intervention 
The intensity of the program is difficult to establish and could be best discussed with 
the patient. In our shldy, the patient visited the nurse twice for the intervention, and 
once at one·year follow-up, and received three phone calls. Some patients were very 
difficult to reach or motivate to visit the nurse, others asked for more frequent calls or 
visits. Although the program should not be too time-consuming. a more attentive 
attitude especially in the beginning was desired by many patients. Especially for those 
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who are in (pre-) contemplation, this 'minimal' intervention was probably not 
sufficient. In order to improve the compliance and support, it is desirable that the 
nurse is flexible and approachable for the patient~. In our program, the nurse was 
available only one morning or afternoon per week, which proved to be unsatisfactory 
for many patients. 
Many different smoking cessation programs have been described!] Programs differed 
in modality and contents of program, setting. intervenor, use of additional 
information and materials, and duration of follow-up, individually/tailored. TI,ey 
varied from rehabilitation programs to very intensive smoking cessation 
interventions. Programs were mainly individual and offered by a nurse. Additional 
written information was distributed and sometimes other supporting materials as 
cassettes and videotapes were offered. Half of the studies offered follow-up telephone 
calls (varying from one telephone call to weekly calls) and the minority also involved 
family members. In general. smoking cessation interventions with a high number of 
contacts and prolonged duration are most successful. Furthermore, a 
multidisciplinary approach (cardiologist, nurse and possibly psychologist) with face-
to·face contacts are determinants of success as well as the number of intervention 
nlOdalities,z8 A review of smoking cessation programs consisting of advice to stop 
smoking from the cardiologist together with a nurse-supported smoking cessation 
programs showed, on average, 20% more quitters than when only the usual care is 
offered.) 
In future, a smoking cessation program could be implemented in a broader 
prevention clinic, where also other risk factors are monitored such as lipids and blood 
pressure as well as dietary advice. For patients who, for example, live further away 
from the hospital. are less mobile, or have demanding jobs, it is preferred if the visit 
could be conlbined with other visits to the hospital, which makes it more worthwhile 
for them to attend the program. Also. more attention should be given to those who 
need lTIore support to stop smoking. Since hospitalisation is associated with a period 
of no smoking, it is desirable to start a smoking cessation program at the ward and 
extend the follow-up at the outpatient clinic. 
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Summary 
Aims To investigate the effect of a smoking cessation program for coronary patients in an 
outpatient setting, and to predict smoking cessation on the basis of baseline smoking 
behaviour, and psychological and clinical factors. 
Metllods This randomised-controlled shtdy, which was a single blind, multi-centre trial in 
which smoking status after one year was the primary endpoint. Patients who were 
randomised to the intervention received a tailored information letter and a nurse-
offered minimal smoking cessation program. 
Results Of the patients in the intervention group, 22% reported to have quit after one year vs. 
20% of the control group. One third ofthe quitters had never attempted to quit before. 
They had more often quit already in the month before the inclusion, were more often 
recently admitted and diagnosed with coronary artery disease, and were more 
convinced to be able to refrain from smoking than continuing smokers. On the other 
hand, persistent smokers had more smokers in their environment and received less 
support from their close relatives and friends than quitters. Furthermore, patients 
who continued smoking had a less favourable psychological profile. 
Conc/tlslOIl For coronary patients who smoke a minimal smoking cessation program is not 
sufficient. A more extensive smoking cessation program, which takes psychosocial 
factors into account, might be more successful. 
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Introduction 
In the last years, several studies have shown that smoking cessation considerably 
improves the prognosis of cardiac patients.' Smoking cessation after being diagnosed 
with coronary artery disease results in forty per cent reduction of early mortality or 
myocardial (re-) infarction.2 In view of these promising figures, it is unfortunate that 
the majority of the smokers with established coronary artery disease persist in their 
hazardous behaviour) To stimulate patients to stop smoking and to support possible 
attempts, smoking cessation programs have been developed. Various studies, mainly 
executed in a clinical setting, have shown that smoking cessation programs are 
effective> and cost-effective.4 
We investigated the effect of a smoking cessation program for coronary patients in an 
outpatient setting in a randomised study design. In order to direct future smoking 
cessation interventions to those who would profit most from the program and to 
define groups who might benefit more from other type of interventions, such as 
psychological counselling or medication, we aimed to predict smoking cessation on 
the basis of baseline smoking behaviour, psychological and clinical factors. 
Methods 
Patient recruitment 
Between February '997 and May 1998. all consecutive patients with established 
coronary artery disease (i.e. a prior myocardial infarction, a prior coronary angioplasty 
or bypass operation, an abnormal angiogram (at least one-vessel disease with >50 % 
stenosis), or a positive stress or exercise test) who smoked daily in the preceding 
month. were eligible. Excluded were patients who did not speak Dutch. those who had 
a history of a serious psychiatric disease, as well as patients with a short life 
expectancy. Patients were recruited from one university hospital, three general 
hospitals and one cardiac rehabilitation centre in Rotterdam. 
Inclusion 
After written informed consent, the patients were randomly assigned: two thirds to 
the smoking cessation intervention (SI) and one third to the usual care (UC). whicll 
most of the time consisted of brief smoking cessation advice only. 
All patients were asked to fill out a set of questionnaires. 111is set of questionnaires 
consisted of demographic characteristics and 80 items (fable I) concerning smoking, 
including Fagerstroms grade of addiction,! the intention to change, and attihlde, social 
influence and self-efficacy (ASE-model'). Additionally. patients were asked to 
complete 4 psychological questionnaires, which had shown in previous studies 
significant differences in scores on depression7.8 anxiety (ZBV)7''J and somatisation 
'Amsterdamse Biologische Vragenlijst' - Neurotic'o, between continued sllloking and 
quitting who had a myocardial infarction." 
Smoking cessation intervention 
Answers to questions of the ASE-model, given by the patients from the intervention 
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Table 1 Baseli11e c1wracteristics of participants in interventioll and usual care group. 
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Demographics 
intervention 
n = _ "~~,?_,,. 
usual care total 
m ... 
.... "'~X~je. "--.---, __ ~'c ______ ~ __ • 164--75%'-'-'-~-- 84 74%-"--~---~~;4'8"--74% 
Mean age (years) 
Mean years of education 
Smoking history 
., '''- "S'n~~k~ri~~t~4-i;~~~~~"" 
Smoked last week 
Quit last month 
# cigarettes 
# years 
Packyears 
Addiction (Fagerstrom) [0;10] 
Attempt to quit 
Last }'ear 
Median Humber 
Total 
Median number 
.I.~_~~_~"t_~~.~ ___ t_~"_~~~~~_~.~,_ .. _ 
Precontemplation 
Contemplation 
Preparation 
Action 
Attitude 
Sel~efll.ca9: .l-?8;Z8! 
Sodallnfluence 
--S-~~~id~g"~~-;~i-;~;,~~;~'t[~6;-6f-
Stimulus [-18;181 
54 (47,6,) 55 (49,66} 54 (48,6J) 
12 {8, 13} 
--- i-69--~78%"--"--
203 94% 
31 14% 
15 {IO,2S} 
35 (,8,4J) 
34 ('9,60} 
5 h,7} 
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group, were entered in a computer database. Then, data were sent to the department 
of Health Promotion and Education of the University of Maastricht, in order to create 
a computer generated personalised letter which generated information based on the 
patient's responses in the questionnaire'\ which formed the first part of the 
intervention. 
A software programme, linked to this database, generated tailored letters: answers on 
questions concerning smoking behaviour, stage of change, perceived outcomes and 
sihtational self-efficacy levels were converted to individual letters, tailored to the 
individual situation which were personalised by using for example patient's name, the 
amount of cigarettes and the number of years smoked. In the letter, information was 
offered on favourable outcomes of smoking cessation such as positive consequences 
on health and environment. Pros and cons of smoking and smoking cessation were 
restnlChtred in order to increase motivation. Furthermore, skills and suggestions for 
coping with difficult moments and situations were presented, again tailored to the 
personal situation. Patients received this letter at home one week after having 
completed the set of questionnaires, and before the counselling visit by the nurse 
along with an invitation to visit one of the three trained nurse counsellors at the 
outpatient clinic within a fortnight. 
In addition, in the Netherlands, a minimal intervention smoking cessation 
programme was developed by the Deparhnent of Psychology of the University of 
Twente, in collaboration with the Department of Health Education and Promotion of 
the University of Maastricht. In this individual nurse· offered program, the nurse 
assists the patient systematically in how to quit smoking by discussing six steps: 
I assessing the smoking profile, 
2 assessing the motivation to quit smoking, and 
3 assessing the expected barriers; 
4 setting a date to stop smoking, 
5 offering supporting aid and 
6 assisting at follow·up, in order to prevent relapse. 
This program had proven to be effective in the general practice.'J 
After assessing the patient's stage of motivation assisted by the nurse, the appropriate 
next step is decided. 4 Supporting aid was offered by means of two self-help brochures: 
one addressing the six steps attitude, social influence and self-efficacy information, 
and one containing information on the risk of smoking for coronary patients. 
Follow-up 
Follow-up care was offered by means of three consecutive phone calls fronl the 
nurse - at two, four and eight weeks after their first visit· and again a visit with the 
nurse after three months. 
TIle same set of questionnaires was presented again to all patients after one year. 
Patients who visited the hospital after one year and who had stopped smoking were 
asked to exhale in a Smokerlyser (Bedfont, Upchurch, England), in order to measure 
carbonmonoxide levels in the expired air. This method was available, cheap and easy 
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to use, and therefore preferred to cotinine measurements, and has a fairly good 
sensitivity (98%) and specificity (81%)." Furthermore, data on medical history such as 
coronary events, revascularisation interventions and comorbidity, were collected from 
the medical records. 
The endpoint was self· reported smoking cessation (for at least the past seven days) 
one year after inclusion, confirmed by carbonmonoxide measurements, if possible 
(Figure I). Secondary endpoints were any attempts to stop smoking, the number of 
cigarettes smoked daily at one year follow·up, and a change in motivation to stop. 
Sample size and data analysis 
TIle percentage of quitters in patients, randomised to the UC group was estimated at 
15% . higher than the general smoking population, but lower than a population of 
recently admitted coronary patients. From previous studies, it was hypothesised that 
the intervention group would double this to 30% - again, higher than a general 
smoking population, who received a smoking cessation program, but lower than 
hospitalised coronary patients.'3 '6-'S To offer the program to as many patients as 
possible and reach a power of at least 80%, by 2-sided testing with a significance of 
a = 0.05, a 2:1 design was chosen with a calculated total sample size of 330. 
Analysis of the efficacy of the smoking was performed according to the intention-to-
treat principle. Comparisons of differences in baseline and outcome variables 
between the groups were performed by a Chi-square analysis for nominal variables, a 
Mann Whitney test for ordinal variables and a T-test for continuous variables. An 
analysis of variance for repeated measures was used for the mean number of smoked 
cigarettes and change in motivational state. Univariable and multivariable logistic 
regression analyses were perfonned to determine independent predictors of smoking 
cessation. Variables which were examined included demographics, medical history 
smoking profile and psychosocial factors. All variables entered the multivariable 
stage, independent of the results in the univariate analyses. The final multivariable 
regression model was constructed by backward deletion of the least significant 
characteristics. TIle predictive accuracy of the multivariable model was evaluated by 
the C·index.'9 We evaluated whether the success of the smoking cessation program 
was related to depression, stage of change, self-efficacy and Fagerstrom score: i.e. we 
tested for interaction between these patient characteristics and allocated strategy. 
Statistical significance for all tests was stated at the 0.05 probability level. 
Results 
Patient Baseline characteristics 
Between February 1997 and May 1998, 333 patients were included, of whom 219 
patients were assigned to the smoking intervention group en 114 to the usual care 
group. In the university hospital, 153 patients (46%) were included, 169 patients were 
enrolled in the three general hospitals and II patients in the cardiac rehabilitation 
centre. 224 (67%) patients were included through the outpatient clinics and 96 at the 
wards. Demographics, smoking history and medical are shown in Table I. The 51· 
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group and the UC-group were comparable, except for 'smoking last week' and the 
number of packyears (product of number of years smoked and number of packages 
(20 cigarettes) smoked daily); both were more favourable for the UC group_ 
Compliance 
Of the 219 patients, who were randomised to the intervention, 186 (85%) attended the 
first visit at the nurse's outpatient clinic; mean duration of the visit was 33 minutes. 
The three consecutive phone calls were made successfully to respectively 180 (82%), 
169 (77%) and 131 (60%) of the patients; the average of all phone calls was 10 minutes. 
133 (61%) patients attended the 3 monUls visit - 12 by telephone - and 105 (48%) 
attended the last visit after one year, of whom 29 telephonically; again the mean 
duration of the visits was 30 minutes. 
One year 
Effect intelVention 
After one year, 12 patients had died (s in the intervention group and 7 in the control 
group), 3 patients had withdrawn their informed consent (all in the control group) and 
21 patients refused to respond (10 in the intervention group and II in the control 
group). OfUle 297 (89%) patients whose smoking behaviour was known (105 through 
the visit and 192 by means of the questionnaire, reminding letter or phone call), 22% 
of the patients in the intervention group reported to have quit vs. 20% of the control 
group (p ~ 0.95). Seventy-three percent of the 297 had completed the questionnaire 
after one year. In those who attended the one year visit, stopped smoking and 
carbonmonoxide in expired air was measured (n = 19). all scores were negative, 
implying that self-reported smoking cessation was reliable. 
Seventy-one percent of the patients in the intervention group had attempted to stop 
smoking during the last year, while 65% of Ule control group had (p ~ 0.35). The 
number of cigarettes smoked was significantly decreased at one year (from 17 to 15 
cigarettes daily for both groups, p ~ 0.031), but no difference was found between Ule 
intervention and the control group. Motivational stage of change decreased in time; 
again not different between the two groups. 
Predictors of smoking cessation 
Table 2 presents baseline characteristics according to smoking status at one· year 
follow-up. Patients who had quit after one year had more often quit already in the 
month before the inclusion than continuing smokers (p < 0.001). Consequently, one-
year quitters were at baseline more often in the action stage, while smokers after one 
year were at baseline more often still in the preparation phase. One third of the 
quitters had never attempted to quit before, while in the persistent smokers tllis 
percentage was 22% (p = 0.049). \Vith regard to self-efficacy, quitters were rnore 
convinced to be able to refrain from smoking in difficult situations (p = 0.017). than 
persistent smokers. Continuing smokers had more smokers in their environment 
(especially the partner: 33% vs. 45%; p ~ 0.048) and received less support from their 
close relatives and friends than quitters (p ~ 0.029). 
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Table 2 Baseline predictors of smokillg cessation after 011e year. 
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Table 2 C011tiuIled 
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Also. patients who stopped smoking were more often enrolled at the clinical wards 
(46% vs. 24% of smokers, p = 0.002). Patients who had more recently been 
diagnosed with coronary artery disease, were more likely to stop smoking ( p ~ 0.048) 
than those who had a longer history of coronary artery disease. Other medical 
predictors were not demonstrated, except for undergoing bypass surgery after 
inclusion (10% of the quitters vs. 3% oftlle continued smokers, p = 0.024) and a trend 
was seen for a positive family history of coronary artery disease. Furthermore, patients 
who continued smoking had a less favourable psychological profile than quitters did. 
They experienced lllore often symptoms of depression. feelings of fatigue and tension 
and had more often total mood dishtrbances (all p " 0.001). 
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In a multivariable logistic regression, the motivational stage of change (OR 1.8, 95% 
confidence interval 1.0 to 3-3), fatigue (OR 0.8, 95% confidence interval 0.8 to 1.0) and 
a bypass operation after inclusion (OR 2.8, 95% confidence interval 1.2 to 6.8) were 
independent predictors of smoking cessation after one year. TIle C·index for the 
smoking cessation model was 0.797, reflecting good ability to discriminate between 
patients who did and did not stop smoking after one year. 
Discussion 
Smoking cessation intervention 
In the current investigation, 22% of the patients in the intervention group reported to 
have quit vs. 20% of the control group, which means that this program was not 
effective. In fact, the percentage quitters in the intervention group was lower, and the 
percentage quitters in the control group higher than expected. It should be 
appreciated that the assumptions of these percentages were uncertain since they are 
based on comparable but not identical studies (general practice 15% vs. 5%, IJ 
inpatients after myocardial infarction 71 vs. 45'6, 57 vs. 48'7 and 70 vs. 53'8 after one 
year). For this particular group of smokers, the minimal intervention was probably not 
sufficient. This was confirmed by the evaluation forms: of the patients who attended 
the outpatient visit after one year and completed an evaluation (87%), more than 80% 
was overall satisfied with the program. Nevertheless, one fifth recommended more 
contacts. Especially in the beginning, stoppers need a lot of support to prevent relapse, 
and the three phone calls in the first two months might not have been sufficient for 
this group of smokers. 
Table J Odds ratios alld tile 95% confidence intervals of factors if! smoking cessation programs.' 
CI 
start 5-4 
additional support (eg. video, tapes, NRT*) 2·7 2.1 • J·5 
admitted for revascularisation 2.6 2.0 - J.4 
study perfonned in USA 2.0 1.6 - 2·5 
group session added to individual 2.0 1.5 - 2·5 
diagnosis myocardial infarction I.J 1.0 . 1.7 
program part of rehabilitation 1.2 0·9 - 1.6 
family involved 1.1 0.8 . 1.5 
unifactorial program 0·9 0.7 - I.I 
follow·up phone calls 0·7 0.6 -0.9 
manuals hand out 0.6 0·4 - 0·9 
outpatient follow-up 0·5 0.4 - 0.6 
multidisciplinary approach 0·5 0·4 . 0.6 
individual support 0·4 0·3 - 0.5 
* Nicotille Replaccmenll1umpy. 
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In a recently published review, ten studies on smoking cessation interventions for 
coronary patients were investigated.2 Unfortunately, the intervention programs were 
often not very precisely described, in particular the intensity and duration of the 
programs were frequently not specified, which makes it impossible to investigate all 
elements in the program that make it successful. If we calculate univariate odds ratios 
for all patients (n = I,076) who received the intervention program in those ten studies, 
comparing quitting (53% of baseline smokers) and persistent smoking, programs 
were most effective which started in-hospital, especially after a serious coronary event, 
and included additional groups sessions and support, such as relaxation tapes and 
nicotine replacement therapy (Table 3). Unfortunately, none of these components 
were incorporated in our study, and factors, such as individual support and manual 
hand·outs, even appeared to be negatively related in the reviewed studies (Table 3), 
which might partly explain the lack of effeel of the program. 
TIle observed percentage quitters in the control group was higher than expected. 
Therefore, the percentage of quitters after one year in an unselected group of baseline 
smokers, who did not participate in the current study, in an outpatient population, 
was investigated. Eight (10%) of the 78 patients (of the 87 non'participants; 90% 
response) had stopped smoking after one year, which was similar to other 
investigations, and less than those who participated in the study (p = o.o42). 11lis 
means that motivation to participate in a smoking cessation intervention and 
answering an extensive set of questionnaires instigates one fifth of the patients to stop 
smoking. 
Nicotine replacement therapy was not prescribed in this program. At the start of this 
study, the side effects of nicotine replacement therapy in heart patients were feared, 
especially if the patient continued to smoke, and cardiologists were reluctant to 
initiate such therapy. Recent studies, however, have shown that nicotine replacement 
therapy can be safely used by coronary patients. H, Nicotine replacement therapy in 
addition to a smoking cessation program doubled the percentage smokers," so in 
future, nicotine replacement should be integrated in the current smoking cessation 
program. 
Predictors 
In previous studies, there is no consensus whether previous endeavours to stop 
smoking are predictive of a successful attempt,a or whether the first attempt is most 
likely to succeed. 2J One third of the quitters in this study had never attempted to quit 
before. Patients who continued smoker had more often made previous attempts to 
quit. The failure of previous attempts might have discouraged them to comply with 
the current program, so it would be advisable to discuss the reason of previous 
failures, before a new attempt is initiated. 
Patients who continued smoking had a less favourable psychological profile. In other 
studies, higher scores of depression and anxiety were predictive for continued 
smoking."'''-p> Unless these problems are improved, it is not very likely these patients 
will stop smoking in the near fuhue. Bupropion, originally an antidepressant, has 
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recently proven to be effective in smoking cessation.,6 This might be a useful 
treahnent for patients with a less favourable psychological profile, but further 
research is necessary in this field. 
Continuing smokers had more smokers in their environment and received less 
support from their significant others than quitters. Social support has already been 
proven to be important for smoking cessation in previous studies. Simply being 
married/7 but also having lower levels of negative support and higher positive social 
supporVt were related with quitting. 
Conclusion 
The current minimal smoking cessation intervention, implemented in an outpatient 
setting. was not effective. The srudy was designed to use available interventions, 
which were already applied in the general population or general practices, in a new 
setting. Because of the modest budget, a simple and easy to perfonn scheme was 
used, adjusted to the current outpatient practice. In the fuhtre, smoking cessation 
programs which are executed at the outpatients clinic but are initiated during 
hospitalisation, especially after a myocardial infarction or a revascularisation 
intervention, which include groups sessions, and which offer additional means of 
assistance, are most likely to be effective. Furthermore, a more intensive and frequent 
follow-up should be offered in order to keep patients motivated and prevent relapse. 
Individual circumstances should be taken into account. For example, investigating 
and discussing the reason for failure of previous attempt might iluprove the chance 
of success for a next attempt. Also, smokers might be offered a psychological 
questionnaire, in order to value to what extent psychological problems might restrain 
them from quitting. Psychological counseHing or psychophannaca might be useful to 
provide better circumstances to quit, in those who have symptoms of depression or 
anxiety. Bupropion, originally an antidepressant, has recently shown to be effective in 
smoking cessation '5 and might be a remedy for this particular group of smokers. Also, 
when advice to stop smoking is offered, it is advisable to involve the closest family 
members. They should be encouraged to stop smoking themselves, if applicable, and 
to support the patient. 
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Introduction 
Exhaustive research has shown that smoking causes cardiovascular disease. <.> 
Cardiovascular disease is the number one cause of mortality and smoking is the most 
important changeable risk factor for cardiovascular disease (Chapter I). 
TIle aim of this thesis was to investigate the effect of smoking cessation on the 
prognosis of coronary artery disease. Furthermore, to make an inventory of steps 
currently taken to make patients stop smoking, and to analyse how effective they are. 
Also, a new smoking cessation program was offered to coronary outpatients, with the 
purpose to investigate whether this program was effective in this setting and whether 
predictors could be indicated for smoking cessation. TIlese predictors were also 
explored in patients who had had a myocardial infarction. In this discussion, 
important findings of these investigations are reflected upon and suggestions for 
future smoking cessation programs and research are made. 
Smoking cessation in coronal)' patients 
Smoking cessation decreases the chance of new events in patients with coronary 
artery disease. Patients who stop smoking after a coronary event have a 35% lower risk 
of a (re) infarction or early ll:1ortality (Chapter 2). In one particular coronary group, 
namely those who underwent coronary bypass graft surgery, long-term srnoking 
cessation led to 14% benefit of survival after 15 years and to a decreased risk of 
repeated revascularisation procedures (Chapter 3). As shown in other studies, 
smoking at baseline was not related with long-term survival.! This finding can be 
mainly explained by other differences between baseline smokers and non-smokers as 
discussed in the next section. 
TIle effect of smoking cessation on other cardiovascular risk factors is not clear. An 
increase in HDL-cholesterol has been demonstrated4,' but also worsening of 
hypertension, possibly caused by the increase in weight.! However, other studies did 
not show an independent effect of smoking cessation on hypertension or total 
cholestero1.6 A positive effect of smoking cessation can also be expected in other 
atherosclerotic symptoms, such as intermittent claudication7 and stroke, although the 
latter has not been clearly established. 
Favourable effects of smoking cessation as secondary prevention have been 
demonstrated, besides its benefit for patients with cardiovascular disease. For 
example, smokers with impaired pulmonary function, especially due to chronic 
obstructive pulmonary disease, who stopped smoking, had significantly slower rates 
of FEVI decline with age than those who continued.8'9 Within a few years after 
quitting, rates of decline diminished to a level similar to that of people who had never 
smoked.''' Although smoking cessation does not significantly improve the short-term 
prognosis of lung cancer," probably because of the irreversible mutations caused by 
smoking", it does improve the quality oflife, since continued smoking is related with 
more pulmonary complications" and weight loss.'4 Also patients with other neoplastic 
diseases, such as oral cancer"p6 carcinoma of the bladder,'7 prostate cancer,'& and 
cervical lesions'9 have a better prognosis after smoking cessation. Finally, smoking 
cessation has a positive effect on the female reproduction system in cases of 
"3 
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miscarriage or infertility,>" and quitting during pregnancy results in a decreased risk 
of low birth-weight, increased gestational age" and lower perinatal morbidity rate" 
compared to continued smoking. 
Cost-effectiveness 
In spite of these promising figures, little attention is paid to smoking cessation 
interventions in health care. The expenses of Health Care in the Netherlands increase 
enormously. In view of this, it is to be expected that there is an increasing interest in 
secondary prevention. The total annual amount of money, which is spent on smoking 
cessation in the Netherlands, is estimated at 22 million guilders (Table I). Of the 
smokers who attempted to stop in 1998, approximately 138,000 smokers (16%) used 
nicotine replacement therapy/J which corresponds with roughly 12 million guilders. 
(Personal communication: D. Vierling, IMS Health Self-medication - Pharmatrend) 
- Nicotine replacement therapy can not be reimbursed in the Netherlands. -
Furthermore, in 1998, 952 smokers attended a smoking cessation program offered by 
community health services. (Personal communication, M. \Villemsen, Dutch 
Foundation on Smoking and Health) Moreover, about 1,500 smokers participated in 
the Allan Carr intervention, total costs 600,000 guilders (Personal communication, 
E. de Mooy, Co-ordination Allen Carr, the Netherlands) The total amount spent on the 
prevention of smoking, including the budget of the Dutch Foundation on Smoking 
and Health, 22 million guilders, is probably largely exceeded by the marketing budget 
of the tobacco industries, an amount that is not made public by the companies 
involved. Every year, about 5.3 billion guilders are spent on tobacco products, of which 
3.3 billion is excise duty. The government spends an estimated 6.5 billion guilders on 
diseases related to smoking. 
Also, smoking and accompanying illnesses induce incapacity for work, which brings 
about costs for employer and government. That is why controlling tobacco use at the 
workplace and protection of the non-smokers from the adverse effects of second-hand 
smoke have been widely applied in the U.S.A." 
Since non-smokers are healthier than smokers, it seems logical to assume that 
smoking cessation will save money on health care. However, non-smokers become on 
average 8 years older than smokers/ and thus require more health costs related to 
older age. In a comparison of total health care costs between smokers respectively 
non-smokers and a general mixed population, costs for non-smokers were 7% (men) 
and 4% (women) higher, whereas for smokers the total costs are 7% respectively II% 
lower than for the general population.'; Fifteen years after smoking cessation, health 
costs· increased due to older age - exceed costs of prevention of smoking-related 
diseases. However, in medical decision analysis, costs are compared with the benefits. 
Benefits of smoking cessation are not only a better prognosis, as regards mortality and 
morbidity, as discussed in chapter 2, but also an improvement in the quality ofHfe, as 
shown by poorer health ratings, respiratory problems, impairment in mobility and 
higher stress levels, especially in the elderly, although the direction of this 
relationship is still unclear.'6 At the moment, a special smoking cessation quality-of-
life questionnaire is being developed, designed to quantify the impact of smoking 
cessation on perceived functioning and weU-being in adults/7 
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Table J Amounts spent on smokillg/smoking cessation (il1 guilders (f)) 
amount 
P!-!tsh_JQ.~~_tl~IaJigll_9IL~mq!sJnKf'-ttq, M~alt11_ _. f ., ,9,9PQ, 9.99,< 
promotion and education 
'-ntety~.!'lJjl:m~ ___ . 
Community services 
Allan Carr 
Book 
Session 
NRT' 
:rotal_ 
Patches 
gums 
Nicotille Replacemellt 111uapy 
J 200,000 
J 1,000, 000 
J 600,000 
J 5,384,300 
J 6.05 6 .700 
f. 
_. "" ~2_, ___ :l4 1 ... .9 99 .. : 
Table 2 Cost-effectiveness of smoking cessation illterventiotls. 
Intervention 
9,!,!n.~!~!.pra~!~~,~~~~,~_ 
Advice only 
Counselling 
Nurse assisted 
NRT' 
Costs per life-year 
__ s_~y~_Ji.n. d~!~~!~) : 
$ 1,5°0 '" 
$ ),000-2,00023 
"* Nicoli/Ie Replacemeut l1lfmpy 
+ 
Smoking cessation interventions are extremely cost-effective. Depending on the 
success rate, the intensity of the intervention and the population, costs per life-year 
saved vary from $200 to $10,000. Compared to a coronary bypass operation (ranging 
from $4,000 to $30,000)" or lipid. lowering treatment (approximately $25,000)." 
smoking cessation programs are very worthwhile. Moreover, the rnore intensive the 
intervention, the lower the cost per QALY saved, which suggests that greater spending 
on interventions yields more net benefit.H However, the comparison of different 
smoking cessation intervention modalities is more complicated since smokers who 
select an intervention themselves differ between the different modalities. Smokers 
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who are 'easier quitters' choose more often self-help treahllents, which might be most 
effective for them. Randomisation will decrease baseline differences, but the 
advantage of selecting the individual's lllost effective intervention is missed.}l 
However, as the provision of brief smoking cessation advice to hospitalised smokers 
is relatively inexpensive and cost-effective, it should become part of standard in-
patient care. 
Smoker's Paradox 
Some large trials in post-myocardial infarction patients have demonstrated a better 
prognosis in baseline smokers, which is called the "smoker's paradox". In an 
extensive shldy of thrombolysis (GUSTO·I), non-smokers experienced lllore often an 
in-hospital reinfarction, shock, stroke, bleeding or mortality than active smokers,l6 
This paradox can be explained by the fact that the smokers were on average II years 
younger than non-smokers do, and had less comorbidity or severe coronary artery 
disease than non-smokers can. l7·)s In our investigation of smoking cessation after a 
myocardial infarction, these findings were confirmed (Chapter 5). Nevertheless, 
smokers had a slightly decreased risk ratio for cardiovascular events, even after 
adjushllent for these differences. It has been suggested that smokers have an 
enhanced systemic fibrinolysis following thrombolysis, which protects against further 
thrombotic adverse events. J9 Measured fibrinogen concentrations after thrombolysis 
support this, but further research in larger populations is needed. 
Smoking cessation interventions 
The favourable results of smoking cessation as secondary prevention justify 
comprehensive time and effort to develop interventions for patients who continue to 
smoke. Smoking cessation programs for patients with coronary artery disease have 
proven to be effective. In shldies of smoking cessation programs for coronary 
patients, patients who received a smoking cessation program quitted 20% more often, 
compared to those who received the usual care (Chapter 2). However, the minimal 
intervention smoking cessation program for coronary outpatients, which was 
described in Chapter 6 and 7, was not effective. Smoking cessation interventions in 
other outpatient settings showed various effects. An intervention with a self-help 
manual and/or a single counselling by a nurse resulted in a higher number of 
attempts in the intervention group, but not in more quitters after one month or six 
months.40 A more intensive smoking cessation intervention (12 contacts and nicotine 
replacement therapy) for early COPD patients, resulted in significantly more quitters 
after one year,41 while an extensive behaviour therapy intervention for diabetics was 
not more successful than physician'S advice onlyy 111ere is no consensus, which 
program must be offered, but those programs were most effective which started in-
hospital, especially after a serious coronary event, and included additional group 
sessions and support, such as relaxation tapes and nicotine replacement therapy 
(Chapter 7). 
Smoking cessation interventions have been offered in different settings (Table 3). 
Public health smoking cessation interventions, such as the Community Intervention 
Trial for Smoking Cessation (COMMIT)" and the Quit and Win contest," had modest 
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but statistically significant impact. In the U.S.A .• various interventions to a decrease 
in prevalence of tobacco use49 and an increase in tobacco-free schools. Peer-pressure 
and access to cigarettes at home were important predictors.;!) Since addiction is a 
persistent and difficult issue, high priority should be given to developing a program 
to prevent people from starting to smoke. The smoking cessation intervention, which 
was described in Chapters 6 and 7, had proven to be effective in a general practice 
setting. ls Pregnant women, who were referred to a smoking cessation program. did 
not respond, while the participation of the women assigned to the immediate 
intervention was 93%; they had fronl two to three times higher rates of cessation/; In 
a smoking cessation program for post-discharge diabetic patients, smoking stahlS was 
only routinely recorded in those patients with a cardiac condition. Ninety-one percent 
of the patients refused to participate in the program, which was attributed to the 
severity and chronicity of the physical condition.57 Nursing interventions have shown 
to be effective (Odds Ratio 1+ 95% confidence interval I,2 to I,7), with some evidence 
that interventions were more effective for cardiovascular hospital in-patients.;s 
Table 3 Smoking cessation ifltervefltio1lS in dfffertmt settings. 
Intervention Effect 
public health 
'-'~~i"i1t~~Ilati;:;nai~~';;naTCb\~i significant'effecT':;O:';i"~~~'~--Z~"~""~"~_'M"~_~ 
Dutch no significant efTect41 
worksite effective if more intensive-lH6 
school favourable effectsi7,-IS 
hospital effective if intensive and in high-ris"k groups, such as 
", __ ~9_~~:~_~~_~?~~~_ry_~~.~~~~~'Y_~_P~~~~~"~:r~~~,~,,c . 
From the above mentioned interventions. it can be concluded that smoking cessation 
programs can be successful, especially if they are extensive or applied in high-risk 
groups of motivated patients. 
After multivariate adjushnent. a higher number of intervention sessions and 
modalities, and the combination of individual and groups meetings were associated 
with intervention success. IS The impact of a coronary event, such as a myocardial 
infarction or revascularisation procedure, and the urgency to change this hazardous 
behaviour, should be exploited to enhance the success of an attempt to quit. Patients 
who continue smoking, despite these warnings, need more intensive or additional 
support in order to quit as will be discussed below. 
Psychosocial factors 
In a large epidemiological survey on cardiovascular disease (Framingham), recent 
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hospitalisation and development of coronary heart disease were predictive for 
smoking cessation.19 
Nevertheless, about half the patients who are admitted for a coronary event are 
smoking one year after the hospitalisation.£o In order to address smoking cessation 
programs to those who are least likely to stop smoking. predictors of persistence in 
this unhealthy behaviour are required. TIle psychological profile and the social 
environment play an important role among coronary patients who smoke.6I In this 
thesis, apart from seriousness of illness, smoking history and motivation to stop. 
social isolation and symptoms of depression were predictive for continued smoking 
in patients who had had a myocardial infarction. Retrospectively. persistent smokers 
had more smokers in their environment. experienced less social support to quit and 
had more often an unfavourable psychological profile (Chapter 5). Coronary 
outpatients. who participated in a smoking cessation intervention, confirmed these 
findings (Chapter 7). This means that coronary patients. who continue smoking. 
might have unfavourable psychosocial circumstances, which restrains them from 
quitting. Psychological counselling or social work support might here be more 
appropriate than a general smoking cessation intervention. 
Previous shtdies have shown that a history of depression is associated with continued 
smoking£' and additional support in order to prevent dysphoric symptoms has been 
suggested.6l The antidepressant bupropion, proven to be effective for smoking 
cessation,6-' showed equal positive effe-tts in smokers with and without a history of 
depression. 
In this study, no association was demonstrated between baseline depression score and 
smoking cessation after one year.£l Other antidepressants showed inconclusive effect 
on smoking cessation; anxiolytics have no beneficial effects for quitting.66 Fuhue 
smoking cessation programs for coronary patients might be supplemented with an 
antidepressant, but this should first be investigated. 
In recent years, there is a growing interest for passive smoking and its effect on 
health. A meta-analysis of epidemiological shtdies on passive smoking and the risk of 
coronary artery disease showed an increased relative risk (RR 1.23, 95% confidence 
interval 1.17 to 1.32) for non-smokers who were exposed to environmental smoking.67 
Although this topic goes beyond the scope of this thesis, environmental smoking may 
be taken into account when discussing prevention and risk of coronary artery disease. 
Role of physicians I hospital 
Current management of smoking in patients with coronary artery disease is still 
insufficient. Following the European guidelines concerning prevention of coronary 
risk factors,M a European survey of registration and management of secondary 
prevention by cardiologists was performed; EUROASPIRE." 11,is survey showed that 
in 18% of the smokers, no entry about smoking could be found in the medical record. 
Although 92% of the current smokers had received advice to stop smoking. this was 
only recorded in 57% of the patients. Follow-up registration of smoking stahts was 
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present in only 35% of all pre·event smokers and only 9% were referred to additional 
therapy (Chapter 4). In 1998, an update of the guidelines was published, mainly 
because of new insights in lipid treabnent.'" The European Survey on risk factor 
managernent was repeated once more. Preliminary results in the Netherlands show 
that management of smoking has not changed markedly. (Personal communication. 
Euroaspire II Working Group) 
Various reasons for under-management of smoking by physicians could be: 
1 not trained to give health education I change behaviour 
2 no tools (medication) to offer 
3 unsatisfactory, because of frequent failure 
4 not responsible for unhealthy behaviour patients I violation of privacy 
5 own smoking behaviour (?) 
In the past, smoking rates among physicians exceeded those of the general 
population. but in I989, 30% of physicians (in training) were smoked which was 
below the average of the total population (33%)." General practitioners smoked more 
(men 41%, women 24%), but medical shldents (I9% and I6%, resp.ectively) less than 
the general population (37% respectively 29%), reflecting the decline in smoking rates 
over the last decades. In the Netherlands, the Medical Alliance against Smoking aims 
to make health workers more aware of the risk of smoking and stresses their 
responsibility. 
Perhaps physicians are not the proper health workers to give a smoking cessation 
intervention,?" but their authority over patients plays a crucial role in advice to stop 
smoking. Physicians should take time to advise all their patients who smoke to quit. 
Smokers, who are committed to quit, should be given additional snpport and offered 
nicotine replacement therapy, if necessary.,8 Training residents in giving advice to 
quit, resulted in en increase of questions raised about smoking habits (77 vs. 68%), 
advice to quit (43 vs. 28%), providing counselling for cessation (25 vs. IO%), giving 
self·help materials (7 vs. 1%), and arranging follow·up visits (5 vs. 1%) compared to the 
period before this training. Also, the self.perception of confidence (5.4 vs. 4.6 (max. 
10)) and effectiveness (5.3 vs. +0) in counselling of the residents increased after the 
training.7} 
In a primary care setting, chart reminders increased documentation of smoking status 
from 33% to 83% and the proportion of all patients counselled increased [rmu 6% to 
I3%,74 A simple sign in the medical stahlS might trigger the physician in the next visit 
"9 
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to discuss smoking again. Also, the use of biological markers of tobacco exposure, 
such as carbon monoxide levels in expired air, can be used as a tool for personal 
feedback. It is simple to measure, relatively cheap and has in several studies shown an 
enhanced effect of smoking cessation advice.'l Finally, in communications with other 
health workers, especially the general practitioner, smoking status should always be 
mentioned, so that reinforcement and follow-up can be offered, even after discharge. 
Smoking cessation program embedded in prevention clinics 
1110 authors of the WHO MONICA study, examined the reason for the decline in 
coronary heart disease mortality: two thirds of the decline were due to a decrease in 
incidence and one third because of a decline in mortality.i6 111e decrease in incidence 
can be explained by positive changes in the risk profile. In contrast to primary 
prevention, even modest treatment effects from secondary prevention can benefit 
large numbers of patients. Patients ,vith clinical evidence of cardiovascular disease are 
likely to be more motivated than their healthy counterparts to make and maintain 
lifestyle changesF In a review of multiple risk factor interventions for primary 
prevention of coronary heart disease, a decrease of 4% (95% confidence interval 4 to 
5) smokers was found.'8 
In various countries in Europe, secondary prevention programs are initiated in order 
to further improve the risk profile of high-risk patients. A comprehensive community 
based program to control cardiovascular diseases was started in North Karelia, 
Finland, in 1972, because of exceptionally high cardiovascular mortality rates. 1be 
effect of the progr~lln (net reduction in North Karelia) after 10 years was estimated 
28% reduction in smoking among the middle aged male population and 14% among 
the female population.'9 The changes in risk factors have extended to entire Finland, 
which, as regards smoking, has led to the lowest prevalence in Europe (see Chapter I). 
Another example, the Bromley Preventive Cardiology Program in England, is a 
secondary outpatient clinic for patients who were admitted and for the first time 
diagnosed as having coronary artery disease. A specialised nurse paid a short visit to 
the patient in the hospital. and subsequently at home within 72 hours after discharge. 
Next, the patient was screened for risk factors in the outpatient clinic and started on a 
health promotion program, consisting of exercise sessions and 8 workshops, on 
coronary risk factors, family risk factors, smoking, diet, physical activity, stress 
management, medication and support groups, which were given by various 
disciplines (e.g. dietician, physiotherapist, pharmacist). In this program, Inerely 12% 
were smoking at the start of the program, which decreased to 8% after 3 lnonths.80 
Future smoking cessation intervention 
In view of previously described results and literature study, a fuhtre outpatient 
smoking cessation program should at least include the following elements. A profile 
should be made of each individual smoker, in which at least three parameters should 
be measured: motivation, physical (or nicotine) addiction and psychosocial 
circumstances. It is important to know in which stage of change a patient is,S1.Sa in 
order to decide the next appropriate step. If a patient is not motivated, the pros and 
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cons of smoking and quitting should be discussed, before strategies for smoking 
cessation are suggested. In cases where nicotine addiction plays an important role, 
nicotine replacement therapy might be used. The odds ratio for abstinence with 
nicotine replacement therapy is I.7 (95% confidence interval 1.6 to 1.8). Eight weeks 
of patch therapy, wearing them during waking hours, are as effective as longer use.8J4 
Except for some rare case-reports in which patients continued smoking in addition to 
the nicotine patches, there is clear evidence that nicotine replacement therapy can be 
used safely by coronary patients.s! Finally, the social environment and psychological 
profile can predict whether a patient is likely to quit)8 If patients have many smokers 
among their family and friends, or receive little support, it is advisable to involve other 
significant people in their circle. Also, if patients suffer from depressive or other 
psychological problems, professional counselling or psycho-pharmaca could be 
prescribed, in order to lay a better basis for quitting. 
TIle Ininimal smoking cessation intervention, which was described in this thesis, was 
not effective (Chapter 7). A meta-analysis of smoking cessation interventions for 
coronary patients (Chapter 2 and 7) showed the importance of starting the 
intervention during hospitalisation. Strong advice to quW' and additional information 
by means of brochures or tailored letters,8 are in themselves already effective. Patients, 
who do not manage to quit or relapse after discharge, might be offered a more 
extensive smoking cessation program at the outpatient clinic. This means that follow-
up care should be extensive, especially in the first months, and continued for at least 
one year. Visits (individual or group sessions) and telephonically follow-up can be 
combined to be effective as well as convenient for both the smoker and the trainer. 
Although the authority of the treating doctor is required to stress the importance of 
smoking cessation, the actual intervention might best be offered by a nurse, social 
worker or health educator. About the frequency and timing of the sessions is still no 
consensus. Especially in the first months, weekly contacts or phone-calls are required, 
followed by I-monthly and once every few months for a year. 
Recently, various guidelines have been published for health workers on smoking 
cessation86.SJ and also in the Netherlands, guidelines for the cardiology deparhnent are 
developed. In future, it would be desirable for each country to have its own guidelines, 
adapted to the local needs and possibilities. Implementation of the guidelines is the 
next important goal. Prevention clinics for atherosclerotic symptoms should include 
a smoking cessation program. The implementation should be multidisciplinary, 
involving nurses, doctors but also dieticians and physiotherapists, in order to reach as 
many patients as possible as well as reinforcing the message. 
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Effective in smoking cessation interventions for coronary patients: 
7. Start intervention immediately after event (during admission) 
~ Intensive therapy more cost-effective 
7 Make smoking "prome" for tailored intervention; motivation, grade of addiction, 
social circumstances 
7 Consider additional drug therapy: nicotine replacement, bupropion 
7 Assess psychological prome (additional treatment for e.g. depression) 
7 Create supportive smoking environment (family, workplace) 
C/Wpl(f 8· O;swss;on 
References 
I u.s. Oeparbnent of Health and Human Services. 
n,e lImltll conse.qllences of smoking: C(lrdiovasCIIlar disf(lse. A report of tilt: S/HgeoH general's office 011 smoking 
t{ llealtil. Rockville, Maryland: 
OHHS (PHS), 90·50204,1990. 
2 Doll R, Peto R, Wheatley K, Gray R, Sutherland r. 
Mortality ill relation to smoking: 40 yeaT5' observations 011 male British doctoT5. 
BMJ I994;J09:90HI. 
Utley JR, Leyland SA, Fogarty CM, Smith WP, Knight EB, Feldman GJ, et al. 
Smokillg is Ilot a predictor of mortality alld morbidity fol/olVing corollary artery bypass graf/Ing. 
1 Card Surg 1996;11:377.84. 
4 Stubbe I, Eskilsson J, Nilsson-Ehle P. 
High·density lipoprotein COllCentratiollS incrNlse af/er stopping smoking. 
BMI 1982;284:15Il-3. 
Gerace TA, Hollis 1, Ockene JK, Svendsen K. MRFIT Research Group. 
Smoking cesmtioll alld c1Jange ill diastolic blood preSSllre, body weiglll, and plasma lipids. 
Prey 1'.1ed 1991;20:602-20. 
6 Tuonrnehto 1, Nissinen A, Puska P, Salonell JT. Ialkanen L. 
LOllg-term effects of cessation of smoking 011 body weigllt, blood presmre and sen/m c1wlesterol ill tile middle-
aged populatioll wil/J high blood pressure. 
Addict Behav 1986;Il:I·9. 
7 Jonason T. Bergstrom R. 
CessatiOIl of smoking in patieJIts witll intenllitfellt claudimliCH. Effects 011 tile risk of peripheral vasCIIlar 
complicatiolls, nI}'ocardial infarctioll and mortality. 
Acta Med Scand 1987;221:253.60. 
8 Townsend Me, DuChene AG. Morgan J, Browner WS. MRFIT Research Group. 
Pulmol/ary jimctioll ill r.:iatioH to cigarette smokillg alld smokillg Cf.ssation. 
Prev Med 1991;20:621.37. 
9 Kanner RE. 
Early illfervmtiolJ ill c1lronic obstructive pulmollary disease. A review oftlie LUllg He{llth Study re-SIIlts. 
Med Clin North Am 1996;80:523-47. 
10 Burchfiel CM, Marcus EB, Curb JO, Maclean q, Vollmer WM, Iohnson LR,et al. 
Effects of smoking and slIIoking Cf.ssatioll 0/1 longitudinal dedille ill pulmonary fUllctioli. 
Am 1 Respir Cri{ Care Med 1995;151:1778.85. 
II Ockene JK, Kllller LH, Svendsen KH, Meilahn E. 
ll1e re/atioll5lJip of smoking Ct55ation 10 corollary Ileart disease alld IUllg mllcer ill ti,e Militiple Risk Factor 
Intervention Trial (MRFIT). 
Am J Public Health 1990;80:954-8. 
12 Roland M, Rlldd RM. 
Genetics alld pulmollary medicine. 7. Somatic mlltatiolls ill tile developmC/lt oflllllg nHicer. 
Thorax 1998;53:979.83. 
13 Dales RE, Dionne G, Leech JA, Lunau 1'.1, Schweitzer l. 
Preoperative predictioll of pI limo nary complications fol/owing tlloracic mrgery. 
Chest 1993;104:155-9. 
14 Brown IK. 
Gender, age, IIsllalweig1lt, alld tobacco 115e as predictors oj weight loss ill patients witli/lll1g ({lIlcer. 
Oneal Nurs Forum 1993;20:466-72. 
15 Bundgaard T, Bentzen SM, Wildt 1. 
TIle prognostic effect of tobacco and alcolJOI coIISumption ill jlltra--oral squalllous (el/ carcinoma. 
Eur J Cancer B Oral Oncol 1994;30B:323-8. 
"3 
C/)(lP!d S· Discussion 
16 Gupta PC, Murti PR, Bhonsle RB, Mehta FS, Pindborg JJ. 
Bffect of cessation oflobacco lise olllhe incidence of ornl l11uCOS(lllesioJls ill a JO'YT follow'lIp study of 12,212 
IISUS. 
Oral Dis 199P:54·8. 
17 Fleshner N, Garland I, Moadel A, Herr H, Ostroff J, Trambert R, et a1. 
Illjlut/lce of smoking status 0/1 tile diseasNelated olltcomes of patieuts with tobacco-associated slIpCljicia/ 
trami/iolwl cell cardlloma ofllle bladder. 
Cancer 1999;86:2337-45. 
18 Myers RP. 
Prostate callcer-lIwrovasClllar pnservatioll; smokillg ce.ssalioll may elllwnce prognosis? 
I vrol 1995;154:158-9. 
19 Szarewski A, Jarvis MI, Sasieni P, Anderson M, Edwards R, Steele SJ, et al. 
Effict ofsmokillg cessatioll 011 cervicallesioll size. 
Lancet 1996;347:941-3. 
20 Fredricsson n, Gilljam H. 
Smoking and reproductioll. Slwrf and long tmll efficts alld beuejils of sllIoking cessatioll. 
Acta Obstet Gynecol Scand 1992;71:580-92. 
21 Ii CQ, Windsor RA, Perkins t, Goldenberg RL, Lowe JB. 
11le impact 011 illfallt birth weight alld gestaliOlwl age of colilline-validated smoking reductioll durillg 
pregnalle}'. 
lAMA 1993;269:1519.24-
22 Ahlsten G, Cnattingius S, Iindmark G. 
Cessation of smoking dllrillg preg1lallCY improves foetal grOlVJlI alld reduces illfallt morbidity ill tile Ileollatal 
period. A population-basfd prospective study. 
Acta Paediatr 1993:82:177·8I_ 
23 Sth'oro. 
RokeIJ, de /zarde }eilen: Vo!wassenen 1998. 
24 Eriksen MO, Gottlieb NH. 
A review of tile limIt" impact of smokil'g COlltrol at tile workplace. 
Am I Health Prom 1998;13:83-104. 
25 Barendregt JJ, Bonneux L, van der Maas PJ-
11le Ilealtil care costs ofslI1okillg. 
N Engl I Med 1997;337:1052-7. 
26 MaX\velI q, Hirdes JP. 
11le prevalence of SlIIokil1g mId implications for qll(llily of life (lIllong tile comnumity-based elderly. 
Am J PreY Med 1993;9:338-45. 
27 Dlufade AD, Shaw J\V, Poster SA, Leischow SJ, I·lays RD, Coons SJ. 
Development oflhe Smokillg Cm(ltion Quality of Life questiollnaire. 
Clin Ther 1999;2I:2II3-30. 
28 Law 11.1, Tang JL 
All (IIw/ysis of tile efficlivult.ss ofilllen'entiolls intended to Ilelp people stop smoking_ 
Arch Intent Med 1995:155:1933"41. 
29 Cummings SR, Rubin SM, Oster G_ 
11,e cost-effictivmess of cOIIIISeling slI10kers 10 quit. 
JAMA 1989;261:75-9. 
30 Kmmholz HM, Cohen BJ, Tsevat I, Pasternak RC, Weinstein Me. 
Cost·effi.ctivmess of a smoking cessation program after m}'o(.{Jrdial infardioll_ 
I Am Call Cardiol 1993;22:1697-7°2. 
31 Fiscella K, Franks P. 
"4 
Cosl-effietivuless of tile lrallsdermalnicotine pateli as all adjlmct 10 pllysiciallS' smokillg cessation coullseling. 
lAMA 1996;275:1247'51. 
Chllp!rr 8 - Discussion 
32 Weinstein MC. Stason WB. 
Cost-efficth'elless of coronary artery bypass surgery. 
Circulation 1982;66:II156·66. 
33 Yusuf S. Anand S, Cost of prevention. 
The case of/ipid lowering. 
Circulation 1996;9P774,6. 
34 Cromwell J. Bartosch WJ, Fiore MC, Hasselblad V, BakerT. 
Cost-efficth·tIless of tIle clinical practice recommtlldafiollS in the AHCPR guideline for smokillg cessation. 
Agency for Health Care Policy and ResiX/rch. 
JAMA 1997;278:1759,66, 
35 Mudde AN, de Vries H, Strecher VJ, 
Cost-effictiveness of smoking cessation modalities: comparing app/e5 willi oranges? 
Prey Med 1996;25:708-16. 
36 Barbash GI, White HD, Modan M, Dia2 R. Hampton JR, Heikkila J, et al. 
SignifiC(lnc~ ofsmokillg in patients receiving tllrombolytic tllerapy for acute myocardial illfarctioll, Experiwce 
glumedfrom tile IlltmwtiOlwl Tissue P/asminogw Adivator/Streptokinase Mortality Trial. 
Circulation 1993;87:53,8, 
37 Barbash GI, Reiner J. White HD, Wilcox RG, Annstrong PW, Sadowski Z, et a!. 
Evailf(ltioll of paradoxic beneficial ~(frcts of smoking in patiwts receivillg tllrombolytic tllempy for acute 
1II}'oc.ardial infarctiol1: mechallism ofllle "smoker's paradox" from tllt~ GUSTO-I trial, lVitll allgiograpllic 
ilisigills. Global Utilization ofStnptokillase and Tissue-P/asmilJogw Adivator for Occluded COrolWry 
Arteries, 
J Am Coll Cardiol 1995;26:1222-9_ 
38 Jorgensen, Kober L, Ottesen MM, Torp,Pedersen C, Videbaek I, Kjoller E_ 
-nle prognostic importallce ofslIlokil1g 5taillS a/ IIle time of awte 11l}'ocardial infarctioll ill 6676 patienls. 
TRACE Siudy Group. 
J Cardiovasc Risk 1999;6:23-7, 
39 Purcell IF. Newall N, Farrer M. 
Lower cardiac mOriality in smokers following tl1rombol),sis for acute 1II}'Ocardial il1farctioll may be related to 
more: effective fibrinolysis, 
QJM '999:92:)27-)). 
40 Janz NK, Becker MI f, Kirscht JP, Eraker SA, Hilli JE, Woolliscrofl: JO, 
Evalualioll of a minimal-contact smokil1g cessatiol1 intervention in all outpafiellt settillg. 
Am J Public Health 1987;77:8°5'9, 
41 Kanner RE, Connett JE, Williams DE, Buist AS. 
Effects ofnllldomized assigUlllent to a smokil1g cessation intervmtiOIl alld cllallges ill smoking Iwbils 011 
respiratory symptoms ill smokers lVitll early clJrollic obstmetive plllmollary distme: tIle LUllg 
Health Study. Am J Med 1999;to6:4to-6. 
42 Sawicki PT, DidjurgeH U. Muhlhauser I, Berger M. 
Behaviour IIlempy vs, doctor's onti-smoking advice ill diabetic patients, 
J Intern Med 1993;234:4°7-9. 
43 Anonymous. 
Comlllul1ily IntervlntiOIl Trialfor Smoking Cessatioll (COMMIT): I. COllOrt resultsfrolll a fOllr-}'ear 
coml/llmity intervention, 
Am J Public Health 1995;85:183'92. 
44 Korhonen T, Su S, Korhonen HJ, Uutela A, Puska P. 
Evaluation of al1atiolla/ Quit and Win cOlllest: detmllillol1ls for successful quitting_ 
Prey Med 1997;26:556-64. 
45 Mudde AN, de Vries H, Dolders MG. 
Hvaluatioll of a Dutch comlllllllity-based smoking cessatioll illterventioll. 
Prey Med 1995;24:61-7°. 
"5 
ChapIn 8 - Discussion 
46 Glasgow RE, Hollis JF, Ary DV, Boles SM. 
Results of a }'i'-ar-/ollg incentives·based Jtlorksite smoking-cessation program. 
Addict Behav 1993;18:455-64. 
47 Thompson B, Kinne S, Lewis FM, Woolridge JA. 
Rnlldomized telepl101le smokjllg·jntervmtioll trinl jlli/lnllv dinxted nl btl/Nollnr workers. 
Monogr Natl Cancer Inst 1993;I4:105-12. 
48 Salina D, Jason LA, Hedeker D, Kaufman J, Lesondak L, McMahon SD, et al. 
A follolV'up of a medin-based, lVorksite sll10king cessation program. 
Am J Community Psychol 1994;22:257-71. 
49 Elder JP, Wildey M, de Moor C, Sallis J, Jr., Eckhardt L, Edwards C, et al. 
711t: 10llg-lenl! preventioll of tobacco !/se amollgjllnior lligll scJwo/ stl!dClltS: classroom (Hid telephone 
illtervtlltiollS. 
Am J Public Health 1993;8p239-44. 
50 Elder JP, Perry CL, Stone EJ, Johnson ee, Yang M, Edmundson EW, et al. 
Tobacco lise mmsurement, pri'dictioll, ami intervmtioll in elementary scllools illfollr states: tire CATCH 
StudV· 
Prey Med 1996;25:486-94. 
51 Silagy C. 
PhysiciaJl advice for smokillg cessation (Cae/lrane revielV). 
lhe Codualle Library, Issue I, 2000. Oxford: Update Sofuvare . 
52 Van Berkel TF, Boersma H, Roos·Hesselink JW. Erdman RA, SimOOIlS ML. 
Impact ojsmoking ceSsatiOIl alld smokillg illiervmtiollS ill patients lVith corollary Ilmrt dismse. 
Eur Heart J 1999;20:1773-1782. 
53 Dolan-Mullen P, Ramirez G, GroffJY. 
A meta-allnlysis of randomized trinls ofpre/lntal smokillg cessntioll illterventiollS. 
Am J Obstet Gynecol I994;17I:Ip8-34' 
54 Hartmann KE, Thorp J, Jr., Pahel·Short L. Koch MA. 
A mlldolllized controlled trinl of smoking cessation i,lfervtlltioll ill prrgnaJIC}' ill (III nCITciemie dillie. 
Obstet Gy:necol 1996;87:621-6. 
55 Pieterse ME, Seydel ER. Mudde AN, de Vries H. 
Uil'.'oerbaarl,eid en effictiviteil vall tell mill/nmal stoppen-met-roken programma voor de Iwisartspmklijk. 
Tijdsc1uift Gezondheidsbevordering. 1994;15:57'71. 
56 O'Connor AM, Davies BL, Dulberg CS, Buhler PL, Nadon C, McBride BH, et al. 
Effictivenm of a pri'gnallC}' smoking cessation program. 
J Obstet Gynecol Neomtal Nurs I992;2I:J85-92. 
57 Haire-Joshu D. Ziff S, Houston C. 
TI,e feasibility of remlitillg lrospifalized pnllents lVitll diabetes for a smoking ce5SatioJl program. 
Diabetes Educ 1995;21:214-8. 
58 Kottke TE, Battista RN, DeFriese GH, Brekke ML 
Attriblltes of sHccessful smoking cessntioll inlervmtjollS ill medical pmctice. A meta-analysis of39 COli trolled 
trials. 
JAMA 1988;259:2883-9. 
59 Freund KM, D'Agostino RB. Belanger AJ, KalUlel WB, Stokes Jd. 
Predictors of smoking cessntion: tile Fmminglwm Study. 
Am J Epidemiol 1992;135:957-64. 
60 Havik OE, l\.iaeland JG. 
Clwnges ill smoking bi'lwvior after (I 1Il}'OCarcii(l/ infarctioll. 
Health PsydlOl 1988;7:4°3-20. 
61 McKenna K, Higgins H. 
Factors influencing smoking ressntioll ill patients lVitll corollnry nrfery disease. 
Patient Educ Cauns 1997;32:197-205. 
Ora!'u;! S - Discussioll 
62 Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss lL, Cooper TB, et al. 
HUlV}' smokers, smokillg cessation, (illd clollidille. Results of a dOl/ble-blilld, randomized trial. 
JAMA 1988;259:2863-6. 
63 Covey LS, Glassman AH, Stetner F. 
Depnssioll alld deprrmive symptoms ill smoking cessatioll. 
Compr Psychiatry 199°;31:35°-4. 
64 Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. 
A colltrolled trial of sl/stailled-relnm: bl/propioll, a lIicotille patch, or botflfor smoking cessation. 
N Engl 1 Med 1999;34°:685'91. 
65 Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT. et al. 
Effimcy ofbllPropioll for smoking cessation ill smokers witli a fonner liis-/ory of major depressioll or a1colzolism_ 
Br J Psychiatry 1999;174:173.8. 
66 Hughes J, Stead L, Lancaster T. 
AIl~iolytics and alitidepressCints for smokillg a.ssatioll (Coc/lral1e review). 
In: The Cochrane library, Issue I, 2000. Oxford: Update Software. 
67 He 1. Vuppuhni S, Allen K, Prerost MR, Hughes J, Whelton PK. 
Passh,t smokillg Cllld the risk of COTOIl(lry IH?-!lrt disease-a meta-(l1wlysis of epidemiologic sflldies. 
N EngJ 1 Med 1999;34°:920.6. 
68 Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. 
Prevtllfiol1 of corollary lle.arl dise.ase ill clilliml practice. Recommtlld(ltiollS of the Task Force of tilt Ellropeml 
Society of Cardiology, Europe(l11 At/lerose/erosis Society alld Ellrope.all Society of Hyperttllsion. 
Eur Heart J 1994;15!I300-31. 
69 Anonymous. 
EUROASPIRE. A European Sociely of Cardiology survey of secolldary prevention of corollary JIWrl dise.ase: 
principal results. EUROASPIRE Study Group. Europeall Actioll 011 Secolldary Prevmlioll tllrollgli 
Illterventioll to Reduce Evmls. 
Eur Heart J 1997;18:1569.82. 
70 Wood D, De Backer G, Faergeman 0, Graham I, Manda G. Pyorala K. 
Prevelltioll of coronary heart disease ill clillical pradic.e. Recommendatiolls oft/I{'; Second joillt Task Force of 
Europeall alld otller Societies 011 Corollary Pri"l'elltioll. 
Eur Heart J 1998;19:1434.15°3. 
71 Dekker HM, Dill AM, Looman CW, Adriaanse HP. 
[Smokillg be1lflvior offamily physiciallS, specialists md stltdt'llts ill Rotterdam, 1989J. 
Ned Tijdschr Geneeskd 199°;134:1495-8. 
72 HuH AL, Kleinhenz ME. 
Smoking asse.ssment alld a.ssatioll skills ill tile inpatient medicine clerkship. 
Teaching & leaming ill Medidne 1990;2:157.160. 
73 CornliZ J, Zellweger JP. MOlillOlid C, DeHey H, Pecoud A, Burnand B. 
Smoking cessation counseling by re,idt'llts ill all olllpa/it'lit clinic. 
Prev Med 1997;26:292-6. 
74 Chang HC, Zimmerman LH, Beck JM. 
Impact of chart remillders 011 slllokilig Ce.5S(ltiOIi practices of pullllollary physicians. 
Am 1 Respir Crit Cale Med 1995;152:984'7. 
75 Lerman C, Orleans cr, Engstrom PF. 
Biological markus ill smoking cessation treatment. 
Semin Oneol 1993;20:359-67. 
76 Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Toionell H, Ruokokoski E, Amouyel P. 
COlltribution oftrellds ill survival alld coronary-fIImt rates to cliallge.s ill corOllary he.art disease mortality: 10-
year re.sultsfrom 37 WHO MONICA project populations. MOliitorilig trellds alld detemlillants ill 
mrdiovasclllar disease. 
Lancet 1999;35):1547-57. 
"7 
Chapter 8 . Discussion 
77 Robinson JG, Leon AS. 
1111; prevention of c.ardiovasclilar disease. Empliasis OIl seealldary prevention. 
Med Clin North Am 1994;78:69'98. 
78 Ebrahim S, Smith GD. 
Systematic review of ralldomised COIltral/ed lrials oflllllitiple riskfaclor illlerventiollS for preventing coronary 
llfllrt disease. 
BMJ 1997;314:1666-74. 
79 Puska P, Salonen JT, Nissinen A, Tuolllilehto J, Vartiainen E, Korhonen H, ct al. 
Change in riskfactorsfor earallary llearl disease during 10 }'ears of a cOIIlIlHmity interventiOJl pragmm (Nartll 
Karelia project). 
8MJ 1983;287:1840.4. 
80 Fox KF, Nuttall M, Wood DA, Arora B, Dawson E, Devane p, et al. 
A c.ardiac preVflllioll and rehabilitation program for aI/ patiellts at first prese/ltalioll lVith coronary artery 
dise{lse in tile popu/atio/I. 
To be submitted. 
81 Dijkstra A, Roijackers J, De Vries H. 
Smokers illfollr stages of re{ldiness to chauge. 
Addict Behav 1998;23:339'5°. 
82 Hellman R, CUlllmings K1f, Haughey BP, Zielezuy MA, O'Shea RM. 
Predictors of attemptillg and succeeding 01 smoking cesmtio/l. 
Health Educ Res 1991;6:77.86. 
83 Silagy C, Mant D, Fowler G, Lancaster T. 
Nicotine rep/acemml 111I:rapy for smoking cessation (Coclirane review). 
In: 111e Cochrane library, Issue I, 2000. Oxford: Update Software. 
84 Silagy C, Mant D, Fowler G, lodge M. 
Meta-analysis Oil efficacy of/liealille replacement tllempies ill smoking cesmtioll. 
Lancet 1994;J4P39-42. 
85 Anonymous. 
Nicotine replaumrmt tlltmpy for paliellls lVitll corOJl(IrY artery disease. Workillg Group for tile Study of 
Tmmdemlal Nicotille ill PaliUl/s lVitli Corollary artery disf(lse. 
Arch Intern Med 1994;154:989.95. 
86 Anonymous. 
11le Agency for Heallll Care Policy and Re&'{lrc1i Smoking Cessatioll Clinical Practice Guideline. 
JAMA 1996;27S:127o.80. 
87 Raw M, McNeill A, West R. 
,,8 
Smoking Cf;ssatioll gllidelinesfor Iletlitlil'rojessiolJa/s. A guide to effictive smoking assalioll interventiolts for 
the hw/tli ({lre S}'stem. 
Health Education Authority. Thorax I998;53:SI-I9. 
"9 


ii 
Summary 
In Chapter I, the relationship bev,vcen smoking and coronary artery disease as well as 
the importance of smoking cessation is introduced. Exhaustive research has shown 
that cigarette smoking is one of the major known risk factors for coronary artery 
disease. The ovenvhelming evidence that smoking causes not only cardiovascular 
disease but also new events in patients who already are diagnosed with coronary artery 
disease, justifies firm promotion of smoking cessation. TIle average smoking rate in 
the Netherlands has stabilised in the last decades around 34%. More attention and 
financial support, especially for teenagers and patients who already experienced the 
consequences of smoking, for example a myocardial infarction, is necessary to further 
reduce this percentage. 
In Chapter 2, a review of nineteen observational studies on the effect of smoking 
cessation in patients with coronary heart disease showed a decline in mortality or non-
fatal myocardial infarction of on average 35%. Mortality after a coronary event was 
38% lower in quitters compared to persistent smokers, while the incidence of death 
or myocardial infarction decreased with almost 50%. Furthermore, in nine 
publications studying trials on smoking cessation programmes in coronary patients, 
20% more patients quit smoking after being subjected to a special smoking cessation 
programme than those who received the usual care. This systematic review of shldies 
observing the impact of smoking cessation on the prognosis of coronary heart disease 
patients confirmed that this lifestyle change is one of the most powerful tools in 
reducing mortality and recurrent coronary events. Special smoking cessation 
programmes improve the success in attempts to quit. 
Chapter 3 describes a 2o-years follow-up study which was performed in 985 patients 
who underwent coronary bypass surgery in the 70's, in order to investigate the 
influence of smoking cessation on mortality. Analysis adjustmented for baseline 
characteristics showed that persistent smokers had a 68% greater risk of death form 
all causes and 75% of cardiac death than patients who had stopped smoking for at 
least one year after surgery. The estimated benefit of survival for the quitters increased 
from three percent at five years to 14% at 15 years. TIle smokers were 41% more likely 
to undergo repeated bypass surgery or percutaneous coronary angioplasty procedures. 
Smoking cessation after coronary bypass surgery improves prognosis and decreases 
the risk of repeated revascularisation procedures. 
EUROASPIRE is a survey to establish to what extent risk factors are managed and 
recorded in coronary patients' medical records in 21 hospitals in Europe. Chapter 4 
described data on smoking status which were collected from medical records of 4863 
consecutive patients who were previously admitted for an acute coronary event. In 
almost 20% of the patients, smoking habits were not documented in their medical 
record, while in only 35% of the smoking patients, smoking status was documented 
again at the foHow-up. Thirty-four percent of the patients were smokers, of whom over 
90% had received advice to quit smoking. As many as 50% of the patients continued 
smoking after the event. Advice to stop smoking motivated patients to seek help and 
to attempt to stop smoking. Thus, there is further potential to reduce the risk of 
recurrent coronary disease. 
S!lmmGf), 
In Chapter 5. baseline characteristics of patients who were admitted for a myocardial 
infarction were related to smoking stahts at short-term and long-tenn follow-up. 
Predictors of quitting or continued could help in deciding to whom additional support 
should he offered. Demographics. medical history, presence of other coronary risk 
factors, psychological determinants and the clinical course were recorded in I472 
unselected, consecutive patients who had been hospitalised for a myocardial 
infarction. At 3 months, persistent smokers were younger than quitters, had been 
admitted for a shorter period, undenvent less often revascularisation procedures, 
smoked more cigarettes per day at baseline and were more socially isolated. After 4 
years, patients who stopped smoking had a larger myocardial infarction and a lower 
displeasure-score at baseline than those who continued smoking. Also, quitters 
received more support from their environment. Patients who do not stop smoking 
after a myocardial infarction sholdd be offered special support. Psychological state 
and social support are two important factors for slnoking cessation, and should be 
taken into account when offering support to quit. 
Although advice and support of smoking cessation is considered as a task of the 
cardiologist, it still has low priority. Chapter 6 describes the enrolment, baseline 
characteristics and problems with implementation of a minimal invasive smoking 
cessation intervention for coronary patients in the outpatient clinic. The smoking 
cessation intervention consisted of a computer generated letter which was tailored to 
the patient's situation, and a nurse offered smoking cessation program consisting of 
a visit at baseline, after 3 months and I year and three phone calls. of the intervention 
group, 85% attended the first visit (non-attendees had more often already quit 
smoking in the month before inclusion). 
Chapter 7 discusses the effects of the smoking cessation program which was 
described in chapter 6. Of the patients in the intervention group, 22% reported to 
have quit vs. 20% of the control group. One third of the quitters had never attempted 
to quit before. Patients who had quit, had more often quit already in the month before 
the inclusion, were more often recently admitted and diagnosed with coronary artery 
disease, and were more convinced to be able to refrain from smoking in difficult 
situations. Persistent smokers had more smokers in their enviromnent and received 
less support from their close relatives and friends than quitters. Furthermore, patients 
who continued smoking had a less favourable psychological profile than quitters. 
Results suggest a that a minimal invasive smoking cessation program for outpatients 
with coronary artery disease is not sufficient. Coronary patients who smoke should be 
enconraged to stop smoking and offered an extensive smoking cessation programme, 
taking psychosocial factors into account. 
In the final chapter, results of the previous chapters are contemplated and also other 
subjects which are involved in smoking cessation are raised. Benefits are discussed of 
smoking cessation in other health areas such as puhnonary problems, oncology and 
infertility. Furthermore. the issue of costs is discussed, for example. the relatively low 
budget, which is spent on information and support, but also the high cost·effectivity 
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Summary 
of smoking cessation interventions. Smoking cessation programs can be successful, 
especially if they are extensive or applied in high-risk groups of motivated patients. A 
higher number of intervention sessions and modalities, and the combination of 
individual and group meetings are associated with a higher success rate. Persistent 
smokers might profit more from psychological counselling or social work support 
than a general smoking cessation intervention. Consequent enquiries for smoking 
behaviour, proper registration and offering additional support, such as behavioural 
interventions and nicotine replacement therapy, should be implemented in every 
health clinic. Recently published guidelines offer useful tools to set up support in 
reducing tobacco use in daily practice. 

Samenvatting 
In Hoofclshtk I wordt de relatie tussen roken en coronarialijden geintrocillceerd en 
tevens het belang van stoppen met roken. Uitgebreid onderzoek heeft aangetoond ciat 
het roken van sigaretten een van de belangrijkste risicofactoren is voor 
coronarialijden. Hierbij is niet aIleen aangetoond ciat roken kan Iijdcn tot hart- en 
vaatziekten. maar oak ciat roken kan lijden tot nieuwe complicaties hij patienten die 
al vaatlijden hebben. Dit tezamcn rechtvaardigt cen actieve honding ten opzichte van 
stoppen. Sinds de tachtiger jaren is het percentage rokers in Nederland stabiel op 
ongeveer 34%. Er is meer aanclacht en financiele ondersteuning nodig om dit 
percentage verder naar heneclen te krijgen, met name gericht op het voorkomen van 
starten met roken door jongeren en op patienten die al de nadelige gevolgen van 
roken hebben ervaren, bijvoorbeeld door een myocard infarct. 
In Hoofdstuk 2, waarin een overzicht wordt gegeven van negentien observationele 
shldies naar het effect van stoppen met roken bij patienten met coronarialijden, werd 
een gemiddelde afname van 35% aangetoond in mortaliteit of een niet·fataal myocard 
infarct. De mortaliteit bij coronarialijden was 38% lager bij stoppers vergeleken met 
patienten die bleven roken, en de incidentie van overlijden of myocard infarct was 
zelfs bijna 50% lager. Daarnaast werd in negen shldies naar het effect van stoppen 
met roken programma's voor coronairpatienten 20% meer stoppers gevonden onder 
patienten die een programma aangeboden hadden gekregen dan bij hen die slechts 
de gewone zorg kregen. Dit overzkht bevestigt het belang van het stoppen met roken 
en het effect op de prognose bij coronairpatienten. Speciale programma's die steun 
bieden bij het stoppen leiclen tot meer succesvolle stoppogingen. 
Hoofdshlk 3 beschrijft een 2o·jaars follow· up van 985 patienten die een bypass 
opera tie hadden ondergaan in de zeventiger jaren, waarbij het effect van stoppen met 
roken werd onderzocht op de mortaliteit. Bij een voor baseline gecontroleerde analyse 
bleken de rokers een 68% groter risko op totale sterfie te hebben en 75% op cardiale 
sterfte dan patienten die tenminste een jaar na de operatie waren gestopt met roken. 
De geschatte winst op overleving groeide voor de stoppers van 3% na 5 jaar tot 14% bij 
15 jaar. De rokers hadden 41% meer kans op een nienwe bypass operatie of een 
angioplastiek ("Dotter· procedure"}. 
EUROASPIRE is een ohservationele studie naar risko factoren en hun behandeling 
bij coronair patienten in 21 ziekenhuizen in Europa. In Hoofdshlk 4 werden de 
rookgegevens uit medische stahlssen van 4863 patienten, die waren opgenomen 
geweest vanwege coronarialijden, beschreven. In bijna 20% van de patienten was het 
rookgedrag niet ingevuld in de stahls. Daarnaast was bij slechts 35% opnieuw de 
rookstatus genoteerd bij of controle na ontslag. Vierendertig procent van de patienten 
rookten bij opname; 90% hiervan had een stoppelHuet·roken advies gekregen. Zeker 
50% van de rokers bleef roken na de opllame. Het advies om te stoppen motiveerde 
patiellten om hulp te zoekell en een stoppoging te doen. Kortom, het risko op nieuwe 
complicaties bij coronairpatienten kan belangrijk verminderd worden, indien meer 
aandacht en tijd besteed wordt aan het roken. 
Samellvalling 
In Hoofdstuk 5 werden verschillende baseline eigenschappen vergeleken bij patienten 
na opname voor een myocard infarct met de rookstatus na korte en lange termijn 
follow-up. 20 kon worden voorspeld wie wei of niet zou stoppen met roken op eigen 
kracht en aan wie dus extra hulp zou moeten worden geboden. Demografische 
kenmerken, medische voorgeschiedenis, aanwezigheid van coronaire risko factoren, 
psychologische eigenschappen en het verloop van de opname werden vastgelegd in 
1472 patienten die waren opgenomen vanwege een myocard infarct. Na 3 maanden 
bleken de nog rokende patienten jonger te zijn, korter te zijn opgenomen geweest in 
het ziekenhuis, minder vaak een interventie te hebben ondergaan, lneer sigaretten te 
roken per dag bij aanvang van de shldie en sociaal meer geisoleerd te zijn dan de 
patienten die waren gestopt met roken. Na 4 jaar werden patienten die waren gestopt 
met roken gekenmerkt door een groter infarct en een lagere score op de ongenoegen-
schaal. Tevens hadden zij meer steun gehad van hun omgeving. Patienten die niet 
stoppen met roken na een myocard infarct moet extra ondersteuning worden 
gegeven. De psychologische kenmerken en de sociale omgeving zijn twee belangrijke 
factoren voor stoppen, waar bij het aanbieden van een stoppen met roken programma 
rekening mee moet worden gehouden. 
Hoewel het geven van een stop-advies plus ondersteuning bij een stoppoging een taak 
van de cardioloog is, heeft het nog steeds een lage prioriteit. Hoofdstuk 6 beschrijft 
de inclusie, baseline kenmerken en problemen bij implementatie van een minimale 
interventie shldie voor stoppen met roken programma voor coronairpatienten in de 
polikliniek. Dit stoppen met roken programma bestond uit een door de computer 
gegenereerde advies.op-maat brief, aangepast aan de situatie van de patient, en een 
door een verpleegkundige geleid programma dat bestond uit 3 bezoeken (bij baseline, 
na 3 maanden en een 1 jaar) en drie telefoongesprekken. 
Hoofdstuk 7 bespreekt het effect van dit stoppen met roken programma. Van de 
patienten in de interventie groep was 22% gestopt tegenover 20% in de controle 
groep. Een derde van de stoppers had nooit eerder een stoppoging gedaan. Patienten 
die waren gestopt, waren vaker al gestopt in de maand voor inclusie, waren vaker 
recent opgenomen geweest in een ziekenhuis en hadden korter geleden te horen 
gekregen dat ze coronarialijden hadden. Bovendien waren ze meer zelfverzekerd te 
kunnen stoppen bij moeilijke situaties. Rokers haddenlneer rokers in hun omgeving 
en ontvingen minder steun van hun familie en vrienclen dan stoppers. Bovendien 
hadden patienten die nog rookten een minder gunstig psychologisch profiel. Deze 
resultaten suggereren dat een minimale stoppen met roken programma voor 
poliklinische patienten met coronarialijden niet effectief is. Coronairpatienten die 
roken !poeten een uitgebreicler stoppen met roken programma aangeboden worden, 
waarbij psychosociale factoren in ogenschouw worden meegenornen. 
In het laatste hoofdshlk worden tevens andere gunstige effecten van stoppen met 
roken behandeld zoals bij iongproblemen, kanker en onvruchtbaarheid. Bovendien 
wordt het kostenaspect beschouwd; het relatieve lage bedrag wat aan voorlichting en 
ondersteuning wordt gegeven, maar ook de hoge kosten·effectiviteit van stoppen met 
roken programma's. Deze kunnen zeer effectief zijn, met name indien ze intensief 
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SamenVDlting 
zijn en toegepast worden bij hoge-risico groepen met een hoge motivatie. Een groot 
aantal sessies en verschillende modaliteiten, en gecombineerde individuele en 
groepssessies zijn gecorreleerd met een grotere kans op succes. Patienten die blijven 
roken hebben Inogelijk meer aan psychologische hulp of sociaal werk dan een 
algemene stoppen met roken interventie. Consequent vragen naar rookgedrag, goede 
registratie en aanbieden van hulp, waaronder gedragstherapie en nicotine-substihttie 
therapie horen thuis in elke medisehe kliniek. Recent gepubliceerde riehtlijnen 
vonnen een leidraad voor het opzetten van ondersteuning bij het terugdringen van 
tabaksgebruik in de dagelijkse praktijk. 
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